<html>

<head>
<meta http-equiv=Content-Type content="text/html; charset=windows-1252">
<meta name=Generator content="Microsoft Word 15 (filtered)">
<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:Helvetica;
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:Courier;
	panose-1:2 7 4 9 2 2 5 2 4 4;}
@font-face
	{font-family:"Tms Rmn";
	panose-1:2 2 6 3 4 5 5 2 3 4;}
@font-face
	{font-family:Helv;
	panose-1:2 11 6 4 2 2 2 3 2 4;}
@font-face
	{font-family:"New York";
	panose-1:2 4 5 3 6 5 6 2 3 4;}
@font-face
	{font-family:System;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Wingdings;
	panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"MS Mincho";
	panose-1:2 2 6 9 4 2 5 8 3 4;}
@font-face
	{font-family:Batang;
	panose-1:2 3 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:SimSun;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:PMingLiU;
	panose-1:2 1 6 1 0 1 1 1 1 1;}
@font-face
	{font-family:"MS Gothic";
	panose-1:2 11 6 9 7 2 5 8 2 4;}
@font-face
	{font-family:Dotum;
	panose-1:2 11 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:SimHei;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:MingLiU;
	panose-1:2 1 6 9 0 1 1 1 1 1;}
@font-face
	{font-family:Mincho;
	panose-1:2 2 6 9 4 3 5 8 3 5;}
@font-face
	{font-family:Gulim;
	panose-1:2 11 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:Century;
	panose-1:2 4 6 4 5 5 5 2 3 4;}
@font-face
	{font-family:"Angsana New";
	panose-1:2 2 6 3 5 4 5 2 3 4;}
@font-face
	{font-family:"Cordia New";
	panose-1:2 11 3 4 2 2 2 2 2 4;}
@font-face
	{font-family:Mangal;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Latha;
	panose-1:2 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Sylfaen;
	panose-1:1 10 5 2 5 3 6 3 3 3;}
@font-face
	{font-family:Vrinda;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Raavi;
	panose-1:2 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:Shruti;
	panose-1:2 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:Sendnya;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Gautami;
	panose-1:2 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:Tunga;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Estrangelo Edessa";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Cambria Math";
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:"Yu Gothic";
	panose-1:2 11 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:DengXian;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:Calibri;
	panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
	{font-family:"Calibri Light";
	panose-1:2 15 3 2 2 2 4 3 2 4;}
@font-face
	{font-family:"Palatino Linotype";
	panose-1:2 4 5 2 5 5 5 3 3 4;}
@font-face
	{font-family:Verdana;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"Arial Unicode MS";
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:"Segoe UI Emoji";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Cambria;
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:"Segoe UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Tahoma;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"Segoe UI Symbol";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:BISansCond;}
@font-face
	{font-family:Marlett;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Arial Black";
	panose-1:2 11 10 4 2 1 2 2 2 4;}
@font-face
	{font-family:"Bahnschrift Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiLight";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Bahnschrift;
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiBold";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift Light SemiCondensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiLight SemiConde";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiCondensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiBold SemiConden";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift Light Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiLight Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiBold Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Candara;
	panose-1:2 14 5 2 3 3 3 2 2 4;}
@font-face
	{font-family:"Candara Light";
	panose-1:2 14 5 2 3 3 3 2 2 4;}
@font-face
	{font-family:"Comic Sans MS";
	panose-1:3 15 7 2 3 3 2 2 2 4;}
@font-face
	{font-family:Consolas;
	panose-1:2 11 6 9 2 2 4 3 2 4;}
@font-face
	{font-family:Constantia;
	panose-1:2 3 6 2 5 3 6 3 3 3;}
@font-face
	{font-family:Corbel;
	panose-1:2 11 5 3 2 2 4 2 2 4;}
@font-face
	{font-family:"Corbel Light";
	panose-1:2 11 3 3 2 2 4 2 2 4;}
@font-face
	{font-family:Ebrima;
	panose-1:2 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Franklin Gothic Medium";
	panose-1:2 11 6 3 2 1 2 2 2 4;}
@font-face
	{font-family:Gabriola;
	panose-1:4 4 6 5 5 16 2 2 13 2;}
@font-face
	{font-family:Gadugi;
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Georgia;
	panose-1:2 4 5 2 5 4 5 2 3 3;}
@font-face
	{font-family:Impact;
	panose-1:2 11 8 6 3 9 2 5 2 4;}
@font-face
	{font-family:"Ink Free";
	panose-1:3 8 4 2 0 5 0 0 0 0;}
@font-face
	{font-family:"Javanese Text";
	panose-1:2 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Leelawadee UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Leelawadee UI Semilight";
	panose-1:2 11 4 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Lucida Console";
	panose-1:2 11 6 9 4 5 4 2 2 4;}
@font-face
	{font-family:"Lucida Sans Unicode";
	panose-1:2 11 6 2 3 5 4 2 2 4;}
@font-face
	{font-family:"Malgun Gothic";
	panose-1:2 11 5 3 2 0 0 2 0 4;}
@font-face
	{font-family:"\@Malgun Gothic";}
@font-face
	{font-family:"Malgun Gothic Semilight";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@Malgun Gothic Semilight";}
@font-face
	{font-family:"Microsoft Himalaya";
	panose-1:1 1 1 0 1 1 1 1 1 1;}
@font-face
	{font-family:"Microsoft JhengHei";
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei";}
@font-face
	{font-family:"Microsoft JhengHei UI";
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei UI";}
@font-face
	{font-family:"Microsoft JhengHei Light";
	panose-1:2 11 3 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei Light";}
@font-face
	{font-family:"Microsoft JhengHei UI Light";
	panose-1:2 11 3 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei UI Light";}
@font-face
	{font-family:"Microsoft New Tai Lue";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Microsoft PhagsPa";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Microsoft Sans Serif";
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:"Microsoft Tai Le";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Microsoft YaHei";
	panose-1:2 11 5 3 2 2 4 2 2 4;}
@font-face
	{font-family:"\@Microsoft YaHei";}
@font-face
	{font-family:"Microsoft YaHei UI";
	panose-1:2 11 5 3 2 2 4 2 2 4;}
@font-face
	{font-family:"\@Microsoft YaHei UI";}
@font-face
	{font-family:"Microsoft YaHei Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@Microsoft YaHei Light";}
@font-face
	{font-family:"Microsoft YaHei UI Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@Microsoft YaHei UI Light";}
@font-face
	{font-family:"Microsoft Yi Baiti";
	panose-1:3 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:MingLiU-ExtB;
	panose-1:2 2 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MingLiU-ExtB";}
@font-face
	{font-family:PMingLiU-ExtB;
	panose-1:2 2 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@PMingLiU-ExtB";}
@font-face
	{font-family:MingLiU_HKSCS-ExtB;
	panose-1:2 2 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MingLiU_HKSCS-ExtB";}
@font-face
	{font-family:"Mongolian Baiti";
	panose-1:3 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MS Gothic";
	panose-1:2 11 6 9 7 2 5 8 2 4;}
@font-face
	{font-family:"MS UI Gothic";
	panose-1:2 11 6 0 7 2 5 8 2 4;}
@font-face
	{font-family:"\@MS UI Gothic";}
@font-face
	{font-family:"MS PGothic";
	panose-1:2 11 6 0 7 2 5 8 2 4;}
@font-face
	{font-family:"\@MS PGothic";}
@font-face
	{font-family:"MV Boli";
	panose-1:2 0 5 0 3 2 0 9 0 0;}
@font-face
	{font-family:"Myanmar Text";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Nirmala UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Nirmala UI Semilight";
	panose-1:2 11 4 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe MDL2 Assets";
	panose-1:5 10 1 2 1 1 1 1 1 1;}
@font-face
	{font-family:"Segoe Print";
	panose-1:2 0 6 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Segoe Script";
	panose-1:3 11 5 4 2 0 0 0 0 3;}
@font-face
	{font-family:"Segoe UI Black";
	panose-1:2 11 10 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Historic";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Semibold";
	panose-1:2 11 7 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Semilight";
	panose-1:2 11 4 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@SimSun";
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:NSimSun;
	panose-1:2 1 6 9 3 1 1 1 1 1;}
@font-face
	{font-family:"\@NSimSun";}
@font-face
	{font-family:SimSun-ExtB;
	panose-1:2 1 6 9 6 1 1 1 1 1;}
@font-face
	{font-family:"\@SimSun-ExtB";}
@font-face
	{font-family:"Sitka Small";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Text";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Subheading";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Heading";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Display";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Banner";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Trebuchet MS";
	panose-1:2 11 6 3 2 2 2 2 2 4;}
@font-face
	{font-family:Webdings;
	panose-1:5 3 1 2 1 5 9 6 7 3;}
@font-face
	{font-family:"\@Yu Gothic";
	panose-1:2 11 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Yu Gothic UI";
	panose-1:2 11 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI";}
@font-face
	{font-family:"Yu Gothic UI Semibold";
	panose-1:2 11 7 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI Semibold";}
@font-face
	{font-family:"Yu Gothic Light";
	panose-1:2 11 3 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic Light";}
@font-face
	{font-family:"Yu Gothic UI Light";
	panose-1:2 11 3 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI Light";}
@font-face
	{font-family:"Yu Gothic Medium";
	panose-1:2 11 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic Medium";}
@font-face
	{font-family:"Yu Gothic UI Semilight";
	panose-1:2 11 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI Semilight";}
@font-face
	{font-family:"HoloLens MDL2 Assets";
	panose-1:5 10 1 2 1 1 1 1 1 1;}
@font-face
	{font-family:"Agency FB";
	panose-1:2 11 5 3 2 2 2 2 2 4;}
@font-face
	{font-family:Algerian;
	panose-1:4 2 7 5 4 10 2 6 7 2;}
@font-face
	{font-family:"Book Antiqua";
	panose-1:2 4 6 2 5 3 5 3 3 4;}
@font-face
	{font-family:"Arial Narrow";
	panose-1:2 11 6 6 2 2 2 3 2 4;}
@font-face
	{font-family:"Arial Rounded MT Bold";
	panose-1:2 15 7 4 3 5 4 3 2 4;}
@font-face
	{font-family:"Baskerville Old Face";
	panose-1:2 2 6 2 8 5 5 2 3 3;}
@font-face
	{font-family:"Bauhaus 93";
	panose-1:4 3 9 5 2 11 2 2 12 2;}
@font-face
	{font-family:"Bell MT";
	panose-1:2 2 5 3 6 3 5 2 3 3;}
@font-face
	{font-family:"Bernard MT Condensed";
	panose-1:2 5 8 6 6 9 5 2 4 4;}
@font-face
	{font-family:"Bodoni MT";
	panose-1:2 7 6 3 8 6 6 2 2 3;}
@font-face
	{font-family:"Bodoni MT Black";
	panose-1:2 7 10 3 8 6 6 2 2 3;}
@font-face
	{font-family:"Bodoni MT Condensed";
	panose-1:2 7 6 6 8 6 6 2 2 3;}
@font-face
	{font-family:"Bodoni MT Poster Compressed";
	panose-1:2 7 7 6 8 6 1 5 2 4;}
@font-face
	{font-family:"Bookman Old Style";
	panose-1:2 5 6 4 5 5 5 2 2 4;}
@font-face
	{font-family:"Bradley Hand ITC";
	panose-1:3 7 4 2 5 3 2 3 2 3;}
@font-face
	{font-family:"Britannic Bold";
	panose-1:2 11 9 3 6 7 3 2 2 4;}
@font-face
	{font-family:"Berlin Sans FB";
	panose-1:2 14 6 2 2 5 2 2 3 6;}
@font-face
	{font-family:"Berlin Sans FB Demi";
	panose-1:2 14 8 2 2 5 2 2 3 6;}
@font-face
	{font-family:Broadway;
	panose-1:4 4 9 5 8 11 2 2 5 2;}
@font-face
	{font-family:"Brush Script MT";
	panose-1:3 6 8 2 4 4 6 7 3 4;}
@font-face
	{font-family:"Bookshelf Symbol 7";
	panose-1:5 1 1 1 1 1 1 1 1 1;}
@font-face
	{font-family:"Californian FB";
	panose-1:2 7 4 3 6 8 11 3 2 4;}
@font-face
	{font-family:"Calisto MT";
	panose-1:2 4 6 3 5 5 5 3 3 4;}
@font-face
	{font-family:Castellar;
	panose-1:2 10 4 2 6 4 6 1 3 1;}
@font-face
	{font-family:"Century Schoolbook";
	panose-1:2 4 6 4 5 5 5 2 3 4;}
@font-face
	{font-family:Centaur;
	panose-1:2 3 5 4 5 2 5 2 3 4;}
@font-face
	{font-family:Chiller;
	panose-1:4 2 4 4 3 16 7 2 6 2;}
@font-face
	{font-family:"Colonna MT";
	panose-1:4 2 8 5 6 2 2 3 2 3;}
@font-face
	{font-family:"Cooper Black";
	panose-1:2 8 9 4 4 3 11 2 4 4;}
@font-face
	{font-family:"Copperplate Gothic Bold";
	panose-1:2 14 7 5 2 2 6 2 4 4;}
@font-face
	{font-family:"Copperplate Gothic Light";
	panose-1:2 14 5 7 2 2 6 2 4 4;}
@font-face
	{font-family:"Curlz MT";
	panose-1:4 4 4 4 5 7 2 2 2 2;}
@font-face
	{font-family:Dubai;
	panose-1:2 11 5 3 3 4 3 3 2 4;}
@font-face
	{font-family:"Dubai Light";
	panose-1:2 11 3 3 3 4 3 3 2 4;}
@font-face
	{font-family:"Dubai Medium";
	panose-1:2 11 6 3 3 4 3 3 2 4;}
@font-face
	{font-family:Elephant;
	panose-1:2 2 9 4 9 5 5 2 3 3;}
@font-face
	{font-family:"Engravers MT";
	panose-1:2 9 7 7 8 5 5 2 3 4;}
@font-face
	{font-family:"Eras Bold ITC";
	panose-1:2 11 9 7 3 5 4 2 2 4;}
@font-face
	{font-family:"Eras Demi ITC";
	panose-1:2 11 8 5 3 5 4 2 8 4;}
@font-face
	{font-family:"Eras Light ITC";
	panose-1:2 11 4 2 3 5 4 2 8 4;}
@font-face
	{font-family:"Eras Medium ITC";
	panose-1:2 11 6 2 3 5 4 2 8 4;}
@font-face
	{font-family:"Felix Titling";
	panose-1:4 6 5 5 6 2 2 2 10 4;}
@font-face
	{font-family:Forte;
	panose-1:3 6 9 2 4 5 2 7 2 3;}
@font-face
	{font-family:"Franklin Gothic Book";
	panose-1:2 11 5 3 2 1 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Demi";
	panose-1:2 11 7 3 2 1 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Demi Cond";
	panose-1:2 11 7 6 3 4 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Heavy";
	panose-1:2 11 9 3 2 1 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Medium Cond";
	panose-1:2 11 6 6 3 4 2 2 2 4;}
@font-face
	{font-family:"Freestyle Script";
	panose-1:3 8 4 2 3 2 5 11 4 4;}
@font-face
	{font-family:"French Script MT";
	panose-1:3 2 4 2 4 6 7 4 6 5;}
@font-face
	{font-family:"Footlight MT Light";
	panose-1:2 4 6 2 6 3 10 2 3 4;}
@font-face
	{font-family:Garamond;
	panose-1:2 2 4 4 3 3 1 1 8 3;}
@font-face
	{font-family:Gigi;
	panose-1:4 4 5 4 6 16 7 2 13 2;}
@font-face
	{font-family:"Gill Sans MT";
	panose-1:2 11 5 2 2 1 4 2 2 3;}
@font-face
	{font-family:"Gill Sans MT Condensed";
	panose-1:2 11 5 6 2 1 4 2 2 3;}
@font-face
	{font-family:"Gill Sans Ultra Bold Condensed";
	panose-1:2 11 10 6 2 1 4 2 2 3;}
@font-face
	{font-family:"Gill Sans Ultra Bold";
	panose-1:2 11 10 2 2 1 4 2 2 3;}
@font-face
	{font-family:"Gloucester MT Extra Condensed";
	panose-1:2 3 8 8 2 6 1 1 1 1;}
@font-face
	{font-family:"Gill Sans MT Ext Condensed Bold";
	panose-1:2 11 9 2 2 1 4 2 2 3;}
@font-face
	{font-family:"Century Gothic";
	panose-1:2 11 5 2 2 2 2 2 2 4;}
@font-face
	{font-family:"Goudy Old Style";
	panose-1:2 2 5 2 5 3 5 2 3 3;}
@font-face
	{font-family:"Goudy Stout";
	panose-1:2 2 9 4 7 3 11 2 4 1;}
@font-face
	{font-family:"Harlow Solid Italic";
	panose-1:4 3 6 4 2 15 2 2 13 2;}
@font-face
	{font-family:Harrington;
	panose-1:4 4 5 5 5 10 2 2 7 2;}
@font-face
	{font-family:Haettenschweiler;
	panose-1:2 11 7 6 4 9 2 6 2 4;}
@font-face
	{font-family:"High Tower Text";
	panose-1:2 4 5 2 5 5 6 3 3 3;}
@font-face
	{font-family:"Imprint MT Shadow";
	panose-1:4 2 6 5 6 3 3 3 2 2;}
@font-face
	{font-family:"Informal Roman";
	panose-1:3 6 4 2 3 4 6 11 2 4;}
@font-face
	{font-family:"Blackadder ITC";
	panose-1:4 2 5 5 5 16 7 2 13 2;}
@font-face
	{font-family:"Edwardian Script ITC";
	panose-1:3 3 3 2 4 7 7 13 8 4;}
@font-face
	{font-family:"Kristen ITC";
	panose-1:3 5 5 2 4 2 2 3 2 2;}
@font-face
	{font-family:Jokerman;
	panose-1:4 9 6 5 6 13 6 2 7 2;}
@font-face
	{font-family:"Juice ITC";
	panose-1:4 4 4 3 4 10 2 2 2 2;}
@font-face
	{font-family:"Kunstler Script";
	panose-1:3 3 4 2 2 6 7 13 13 6;}
@font-face
	{font-family:"Wide Latin";
	panose-1:2 10 10 7 5 5 5 2 4 4;}
@font-face
	{font-family:"Lucida Bright";
	panose-1:2 4 6 2 5 5 5 2 3 4;}
@font-face
	{font-family:"Lucida Calligraphy";
	panose-1:3 1 1 1 1 1 1 1 1 1;}
@font-face
	{font-family:"Lucida Fax";
	panose-1:2 6 6 2 5 5 5 2 2 4;}
@font-face
	{font-family:"Lucida Handwriting";
	panose-1:3 1 1 1 1 1 1 1 1 1;}
@font-face
	{font-family:"Lucida Sans";
	panose-1:2 11 6 2 3 5 4 2 2 4;}
@font-face
	{font-family:"Lucida Sans Typewriter";
	panose-1:2 11 5 9 3 5 4 3 2 4;}
@font-face
	{font-family:Magneto;
	panose-1:4 3 8 5 5 8 2 2 13 2;}
@font-face
	{font-family:"Maiandra GD";
	panose-1:2 14 5 2 3 3 8 2 2 4;}
@font-face
	{font-family:"Matura MT Script Capitals";
	panose-1:3 2 8 2 6 6 2 7 2 2;}
@font-face
	{font-family:Mistral;
	panose-1:3 9 7 2 3 4 7 2 4 3;}
@font-face
	{font-family:"Modern No\. 20";
	panose-1:2 7 7 4 7 5 5 2 3 3;}
@font-face
	{font-family:"Monotype Corsiva";
	panose-1:3 1 1 1 1 2 1 1 1 1;}
@font-face
	{font-family:"Niagara Engraved";
	panose-1:4 2 5 2 7 7 3 3 2 2;}
@font-face
	{font-family:"Niagara Solid";
	panose-1:4 2 5 2 7 7 2 2 2 2;}
@font-face
	{font-family:"OCR A Extended";
	panose-1:2 1 5 9 2 1 2 1 3 3;}
@font-face
	{font-family:"Old English Text MT";
	panose-1:3 4 9 2 4 5 8 3 8 6;}
@font-face
	{font-family:Onyx;
	panose-1:4 5 6 2 8 7 2 2 2 3;}
@font-face
	{font-family:"MS Outlook";
	panose-1:5 1 1 0 1 0 0 0 0 0;}
@font-face
	{font-family:"Palace Script MT";
	panose-1:3 3 3 2 2 6 7 12 11 5;}
@font-face
	{font-family:Papyrus;
	panose-1:3 7 5 2 6 5 2 3 2 5;}
@font-face
	{font-family:Parchment;
	panose-1:3 4 6 2 4 7 8 4 8 4;}
@font-face
	{font-family:Perpetua;
	panose-1:2 2 5 2 6 4 1 2 3 3;}
@font-face
	{font-family:"Perpetua Titling MT";
	panose-1:2 2 5 2 6 5 5 2 8 4;}
@font-face
	{font-family:Playbill;
	panose-1:4 5 6 3 10 6 2 2 2 2;}
@font-face
	{font-family:"Poor Richard";
	panose-1:2 8 5 2 5 5 5 2 7 2;}
@font-face
	{font-family:Pristina;
	panose-1:3 6 4 2 4 4 6 8 2 4;}
@font-face
	{font-family:"Rage Italic";
	panose-1:3 7 5 2 4 5 7 7 3 4;}
@font-face
	{font-family:Ravie;
	panose-1:4 4 8 5 5 8 9 2 6 2;}
@font-face
	{font-family:"MS Reference Sans Serif";
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"MS Reference Specialty";
	panose-1:5 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Rockwell Condensed";
	panose-1:2 6 6 3 5 4 5 2 1 4;}
@font-face
	{font-family:Rockwell;
	panose-1:2 6 6 3 2 2 5 2 4 3;}
@font-face
	{font-family:"Rockwell Extra Bold";
	panose-1:2 6 9 3 4 5 5 2 4 3;}
@font-face
	{font-family:"Script MT Bold";
	panose-1:3 4 6 2 4 6 7 8 9 4;}
@font-face
	{font-family:"Showcard Gothic";
	panose-1:4 2 9 4 2 1 2 2 6 4;}
@font-face
	{font-family:"Snap ITC";
	panose-1:4 4 10 7 6 10 2 2 2 2;}
@font-face
	{font-family:Stencil;
	panose-1:4 4 9 5 13 8 2 2 4 4;}
@font-face
	{font-family:"Tw Cen MT";
	panose-1:2 11 6 2 2 1 4 2 6 3;}
@font-face
	{font-family:"Tw Cen MT Condensed";
	panose-1:2 11 6 6 2 1 4 2 2 3;}
@font-face
	{font-family:"Tw Cen MT Condensed Extra Bold";
	panose-1:2 11 8 3 2 2 2 2 2 4;}
@font-face
	{font-family:"Tempus Sans ITC";
	panose-1:4 2 4 4 3 13 7 2 2 2;}
@font-face
	{font-family:"Viner Hand ITC";
	panose-1:3 7 5 2 3 5 2 2 2 3;}
@font-face
	{font-family:Vivaldi;
	panose-1:3 2 6 2 5 5 6 9 8 4;}
@font-face
	{font-family:"Vladimir Script";
	panose-1:3 5 4 2 4 4 7 7 3 5;}
@font-face
	{font-family:"Wingdings 2";
	panose-1:5 2 1 2 1 5 7 7 7 7;}
@font-face
	{font-family:"Wingdings 3";
	panose-1:5 4 1 2 1 8 7 7 7 7;}
@font-face
	{font-family:AngsanaUPC;}
@font-face
	{font-family:CordiaUPC;}
@font-face
	{font-family:Abadi;}
@font-face
	{font-family:"Abadi Extra Light";}
@font-face
	{font-family:Aharoni;}
@font-face
	{font-family:Aldhabi;}
@font-face
	{font-family:Aparajita;}
@font-face
	{font-family:"Arabic Typesetting";}
@font-face
	{font-family:"Arial Nova";}
@font-face
	{font-family:"Arial Nova Cond";}
@font-face
	{font-family:"Arial Nova Cond Light";}
@font-face
	{font-family:"Arial Nova Light";}
@font-face
	{font-family:"Avenir Next LT Pro";}
@font-face
	{font-family:"Avenir Next LT Pro Light";}
@font-face
	{font-family:BatangChe;}
@font-face
	{font-family:Bembo;}
@font-face
	{font-family:Biome;}
@font-face
	{font-family:"Biome Light";}
@font-face
	{font-family:"Browallia New";}
@font-face
	{font-family:BrowalliaUPC;}
@font-face
	{font-family:Cavolini;}
@font-face
	{font-family:Dante;}
@font-face
	{font-family:DaunPenh;}
@font-face
	{font-family:David;}
@font-face
	{font-family:Daytona;}
@font-face
	{font-family:"Daytona Condensed";}
@font-face
	{font-family:"Daytona Condensed Light";}
@font-face
	{font-family:"Daytona Light";}
@font-face
	{font-family:"DengXian Light";}
@font-face
	{font-family:DilleniaUPC;}
@font-face
	{font-family:DokChampa;}
@font-face
	{font-family:DotumChe;}
@font-face
	{font-family:"Elephant Pro";}
@font-face
	{font-family:EucrosiaUPC;}
@font-face
	{font-family:Euphemia;}
@font-face
	{font-family:FangSong;}
@font-face
	{font-family:FrankRuehl;}
@font-face
	{font-family:FreesiaUPC;}
@font-face
	{font-family:"Georgia Pro";}
@font-face
	{font-family:"Georgia Pro Black";}
@font-face
	{font-family:"Georgia Pro Cond";}
@font-face
	{font-family:"Georgia Pro Cond Black";}
@font-face
	{font-family:"Georgia Pro Cond Light";}
@font-face
	{font-family:"Georgia Pro Cond Semibold";}
@font-face
	{font-family:"Georgia Pro Light";}
@font-face
	{font-family:"Georgia Pro Semibold";}
@font-face
	{font-family:"Gill Sans Nova";}
@font-face
	{font-family:"Gill Sans Nova Cond";}
@font-face
	{font-family:"Gill Sans Nova Cond Lt";}
@font-face
	{font-family:"Gill Sans Nova Cond Ultra Bold";}
@font-face
	{font-family:"Gill Sans Nova Cond XBd";}
@font-face
	{font-family:"Gill Sans Nova Light";}
@font-face
	{font-family:"Gill Sans Nova Ultra Bold";}
@font-face
	{font-family:Gisha;}
@font-face
	{font-family:Grotesque;}
@font-face
	{font-family:"Grotesque Light";}
@font-face
	{font-family:GulimChe;}
@font-face
	{font-family:Gungsuh;}
@font-face
	{font-family:GungsuhChe;}
@font-face
	{font-family:"Hadassah Friedlaender";}
@font-face
	{font-family:HGGothicE;}
@font-face
	{font-family:HGMaruGothicMPRO;}
@font-face
	{font-family:HGMinchoE;}
@font-face
	{font-family:HGPGothicE;}
@font-face
	{font-family:HGPMinchoE;}
@font-face
	{font-family:HGPSoeiKakugothicUB;}
@font-face
	{font-family:HGSGothicE;}
@font-face
	{font-family:HGSMinchoE;}
@font-face
	{font-family:HGSoeiKakugothicUB;}
@font-face
	{font-family:HGSSoeiKakugothicUB;}
@font-face
	{font-family:IrisUPC;}
@font-face
	{font-family:"Iskoola Pota";}
@font-face
	{font-family:JasmineUPC;}
@font-face
	{font-family:KaiTi;}
@font-face
	{font-family:Kalinga;}
@font-face
	{font-family:Kartika;}
@font-face
	{font-family:"Khmer UI";}
@font-face
	{font-family:Kigelia;}
@font-face
	{font-family:"Kigelia Arabic";}
@font-face
	{font-family:"Kigelia Arabic Light";}
@font-face
	{font-family:"Kigelia Light";}
@font-face
	{font-family:KodchiangUPC;}
@font-face
	{font-family:Kokila;}
@font-face
	{font-family:"Lao UI";}
@font-face
	{font-family:Leelawadee;}
@font-face
	{font-family:"Levenim MT";}
@font-face
	{font-family:LilyUPC;}
@font-face
	{font-family:"Mangal Pro";}
@font-face
	{font-family:Meiryo;}
@font-face
	{font-family:"Meiryo UI";}
@font-face
	{font-family:"Microsoft GothicNeo";}
@font-face
	{font-family:"Microsoft GothicNeo Light";}
@font-face
	{font-family:"Microsoft Uighur";}
@font-face
	{font-family:MingLiU_HKSCS;}
@font-face
	{font-family:Miriam;}
@font-face
	{font-family:"Miriam Fixed";}
@font-face
	{font-family:"Modern Love";}
@font-face
	{font-family:"Modern Love Caps";}
@font-face
	{font-family:"Modern Love Grunge";}
@font-face
	{font-family:MoolBoran;}
@font-face
	{font-family:"MS PMincho";}
@font-face
	{font-family:"MT Extra";}
@font-face
	{font-family:Narkisim;}
@font-face
	{font-family:"Neue Haas Grotesk Text Pro";}
@font-face
	{font-family:"News Gothic MT";}
@font-face
	{font-family:Nyala;}
@font-face
	{font-family:OCRB;}
@font-face
	{font-family:"Plantagenet Cherokee";}
@font-face
	{font-family:Posterama;}
@font-face
	{font-family:"Quire Sans";}
@font-face
	{font-family:"Quire Sans Light";}
@font-face
	{font-family:"Quire Sans Pro Light";}
@font-face
	{font-family:"Rockwell Light";}
@font-face
	{font-family:"Rockwell Nova";}
@font-face
	{font-family:"Rockwell Nova Cond";}
@font-face
	{font-family:"Rockwell Nova Cond Light";}
@font-face
	{font-family:"Rockwell Nova Extra Bold";}
@font-face
	{font-family:"Rockwell Nova Light";}
@font-face
	{font-family:Rod;}
@font-face
	{font-family:"Sabon Next LT";}
@font-face
	{font-family:"Sagona Book";}
@font-face
	{font-family:"Sagona ExtraLight";}
@font-face
	{font-family:"Sakkal Majalla";}
@font-face
	{font-family:"Sanskrit Text";}
@font-face
	{font-family:Selawik;}
@font-face
	{font-family:"Selawik Light";}
@font-face
	{font-family:"Selawik Semibold";}
@font-face
	{font-family:"Shonar Bangla";}
@font-face
	{font-family:"Simplified Arabic";}
@font-face
	{font-family:"Simplified Arabic Fixed";}
@font-face
	{font-family:"Sitka Banner Semibold";}
@font-face
	{font-family:"Sitka Display Semibold";}
@font-face
	{font-family:"Sitka Heading Semibold";}
@font-face
	{font-family:"Sitka Small Semibold";}
@font-face
	{font-family:"Sitka Subheading Semibold";}
@font-face
	{font-family:"Sitka Text Semibold";}
@font-face
	{font-family:"Source Sans Pro";}
@font-face
	{font-family:"Source Sans Pro Black";}
@font-face
	{font-family:"Source Sans Pro ExtraLight";}
@font-face
	{font-family:"Source Sans Pro Light";}
@font-face
	{font-family:"Source Sans Pro SemiBold";}
@font-face
	{font-family:"Speak Pro";}
@font-face
	{font-family:"Speak Pro Light";}
@font-face
	{font-family:STCaiyun;}
@font-face
	{font-family:STFangsong;}
@font-face
	{font-family:STHupo;}
@font-face
	{font-family:STKaiti;}
@font-face
	{font-family:STXihei;}
@font-face
	{font-family:STXingkai;}
@font-face
	{font-family:STXinwei;}
@font-face
	{font-family:STZhongsong;}
@font-face
	{font-family:"TH SarabunPSK";}
@font-face
	{font-family:"The Hand";}
@font-face
	{font-family:"The Hand Black";}
@font-face
	{font-family:"The Hand Extrablack";}
@font-face
	{font-family:"The Hand Light";}
@font-face
	{font-family:"The Serif Hand";}
@font-face
	{font-family:"The Serif Hand Black";}
@font-face
	{font-family:"The Serif Hand Extrablack";}
@font-face
	{font-family:"The Serif Hand Light";}
@font-face
	{font-family:"Tisa Offc Serif Pro";}
@font-face
	{font-family:"Tisa Offc Serif Pro Thin";}
@font-face
	{font-family:"Trade Gothic Next";}
@font-face
	{font-family:"Trade Gothic Next Cond";}
@font-face
	{font-family:"Trade Gothic Next Cond Hv";}
@font-face
	{font-family:"Trade Gothic Next Heavy";}
@font-face
	{font-family:"Trade Gothic Next Light";}
@font-face
	{font-family:"Traditional Arabic";}
@font-face
	{font-family:"UD Digi Kyokasho N-B";}
@font-face
	{font-family:"UD Digi Kyokasho N-R";}
@font-face
	{font-family:"UD Digi Kyokasho NK-B";}
@font-face
	{font-family:"UD Digi Kyokasho NK-R";}
@font-face
	{font-family:"UD Digi Kyokasho NP-B";}
@font-face
	{font-family:"UD Digi Kyokasho NP-R";}
@font-face
	{font-family:Univers;}
@font-face
	{font-family:"Univers Condensed";}
@font-face
	{font-family:"Univers Condensed Light";}
@font-face
	{font-family:"Univers Light";}
@font-face
	{font-family:"Urdu Typesetting";}
@font-face
	{font-family:Utsaah;}
@font-face
	{font-family:Vani;}
@font-face
	{font-family:"Verdana Pro";}
@font-face
	{font-family:"Verdana Pro Black";}
@font-face
	{font-family:"Verdana Pro Cond";}
@font-face
	{font-family:"Verdana Pro Cond Black";}
@font-face
	{font-family:"Verdana Pro Cond Light";}
@font-face
	{font-family:"Verdana Pro Cond SemiBold";}
@font-face
	{font-family:"Verdana Pro Light";}
@font-face
	{font-family:"Verdana Pro SemiBold";}
@font-face
	{font-family:Vijaya;}
@font-face
	{font-family:"Walbaum Display";}
@font-face
	{font-family:"Walbaum Display Heavy";}
@font-face
	{font-family:"Walbaum Display Light";}
@font-face
	{font-family:"Walbaum Display SemiBold";}
@font-face
	{font-family:"Walbaum Heading";}
@font-face
	{font-family:"Walbaum Text";}
@font-face
	{font-family:"Yu Mincho";}
@font-face
	{font-family:"Yu Mincho Demibold";}
@font-face
	{font-family:"Yu Mincho Light";}
@font-face
	{font-family:"TimesNewRoman\,Italic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:TimesNewRoman;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Arial\,Italic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:TimesNewRomanPSMT;}
@font-face
	{font-family:"Times New Roman Bold";
	panose-1:2 2 8 3 7 5 5 2 3 4;}
@font-face
	{font-family:PraxisCom-Regular;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Arial Bold";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:EUAlbertina;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Times;
	panose-1:2 2 6 3 5 4 5 2 3 4;}
@font-face
	{font-family:"\@TimesNewRoman\,Italic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Arial\,Italic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MS Mincho";
	panose-1:2 2 6 9 4 2 5 8 3 4;}
@font-face
	{font-family:"\@Batang";
	panose-1:2 3 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:"\@BatangChe";}
@font-face
	{font-family:"\@Gungsuh";}
@font-face
	{font-family:"\@GungsuhChe";}
@font-face
	{font-family:"\@DengXian Light";}
@font-face
	{font-family:"\@Gulim";
	panose-1:2 11 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:"\@GulimChe";}
@font-face
	{font-family:"\@Dotum";
	panose-1:2 11 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:"\@DotumChe";}
@font-face
	{font-family:"\@Meiryo";}
@font-face
	{font-family:"\@Meiryo UI";}
@font-face
	{font-family:"\@MingLiU";
	panose-1:2 1 6 9 0 1 1 1 1 1;}
@font-face
	{font-family:"\@PMingLiU";
	panose-1:2 1 6 1 0 1 1 1 1 1;}
@font-face
	{font-family:"\@MingLiU_HKSCS";}
@font-face
	{font-family:"\@MS PMincho";}
@font-face
	{font-family:"\@STXingkai";}
@font-face
	{font-family:"\@STZhongsong";}
@font-face
	{font-family:"\@Yu Mincho";}
@font-face
	{font-family:"\@Arial Unicode MS";
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:Times-Roman;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:CourierNewPSMT;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"SAS Monospace";}
@font-face
	{font-family:"Bookshelf Symbol 3";}
@font-face
	{font-family:Goudy;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Garamond-Italic;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Arial\,Bold";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:DIN-Bold;}
@font-face
	{font-family:"CG Times \(W1\)";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"HelveticaNeue Condensed";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@HGMaruGothicMPRO";}
@font-face
	{font-family:CourierStd;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Roman;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:EFPPNA+TimesNewRoman;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@TimesNewRoman";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"TimesNewRomanPSMT\,Times New Rom";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"TimesNewRoman\,Times New Roman";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"TimesNewRoman\,Bold";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"CG Times";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Minion;}
@font-face
	{font-family:CourierNew;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Noto Sans Symbols";}
@font-face
	{font-family:LZLLQG+TimesNewRoman;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:TimesNewRomanPS;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:HelveticaNeueLTStd-Cn;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Wingdings-Regular;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@HelveticaNeueLTStd-Cn";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Wingdings-Regular";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Geneva;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"TimesNewRoman\,BoldItalic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:ArialMT;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
h1
	{mso-style-link:"Heading 1 Char";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:17.85pt;
	text-indent:-17.85pt;
	line-height:13.0pt;
	font-size:13.0pt;
	font-family:"Times New Roman",serif;
	text-transform:uppercase;
	font-weight:bold;}
h2
	{mso-style-link:"Heading 2 Char";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Helvetica",sans-serif;
	font-weight:bold;
	font-style:italic;}
h3
	{mso-style-link:"Heading 3 Char";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:4.0pt;
	margin-left:0in;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
h4
	{mso-style-link:"Heading 4 Char";
	margin:0in;
	text-align:justify;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
h5
	{mso-style-link:"Heading 5 Char";
	margin:0in;
	text-align:justify;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:normal;}
h6
	{mso-style-link:"Heading 6 Char";
	margin:0in;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:normal;
	font-style:italic;}
p.MsoHeading7, li.MsoHeading7, div.MsoHeading7
	{mso-style-link:"Heading 7 Char";
	margin:0in;
	text-align:justify;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-style:italic;}
p.MsoHeading8, li.MsoHeading8, div.MsoHeading8
	{mso-style-link:"Heading 8 Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.35pt;
	text-align:justify;
	text-indent:-28.35pt;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;
	font-style:italic;}
p.MsoHeading9, li.MsoHeading9, div.MsoHeading9
	{mso-style-link:"Heading 9 Char";
	margin:0in;
	text-align:justify;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;
	font-style:italic;}
p.MsoToc1, li.MsoToc1, div.MsoToc1
	{margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc3, li.MsoToc3, div.MsoToc3
	{margin-top:3.0pt;
	margin-right:.25in;
	margin-bottom:0in;
	margin-left:84.0pt;
	text-indent:-48.0pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoCommentText, li.MsoCommentText, div.MsoCommentText
	{mso-style-link:"Comment Text Char";
	margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.MsoHeader, li.MsoHeader, div.MsoHeader
	{mso-style-link:"Header Char";
	margin:0in;
	font-size:10.0pt;
	font-family:"Helvetica",sans-serif;}
p.MsoFooter, li.MsoFooter, div.MsoFooter
	{mso-style-link:"Footer Char";
	margin:0in;
	font-size:8.0pt;
	font-family:"Helvetica",sans-serif;}
p.MsoEndnoteText, li.MsoEndnoteText, div.MsoEndnoteText
	{mso-style-link:"Endnote Text Char";
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyText, li.MsoBodyText, div.MsoBodyText
	{mso-style-link:"Body Text Char";
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:green;
	font-style:italic;}
p.MsoBodyTextIndent, li.MsoBodyTextIndent, div.MsoBodyTextIndent
	{mso-style-link:"Body Text Indent Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	text-align:justify;
	text-autospace:none;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyText2, li.MsoBodyText2, div.MsoBodyText2
	{mso-style-link:"Body Text 2 Char";
	margin:0in;
	text-align:justify;
	line-height:13.0pt;
	text-autospace:none;
	border:none;
	padding:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:blue;
	font-weight:bold;
	text-decoration:underline;}
p.MsoBodyText3, li.MsoBodyText3, div.MsoBodyText3
	{mso-style-link:"Body Text 3 Char";
	margin:0in;
	text-align:justify;
	text-autospace:none;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:blue;}
p.MsoBodyTextIndent2, li.MsoBodyTextIndent2, div.MsoBodyTextIndent2
	{mso-style-link:"Body Text Indent 2 Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.7pt;
	text-align:justify;
	line-height:13.0pt;
	text-autospace:none;
	border:none;
	padding:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:blue;
	font-weight:bold;}
p.MsoBodyTextIndent3, li.MsoBodyTextIndent3, div.MsoBodyTextIndent3
	{mso-style-link:"Body Text Indent 3 Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:31.65pt;
	text-align:justify;
	line-height:13.0pt;
	text-autospace:none;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
a:link, span.MsoHyperlink
	{color:blue;
	text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
	{color:purple;
	text-decoration:underline;}
p.MsoDocumentMap, li.MsoDocumentMap, div.MsoDocumentMap
	{mso-style-link:"Document Map Char";
	margin:0in;
	line-height:13.0pt;
	background:navy;
	font-size:11.0pt;
	font-family:"Tahoma",sans-serif;}
p
	{margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoCommentSubject, li.MsoCommentSubject, div.MsoCommentSubject
	{mso-style-link:"Comment Subject Char";
	margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.MsoAcetate, li.MsoAcetate, div.MsoAcetate
	{mso-style-link:"Balloon Text Char";
	margin:0in;
	line-height:13.0pt;
	font-size:8.0pt;
	font-family:"Tahoma",sans-serif;}
p.MsoNoSpacing, li.MsoNoSpacing, div.MsoNoSpacing
	{margin:0in;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoRMPane, li.MsoRMPane, div.MsoRMPane
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListParagraph, li.MsoListParagraph, div.MsoListParagraph
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListParagraphCxSpFirst, li.MsoListParagraphCxSpFirst, div.MsoListParagraphCxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListParagraphCxSpMiddle, li.MsoListParagraphCxSpMiddle, div.MsoListParagraphCxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListParagraphCxSpLast, li.MsoListParagraphCxSpLast, div.MsoListParagraphCxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.EMEAEnBodyText, li.EMEAEnBodyText, div.EMEAEnBodyText
	{mso-style-name:"EMEA En Body Text";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	text-align:justify;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.AHeader1, li.AHeader1, div.AHeader1
	{mso-style-name:"AHeader 1";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:14.2pt;
	text-indent:-14.2pt;
	font-size:12.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
p.AHeader2, li.AHeader2, div.AHeader2
	{mso-style-name:"AHeader 2";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:35.45pt;
	text-indent:-21.25pt;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
p.AHeader3, li.AHeader3, div.AHeader3
	{mso-style-name:"AHeader 3";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:63.8pt;
	text-indent:-28.35pt;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
p.AHeader2abc, li.AHeader2abc, div.AHeader2abc
	{mso-style-name:"AHeader 2 abc";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:63.8pt;
	text-align:justify;
	text-indent:-28.35pt;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;}
p.AHeader3abc, li.AHeader3abc, div.AHeader3abc
	{mso-style-name:"AHeader 3 abc";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:85.05pt;
	text-align:justify;
	text-indent:-21.25pt;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;}
p.Default, li.Default, div.Default
	{mso-style-name:Default;
	margin:0in;
	text-autospace:none;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.BodytextAgency, li.BodytextAgency, div.BodytextAgency
	{mso-style-name:"Body text \(Agency\)";
	mso-style-link:"Body text \(Agency\) Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:7.0pt;
	margin-left:0in;
	line-height:14.0pt;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
span.BodytextAgencyChar
	{mso-style-name:"Body text \(Agency\) Char";
	mso-style-link:"Body text \(Agency\)";
	font-family:"Verdana",sans-serif;}
p.No-numheading3Agency, li.No-numheading3Agency, div.No-numheading3Agency
	{mso-style-name:"No-num heading 3 \(Agency\)";
	mso-style-link:"No-num heading 3 \(Agency\) Char";
	margin-top:14.0pt;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
span.No-numheading3AgencyChar
	{mso-style-name:"No-num heading 3 \(Agency\) Char";
	mso-style-link:"No-num heading 3 \(Agency\)";
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
span.CommentSubjectChar
	{mso-style-name:"Comment Subject Char";
	mso-style-link:"Comment Subject";
	font-weight:bold;}
p.NormalAgency, li.NormalAgency, div.NormalAgency
	{mso-style-name:"Normal \(Agency\)";
	mso-style-link:"Normal \(Agency\) Char";
	margin:0in;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
span.NormalAgencyChar
	{mso-style-name:"Normal \(Agency\) Char";
	mso-style-link:"Normal \(Agency\)";
	font-family:"Verdana",sans-serif;}
p.TableLeft, li.TableLeft, div.TableLeft
	{mso-style-name:"Table Left";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.SOPLevel1, li.SOPLevel1, div.SOPLevel1
	{mso-style-name:"SOP Level 1";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:9.0pt;
	margin-left:.25in;
	text-indent:-.25in;
	font-size:12.0pt;
	font-family:"Calibri",sans-serif;
	font-weight:bold;
	text-decoration:underline;}
p.SOPLevel2, li.SOPLevel2, div.SOPLevel2
	{mso-style-name:"SOP Level 2";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:9.0pt;
	margin-left:42.55pt;
	text-indent:-28.35pt;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.SOPLevel3, li.SOPLevel3, div.SOPLevel3
	{mso-style-name:"SOP Level 3";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:9.0pt;
	margin-left:56.7pt;
	text-indent:-35.45pt;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.SOPLevel4, li.SOPLevel4, div.SOPLevel4
	{mso-style-name:"SOP Level 4";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:9.0pt;
	margin-left:77.95pt;
	text-indent:-49.6pt;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.SOPLevel5, li.SOPLevel5, div.SOPLevel5
	{mso-style-name:"SOP Level 5";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:9.0pt;
	margin-left:99.25pt;
	text-indent:-56.7pt;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.SOPLevel6, li.SOPLevel6, div.SOPLevel6
	{mso-style-name:"SOP Level 6";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:9.0pt;
	margin-left:1.5in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.SOPLevel7, li.SOPLevel7, div.SOPLevel7
	{mso-style-name:"SOP Level 7";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:9.0pt;
	margin-left:1.75in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.SOPLevel8, li.SOPLevel8, div.SOPLevel8
	{mso-style-name:"SOP Level 8";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:9.0pt;
	margin-left:2.0in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.SOPLevel9, li.SOPLevel9, div.SOPLevel9
	{mso-style-name:"SOP Level 9";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:9.0pt;
	margin-left:2.25in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.TitleA, li.TitleA, div.TitleA
	{mso-style-name:"Title A";
	margin:0in;
	text-align:center;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
span.Heading6Char
	{mso-style-name:"Heading 6 Char";
	mso-style-link:"Heading 6";
	font-style:italic;}
span.CommentTextChar
	{mso-style-name:"Comment Text Char";
	mso-style-link:"Comment Text";}
span.EndnoteTextChar
	{mso-style-name:"Endnote Text Char";
	mso-style-link:"Endnote Text";
	font-family:"Malgun Gothic",sans-serif;}
p.Normal11pt, li.Normal11pt, div.Normal11pt
	{mso-style-name:"Normal + 11 pt\,Bold";
	margin:0in;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.mdTblEntry, li.mdTblEntry, div.mdTblEntry
	{mso-style-name:"md_Tbl Entry";
	margin:0in;
	line-height:12.95pt;
	page-break-after:avoid;
	punctuation-wrap:simple;
	text-autospace:none;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.xnormal11pt, li.xnormal11pt, div.xnormal11pt
	{mso-style-name:x_normal11pt;
	margin:0in;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
span.Heading1Char
	{mso-style-name:"Heading 1 Char";
	mso-style-link:"Heading 1";
	text-transform:uppercase;
	font-weight:bold;}
span.Heading2Char
	{mso-style-name:"Heading 2 Char";
	mso-style-link:"Heading 2";
	font-family:"Helvetica",sans-serif;
	font-weight:bold;
	font-style:italic;}
span.Heading3Char
	{mso-style-name:"Heading 3 Char";
	mso-style-link:"Heading 3";
	font-weight:bold;}
span.Heading4Char
	{mso-style-name:"Heading 4 Char";
	mso-style-link:"Heading 4";
	font-weight:bold;}
span.Heading5Char
	{mso-style-name:"Heading 5 Char";
	mso-style-link:"Heading 5";}
span.Heading7Char
	{mso-style-name:"Heading 7 Char";
	mso-style-link:"Heading 7";
	font-style:italic;}
span.Heading8Char
	{mso-style-name:"Heading 8 Char";
	mso-style-link:"Heading 8";
	font-weight:bold;
	font-style:italic;}
span.Heading9Char
	{mso-style-name:"Heading 9 Char";
	mso-style-link:"Heading 9";
	font-weight:bold;
	font-style:italic;}
span.HeaderChar
	{mso-style-name:"Header Char";
	mso-style-link:Header;
	font-family:"Helvetica",sans-serif;}
span.FooterChar
	{mso-style-name:"Footer Char";
	mso-style-link:Footer;
	font-family:"Helvetica",sans-serif;}
span.BodyTextIndentChar
	{mso-style-name:"Body Text Indent Char";
	mso-style-link:"Body Text Indent";}
span.BodyText3Char
	{mso-style-name:"Body Text 3 Char";
	mso-style-link:"Body Text 3";
	color:blue;}
span.BodyTextIndent2Char
	{mso-style-name:"Body Text Indent 2 Char";
	mso-style-link:"Body Text Indent 2";
	color:blue;
	font-weight:bold;}
span.BodyTextChar
	{mso-style-name:"Body Text Char";
	mso-style-link:"Body Text";
	color:green;
	font-style:italic;}
span.BodyText2Char
	{mso-style-name:"Body Text 2 Char";
	mso-style-link:"Body Text 2";
	color:blue;
	font-weight:bold;
	text-decoration:underline;}
span.DocumentMapChar
	{mso-style-name:"Document Map Char";
	mso-style-link:"Document Map";
	font-family:"Tahoma",sans-serif;
	background:navy;}
span.BodyTextIndent3Char
	{mso-style-name:"Body Text Indent 3 Char";
	mso-style-link:"Body Text Indent 3";}
span.BalloonTextChar
	{mso-style-name:"Balloon Text Char";
	mso-style-link:"Balloon Text";
	font-family:"Tahoma",sans-serif;}
span.msoIns
	{mso-style-name:"";
	text-decoration:underline;
	color:teal;}
span.msoDel
	{mso-style-name:"";
	text-decoration:line-through;
	color:red;}
.MsoChpDefault
	{font-size:10.0pt;}
 /* Page Definitions */
 @page WordSection1
	{size:595.35pt 842.0pt;
	margin:56.9pt 70.55pt 56.9pt 70.55pt;}
div.WordSection1
	{page:WordSection1;}
 /* List Definitions */
 ol
	{margin-bottom:0in;}
ul
	{margin-bottom:0in;}
-->
</style>

</head>

<body lang=EN-US link=blue vlink=purple style='word-wrap:break-word'>

<div class=WordSection1>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>ANNEX
I</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=TitleA><span lang=EN-GB>SUMMARY OF PRODUCT CHARACTERISTICS</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>1. </span><b><span lang=EN-GB>NAME OF
THE MEDICINAL PRODUCT</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Pemetrexed
Hospira 100&nbsp;mg powder for concentrate for solution for infusion </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Pemetrexed
Hospira 500&nbsp;mg powder for concentrate for solution for infusion </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Pemetrexed
Hospira 1,000&nbsp;mg powder for concentrate for solution for infusion </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>2. QUALITATIVE AND QUANTITATIVE
COMPOSITION</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Pemetrexed
Hospira 100&nbsp;mg powder for concentrate for solution for infusion </span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Each vial
contains 100&nbsp;mg of pemetrexed (as pemetrexed disodium hemipentahydrate). </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><u><span lang=EN-GB>Excipient
with known effect</span></u></i><i><span lang=EN-GB> </span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Each vial
contains approximately 11&nbsp;mg sodium.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Pemetrexed
Hospira 500&nbsp;mg powder for concentrate for solution for infusion </span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Each vial
contains 500&nbsp;mg of pemetrexed (as pemetrexed disodium hemipentahydrate). </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><u><span lang=EN-GB>Excipient
with known effect</span></u></i><i><span lang=EN-GB> </span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Each vial
contains approximately 54&nbsp;mg sodium.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Pemetrexed
Hospira 1,000&nbsp;mg powder for concentrate for solution for infusion </span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Each vial
contains 1,000&nbsp;mg of pemetrexed (as pemetrexed disodium hemipentahydrate).
</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><u><span lang=EN-GB>Excipient
with known effect</span></u></i><i><span lang=EN-GB> </span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Each vial
contains approximately 108&nbsp;mg sodium.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>After
reconstitution (see section 6.6), each vial contains 25&nbsp;mg/ml of
pemetrexed.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>For the full
list of excipients, see section 6.1.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>3. PHARMACEUTICAL <span style='text-transform:uppercase'>form</span></span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Powder for
concentrate for solution for infusion. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>White to either
light yellow or green-yellow lyophilised powder.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB style='text-transform:uppercase'>4. Clinical particulars</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>4.1 Therapeutic indications</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Malignant
pleural mesothelioma</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Pemetrexed
Hospira in combination with cisplatin is indicated for the treatment of
chemotherapy nave patients with unresectable malignant pleural mesothelioma. </span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Non-small cell lung cancer</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Pemetrexed Hospira</span><span lang=EN-GB> in combination with
cisplatin is indicated for the first-line treatment of patients with locally
advanced or metastatic non-small cell lung cancer other than predominantly
squamous cell histology (see section 5.1). </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Pemetrexed
Hospira</span><span lang=EN-GB> is indicated as monotherapy for the maintenance
treatment of locally advanced or metastatic non-small cell lung cancer other
than predominantly squamous cell histology in patients whose disease has not
progressed immediately following platinum-based chemotherapy (see section&nbsp;5.1).
</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Pemetrexed
Hospira</span><span lang=EN-GB> is indicated as monotherapy for the second-line
treatment of patients with locally advanced or metastatic non-small cell lung
cancer other than predominantly squamous cell histology (see section 5.1).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>4.2 Posology and method of administration</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Pemetrexed
Hospira</span><span lang=EN-GB> must only be administered under the supervision
of a physician qualified in the use of anti-cancer chemotherapy.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Posology</span></u></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Pemetrexed Hospira</span></u></i><i><u><span lang=EN-GB> in
combination with cisplatin</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The recommended
dose of Pemetrexed Hospira is 500&nbsp;mg/m<sup>2</sup> of body surface area
(BSA) administered as an intravenous infusion over 10&nbsp;minutes on the first
day of each 21&#8209;day cycle. The recommended dose of cisplatin is 75&nbsp;mg/m<sup>2
</sup>BSA infused over two hours approximately 30&nbsp;minutes after completion
of the pemetrexed infusion on the first day of each 21&#8209;day cycle. <u>Patients
must receive adequate anti&#8209;emetic treatment and appropriate hydration
prior to and/or after receiving cisplatin</u> (see also cisplatin Summary of
Product Characteristics for specific dosing advice). </span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><i><u><span lang=EN-GB>Pemetrexed
Hospira </span></u></i><i><u><span lang=EN-GB>as single agent</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In patients
treated for non-small cell lung cancer after prior chemotherapy, the
recommended dose of Pemetrexed Hospira is 500&nbsp;mg/m<sup>2</sup> BSA
administered as an intravenous infusion over 10&nbsp;minutes on the first day
of each 21&#8209;day cycle. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><u><span lang=EN-GB>Pre-medication
regimen</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>To reduce the
incidence and severity of skin reactions, a corticosteroid should be given the
day prior to, on the day of, and the day after pemetrexed administration. The
corticosteroid should be equivalent to 4&nbsp;mg of dexamethasone administered
orally twice a day (see section 4.4). </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>To reduce
toxicity, patients treated with pemetrexed must also receive vitamin
supplementation (see section 4.4). Patients must take oral folic acid or a
multivitamin containing folic acid (350 to 1,000&nbsp;micrograms) on a daily
basis. At least five doses of folic acid must be taken during the seven days
preceding the first dose of pemetrexed, and dosing must continue during the full
course of therapy and for 21 days after the last dose of pemetrexed. Patients
must also receive an intramuscular injection of vitamin B<sub>12</sub>
(1,000&nbsp;micrograms) in the week preceding the first dose of pemetrexed and
once every three cycles thereafter. Subsequent vitamin B<sub>12</sub>
injections may be given on the same day as pemetrexed. </span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><i><u><span lang=EN-GB>Monitoring</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Patients
receiving pemetrexed should be monitored before each dose with a complete blood
count, including a differential white cell count (WCC) and platelet count.
Prior to each chemotherapy administration, blood chemistry tests should be
collected to evaluate renal and hepatic function. Before the start of any cycle
of chemotherapy, patients are required to have the following: absolute
neutrophil count (ANC) should be &#8805; 1,500&nbsp;cells/mm<sup>3</sup> and
platelets should be &#8805; 100,000&nbsp;cells/mm<sup>3</sup>. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Creatinine
clearance should be &#8805; 45&nbsp;ml/min. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The total bilirubin
should be &#8804; 1.5&#8209;times upper limit of normal. Alkaline phosphatase
(AP), aspartate aminotransferase (AST or SGOT), and alanine aminotransferase
(ALT or SGPT) should be &#8804; 3&#8209;times upper limit of normal. Alkaline
phosphatase, AST, and ALT &#8804; 5&#8209;times upper limit of normal is
acceptable if liver has tumour involvement. </span></p>

<p class=MsoNormal style='line-height:normal'><i><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=MsoNormal style='line-height:normal'><i><u><span lang=EN-GB>Dose adjustments</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Dose adjustments
at the start of a subsequent cycle should be based on nadir haematologic counts
or maximum non-haematologic toxicity from the preceding cycle of therapy.
Treatment may be delayed to allow sufficient time for recovery. Upon recovery,
patients should be re-treated using the guidelines in Tables 1, 2, and 3, which
are applicable for Pemetrexed Hospira used as a single agent or in combination
with cisplatin. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse;border:none'>
 <tr>
  <td width="100%" colspan=2 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><b><span lang=EN-GB>Table 1. Dose modification table
  for </span></b><b><span lang=EN-GB>Pemetrexed Hospira</span></b><b><span
  lang=EN-GB> (as single agent or in combination) and cisplatin - Haematologic toxicities</span></b></p>
  </td>
 </tr>
 <tr>
  <td width="55%" valign=top style='width:55.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>Nadir ANC &lt; 500/mm<sup>3</sup> and nadir platelets &#8805;
  50,000/mm<sup>3</sup></span></p>
  </td>
  <td width="45%" valign=top style='width:45.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>75% of previous dose (both Pemetrexed Hospira and cisplatin) </span></p>
  </td>
 </tr>
 <tr>
  <td width="55%" valign=top style='width:55.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>Nadir platelets &lt; 50,000/mm<sup>3 </sup>regardless of nadir ANC
  </span></p>
  </td>
  <td width="45%" valign=top style='width:45.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>75% of previous dose (both Pemetrexed Hospira and cisplatin) </span></p>
  </td>
 </tr>
 <tr>
  <td width="55%" valign=top style='width:55.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>Nadir platelets &lt; 50,000/mm<sup>3</sup> with bleeding<sup>a</sup>,
  regardless of nadir ANC </span></p>
  </td>
  <td width="45%" valign=top style='width:45.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>50% of previous dose (both Pemetrexed Hospira and cisplatin) </span></p>
  </td>
 </tr>
 <tr>
  <td width="100%" colspan=2 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><sup><span
  lang=EN-GB>a</span></sup><span lang=EN-GB> These criteria meet the National
  Cancer Institute Common Toxicity Criteria (CTC v2.0; NCI 1998) definition of
  &#8805; CTC Grade 2 bleeding. </span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>If patients develop
non-haematologic toxicities &#8805; Grade 3 (excluding neurotoxicity), Pemetrexed
Hospira should be withheld until resolution to less than or equal to the
patient's pre-therapy value. Treatment should be resumed according to the
guidelines in Table 2. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse;border:none'>
 <tr>
  <td width="100%" colspan=3 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
  lang=EN-GB>Table 2. Dose modification table for </span></b><b><span
  lang=EN-GB>Pemetrexed Hospira</span></b><b><span lang=EN-GB> (as single agent
  or in combination) and cisplatin - Non-haematologic toxicities </span></b><sup><span
  lang=EN-GB>a, b</span></sup></p>
  </td>
 </tr>
 <tr>
  <td width="40%" valign=top style='width:40.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="30%" valign=top style='width:30.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Dose of </span></b><b><span
  lang=EN-GB>Pemetrexed Hospira</span></b><b><span lang=EN-GB> (mg/m<sup>2</sup>)</span></b></p>
  </td>
  <td width="30%" valign=top style='width:30.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Dose for cisplatin
  (mg/m<sup>2</sup>)</span></b></p>
  </td>
 </tr>
 <tr>
  <td width="40%" valign=top style='width:40.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Any Grade 3 or
  4 toxicities except mucositis </span></p>
  </td>
  <td width="30%" valign=top style='width:30.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>75% of
  previous dose </span></p>
  </td>
  <td width="30%" valign=top style='width:30.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>75% of
  previous dose </span></p>
  </td>
 </tr>
 <tr>
  <td width="40%" valign=top style='width:40.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Any diarrhoea
  requiring hospitalisation (irrespective of grade) or Grade 3 or 4 diarrhoea </span></p>
  </td>
  <td width="30%" valign=top style='width:30.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>75% of
  previous dose </span></p>
  </td>
  <td width="30%" valign=top style='width:30.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>75% of
  previous dose </span></p>
  </td>
 </tr>
 <tr>
  <td width="40%" valign=top style='width:40.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Grade 3 or 4
  mucositis </span></p>
  </td>
  <td width="30%" valign=top style='width:30.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>50% of
  previous dose </span></p>
  </td>
  <td width="30%" valign=top style='width:30.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>100% of
  previous dose </span></p>
  </td>
 </tr>
 <tr>
  <td width="100%" colspan=3 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><sup><span lang=EN-GB>a </span></sup><span
  lang=EN-GB>National Cancer Institute Common Toxicity Criteria (CTC v2.0; NCI
  1998) </span></p>
  <p class=MsoNormal style='line-height:normal'><sup><span lang=EN-GB>b </span></sup><span
  lang=EN-GB>Excluding neurotoxicity </span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In the event of
neurotoxicity, the recommended dose adjustment for Pemetrexed Hospira and
cisplatin is documented in Table 3. Patients should discontinue therapy if
Grade 3 or 4 neurotoxicity is observed. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse;border:none'>
 <tr>
  <td width="100%" colspan=3 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
  lang=EN-GB>Table 3. Dose modification table for </span></b><b><span
  lang=EN-GB>Pemetrexed Hospira</span></b><b><span lang=EN-GB> (as single agent
  or in combination) and cisplatin - Neurotoxicity</span></b></p>
  </td>
 </tr>
 <tr>
  <td width="20%" valign=top style='width:20.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>CTC</span></b><sup><span
  lang=EN-GB> a</span></sup><b><span lang=EN-GB> Grade</span></b></p>
  </td>
  <td width="40%" valign=top style='width:40.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Dose of </span></b><b><span
  lang=EN-GB>Pemetrexed Hospira</span></b><b><span lang=EN-GB> (mg/m<sup>2</sup>)</span></b></p>
  </td>
  <td width="40%" valign=top style='width:40.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Dose for cisplatin
  (mg/m<sup>2</sup>)</span></b></p>
  </td>
 </tr>
 <tr>
  <td width="20%" valign=top style='width:20.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>0&#8209;1 </span></p>
  </td>
  <td width="40%" valign=top style='width:40.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>100% of
  previous dose </span></p>
  </td>
  <td width="40%" valign=top style='width:40.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>100% of
  previous dose </span></p>
  </td>
 </tr>
 <tr>
  <td width="20%" valign=top style='width:20.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>2 </span></p>
  </td>
  <td width="40%" valign=top style='width:40.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>100% of
  previous dose </span></p>
  </td>
  <td width="40%" valign=top style='width:40.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>50% of
  previous dose </span></p>
  </td>
 </tr>
 <tr>
  <td width="100%" colspan=3 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><sup><span lang=EN-GB>a </span></sup><span
  lang=EN-GB>National Cancer Institute Common Toxicity Criteria (CTC v2.0; NCI
  1998) </span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Treatment with Pemetrexed
Hospira should be discontinued if a patient experiences any haematologic or
non-haematologic Grade 3 or 4 toxicity after 2 dose reductions or immediately
if Grade 3 or 4 neurotoxicity is observed. </span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><i><u><span lang=EN-GB>Special
populations</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Elderly</span></i><span
lang=EN-GB> </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In clinical
studies, there has been no indication that patients 65&nbsp;years of age or
older are at increased risk of adverse reactions compared to patients younger
than 65&nbsp;years old. No dose reductions other than those recommended for all
patients are necessary. </span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Paediatric
population</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>There is no
relevant use of pemetrexed in the paediatric population in malignant pleural
mesothelioma and non-small cell lung cancer. </span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Patients with
renal impairment </span></i><i><span lang=EN-GB>(Standard Cockcroft and Gault
formula or glomerular filtration rate measured Tc99m-DPTA serum clearance
method)</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB></span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Pemetrexed is
primarily eliminated unchanged by renal excretion. In clinical studies,
patients with creatinine clearance of &#8805; 45&nbsp;ml/min required no dose
adjustments other than those recommended for all patients. There are insufficient
data on the use of pemetrexed in patients with creatinine clearance below 45&nbsp;ml/min;
therefore, the use of pemetrexed is not recommended (see section 4.4). </span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Patients with
hepatic impairment</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>No relationships
between AST (SGOT), ALT (SGPT), or total bilirubin and pemetrexed
pharmacokinetics were identified. However, patients with hepatic impairment,
such as bilirubin &gt;&nbsp;1.5&#8209;times the upper limit of normal and/or
aminotransferase &gt; 3.0&#8209;times the upper limit of normal (hepatic
metastases absent) or &gt; 5.0&#8209;times the upper limit of normal (hepatic
metastases present), have not been specifically studied.</span></p>

<p class=MsoNormal style='text-align:justify;line-height:normal;text-autospace:
none'><b><i><span lang=EN-GB>&nbsp;</span></i></b></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Method of
administration </span></u></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Pemetrexed Hospira is for intravenous use. Pemetrexed
Hospira should be administered as an intravenous infusion over 10&nbsp;minutes
on the first day of each 21-day cycle.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>For precautions
to be taken before handling or administering Pemetrexed Hospira and for
instructions on reconstitution and dilution of Pemetrexed Hospira before
administration, see section 6.6.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>4.3 Contraindications</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Hypersensitivity
to the active substance or to any of the excipients listed in section 6.1. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Breast-feeding
(see section 4.6). </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Concomitant
yellow fever vaccine (see section 4.5).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>4.4 Special warnings and precautions for use</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Pemetrexed can
suppress bone marrow function as manifested by neutropenia, thrombocytopenia,
and anaemia (or pancytopenia) (see section 4.8). Myelosuppression is usually
the dose-limiting toxicity. Patients should be monitored for myelosuppression
during therapy and pemetrexed should not be given to patients until absolute
neutrophil count (ANC) returns to &#8805; 1,500&nbsp;cells/mm<sup>3</sup> and
platelet count returns to &#8805; 100,000&nbsp;cells/mm<sup>3</sup>. Dose
reductions for subsequent cycles are based on nadir ANC, platelet count, and
maximum non-haematologic toxicity seen from the previous cycle (see section
4.2). </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Less toxicity
and reduction in Grade 3/4 haematologic and non-haematologic toxicities, such
as neutropenia, febrile neutropenia, and infection with Grade 3/4 neutropenia,
were reported when pre&#8209;treatment with folic acid and vitamin B<sub>12</sub>
was administered. Therefore, all patients treated with pemetrexed must be
instructed to take folic acid and vitamin B<sub>12</sub> as a prophylactic
measure to reduce treatment-related toxicity (see section 4.2). </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Skin reactions
have been reported in patients not pre-treated with a corticosteroid.
Pre-treatment with dexamethasone (or equivalent) can reduce the incidence and
severity of skin reactions (see section&nbsp;4.2). </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>An insufficient
number of patients have been studied with creatinine clearance of below 45&nbsp;ml/min.
Therefore, the use of pemetrexed in patients with creatinine clearance of
&lt;45&nbsp;ml/min is not recommended (see section 4.2). </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Patients with
mild to moderate renal insufficiency (creatinine clearance from 45 to 79&nbsp;ml/min)
should avoid taking non-steroidal anti-inflammatory drugs (NSAIDs), such as
ibuprofen, and acetylsalicylic acid (&gt;1.3&nbsp;g daily) for 2 days before,
on the day of, and 2&nbsp;days following pemetrexed administration (see section
4.5). </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In patients with
mild to moderate renal insufficiency eligible for pemetrexed therapy, NSAIDs
with long elimination half-lives should be interrupted for at least 5 days
prior to, on the day of, and at least 2&nbsp;days following pemetrexed
administration (see section 4.5). </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Serious renal
events, including acute renal failure, have been reported with pemetrexed alone
or in association with other chemotherapeutic agents. Many of the patients in
whom these occurred had underlying risk factors for the development of renal
events, including dehydration or pre-existing hypertension or diabetes.
Nephrogenic diabetes insipidus and renal tubular necrosis were also reported in
post marketing setting with pemetrexed alone or with other chemotherapeutic
agents. Most of these events resolved after pemetrexed withdrawal. Patients
should be regularly monitored for acute tubular necrosis, decreased renal
function and signs and symptoms of nephrogenic diabetes insipidus (e.g.&nbsp;hypernatraemia).
</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The effect of
third space fluid, such as pleural effusion or ascites, on pemetrexed is not
fully defined. A phase 2 study of pemetrexed in 31 solid tumour patients with
stable third space fluid demonstrated no difference in pemetrexed dose
normalised plasma concentrations or clearance compared to patients without
third space fluid collections. Thus, drainage of third space fluid collection
prior to pemetrexed treatment should be considered, but may not be necessary. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Due to the
gastrointestinal toxicity of pemetrexed given in combination with cisplatin,
severe dehydration has been observed. Therefore, patients should receive
adequate antiemetic treatment and appropriate hydration prior to and/or after
receiving treatment. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Serious
cardiovascular events, including myocardial infarction and cerebrovascular events
have been uncommonly reported during clinical studies with pemetrexed, usually
when given in combination with another cytotoxic agent. Most of the patients in
whom these events have been observed had pre&#8209;existing cardiovascular risk
factors (see section 4.8). </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Immunodepressed
status is common in cancer patients. As a result, concomitant use of live
attenuated vaccines is not recommended (see section 4.3 and 4.5). </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Pemetrexed can
have genetically damaging effects. Sexually mature males are advised not to
father a child during the treatment and up to 6&nbsp;months thereafter.
Contraceptive measures or abstinence are recommended. Owing to the possibility
of pemetrexed treatment causing irreversible infertility, men are advised to
seek counselling on sperm storage before starting treatment. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Women of
childbearing potential must use effective contraception during treatment with
pemetrexed (see section 4.6). </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Cases of
radiation pneumonitis have been reported in patients treated with radiation
either prior, during, or subsequent to their pemetrexed therapy. Particular
attention should be paid to these patients, and caution exercised with use of
other radiosensitising agents. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Cases of
radiation recall have been reported in patients who received radiotherapy weeks
or years previously. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Excipients</span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><u><span
lang=EN-GB>Pemetrexed Hospira 100&nbsp;mg powder for concentrate for solution
for infusion</span></u></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>This medicinal product contains less than 1&nbsp;mmol sodium
(23&nbsp;mg) per vial, that is to say essentially sodium- free. </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><u><span
lang=EN-GB>Pemetrexed Hospira 500&nbsp;mg powder for concentrate for solution
for infusion</span></u></i><span lang=EN-GB> </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>This medicinal product contains 54&nbsp;mg sodium per vial,
equivalent to 2.7% of the WHO recommended maximum daily intake of 2&nbsp;g
sodium for an adult. </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><u><span
lang=EN-GB>Pemetrexed Hospira 1,000&nbsp;mg powder for concentrate for solution
for infusion</span></u></i><span lang=EN-GB> </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>This medicinal product contains 108&nbsp;mg sodium per vial,
equivalent to 5.4% of the WHO recommended maximum daily intake of 2&nbsp;g
sodium for an adult. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>4.5 Interaction
with other medicinal products and other forms of interaction</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Pemetrexed is
mainly eliminated unchanged renally by tubular secretion and to a lesser extent
by glomerular filtration. Concomitant administration of nephrotoxic medicinal
products (e.g., aminoglycoside, loop diuretics, platinum compounds, ciclosporin)
could potentially result in delayed clearance of pemetrexed. This combination
should be used with caution. If necessary, creatinine clearance should be
closely monitored. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Concomitant
administration of substances that are also tubularly secreted (e.g.,
probenecid, penicillin) could potentially result in delayed clearance of
pemetrexed. Caution should be made when these medicinal products are combined
with pemetrexed. If necessary, creatinine clearance should be closely
monitored. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In patients with
normal renal function (creatinine clearance &#8805; 80&nbsp;ml/min), high doses
of non-steroidal anti-inflammatory drugs (NSAIDs, such as ibuprofen &gt; 1600&nbsp;mg/day)
and acetylsalicylic acid at higher doses (&#8805;&nbsp;1.3&nbsp;g daily) may
decrease pemetrexed elimination and, consequently, increase the occurrence of
pemetrexed adverse reactions. Therefore, caution should be made when
administering higher doses of NSAIDs or acetylsalicylic acid, concurrently with
pemetrexed to patients with normal function (creatinine clearance &#8805; 80&nbsp;ml/min).
</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In patients with
mild to moderate renal insufficiency (creatinine clearance from 45 to 79&nbsp;ml/min),
the concomitant administration of pemetrexed with NSAIDs (e.g., ibuprofen) or acetylsalicylic
acid at higher doses should be avoided for 2&nbsp;days before, on the day of,
and 2&nbsp;days following pemetrexed administration (see section 4.4). </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In the absence
of data regarding potential interaction with NSAIDs having longer half-lives
such as piroxicam or rofecoxib, the concomitant administration with pemetrexed
in patients with mild to moderate renal insufficiency should be interrupted for
at least 5&nbsp;days prior to, on the day of, and at least 2&nbsp;days
following pemetrexed administration (see section 4.4). If concomitant
administration of NSAIDs is necessary, patients should be monitored closely for
toxicity, especially myelosuppression and gastrointestinal toxicity. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Pemetrexed
undergoes limited hepatic metabolism. Results from <i>in vitro</i> studies with
human liver microsomes indicated that pemetrexed would not be predicted to
cause clinically significant inhibition of the metabolic clearance of medicinal
products metabolised by CYP3A, CYP2D6, CYP2C9, and CYP1A2. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Interactions common to all cytotoxics</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Due to the increased thrombotic risk in patients with cancer, the
use of anticoagulation treatment is frequent. The high intra-individual
variability of the coagulation status during diseases and the possibility of
interaction between oral anticoagulants and anti-cancer chemotherapy require
increased frequency of INR (International Normalised Ratio) monitoring, if it
is decided to treat the patient with oral anticoagulants. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Concomitant use contraindicated:
<i>Yellow fever vaccine:</i> risk of fatal generalised vaccinale disease (see
section 4.3). </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Concomitant use not
recommended: <i>Live attenuated vaccines (except yellow fever, for which
concomitant use is contraindicated): r</i>isk of systemic, possibly fatal,
disease. The risk is increased in subjects who are already immunosuppressed by
their underlying disease. Use an inactivated vaccine where it exists
(poliomyelitis) (see section 4.4).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>4.6 Fertility, pregnancy and lactation</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Women of childbearing potential/Contraception in males and females</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Women of childbearing potential must use effective contraception
during treatment with pemetrexed. Pemetrexed can have genetically damaging
effects. Sexually mature males are advised not to father a child during the
treatment, and up to 6 months thereafter. Contraceptive measures or abstinence
are recommended. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Pregnancy</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>There are no
data from the use of pemetrexed in pregnant women; but pemetrexed, like other
anti-metabolites, is suspected to cause serious birth defects when administered
during pregnancy. Animal studies have shown reproductive toxicity (see section
5.3). Pemetrexed should not be used during pregnancy unless clearly necessary,
after a careful consideration of the needs of the mother and the risk for the
foetus (see section 4.4). </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Breast-feeding</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>It is unknown
whether pemetrexed is excreted in human milk, and adverse reactions on the breast&#8209;feeding
child cannot be excluded. Breast-feeding must be discontinued during pemetrexed
therapy (see section 4.3). </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Fertility</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Owing to the possibility
of pemetrexed treatment causing irreversible infertility, men are advised to
seek counselling on sperm storage before starting treatment.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>4.7 Effects on ability to drive and use machines</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>No studies on
the effects on the ability to drive and use machines have been performed.
However, it has been reported that pemetrexed may cause fatigue. Therefore,
patients should be cautioned against driving or operating machines if this
event occurs.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.5pt;text-indent:-28.5pt'><b><span
lang=EN-GB>4.8<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></b><b><span lang=EN-GB>Undesirable effects</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Summary of
the safety profile</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The most
commonly reported undesirable effects related to pemetrexed, whether used as
monotherapy or in combination, are bone marrow suppression manifested as
anaemia, neutropenia, leucopenia, thrombocytopenia; and gastrointestinal
toxicities, manifested as anorexia, nausea, vomiting, diarrhoea, constipation,
pharyngitis, mucositis, and stomatitis. Other undesirable effects include renal
toxicities, increased aminotransferases, alopecia, fatigue, dehydration, rash,
infection/sepsis and neuropathy. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Rarely seen
events include Stevens-Johnson syndrome and toxic epidermal necrolysis. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Tabulated
list of adverse reactions</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB></span></p>

<p class=MsoEndnoteText><span style='color:black'>The table 4 lists the adverse
drug events regardless of causality associated with pemetrexed used either as a
monotherapy treatment or in combination with cisplatin from the pivotal
registration studies (</span><span lang=EN-GB>JMCH</span><span
style='color:black'>, </span><span lang=EN-GB>JMEI, JMBD, </span>JMEN and
PARAMOUNT)<span style='color:black'> and from the post marketing period.</span></p>

<p class=MsoEndnoteText><s><span style='color:black'><span style='text-decoration:
 none'>&nbsp;</span></span></s></p>

<p class=MsoNormal style='line-height:normal'><span style='color:black'>ADRs
are listed by MedDRA body system organ class. The following convention has been
used for classification of frequency: </span><span lang=EN-GB>very common:
&#8805;&nbsp;1/10; common: &#8805;&nbsp;1/100 to &lt;&nbsp;1/10; uncommon:
&#8805;&nbsp;1/1,000 to &lt;&nbsp;1/100; rare: &#8805;&nbsp;1/10,000 to &lt;&nbsp;1/1,000;
very rare: &lt;&nbsp;1/10,000) <span style='color:black'>and not known (cannot
be estimated from the available data).</span></span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Table 4.
Frequencies of all grades adverse drug events regardless of causality from the
pivotal registration studies: JMEI (Pemetrexed vs Docetaxel), JMDB (Pemetrexed and
Cisplatin versus Gemcitabine and Cisplatin, JMCH (Pemetrexed plus Cisplatin
versus Cisplatin), JMEN and PARAMOUNT (Pemetrexed plus Best Supportive Care
versus Placebo plus Best Supportive Care) and from post-marketing period.</span></b></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=684
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=102 valign=top style='width:76.3pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><a name="_Hlk30072304"><b>System
  Organ Class </b></a></p>
  <p class=Normal11pt style='page-break-after:auto'><b>(MedDRA)</b></p>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=104 valign=top style='width:78.0pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Very common</span></b></p>
  <p class=Normal11pt style='page-break-after:auto'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><b><span lang=EN-GB>Common</span></b></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><b><span lang=EN-GB>Uncommon</span></b></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><b><span lang=EN-GB>Rare</span></b></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><b><span lang=EN-GB>Very
  rare</span></b></p>
  </td>
  <td width=81 valign=top style='width:61.0pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><b><span lang=EN-GB>Not
  known</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=102 valign=top style='width:76.3pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Infections
  and infestations</span></p>
  </td>
  <td width=104 valign=top style='width:78.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Infection<sup>a</sup></span></p>
  <p class=MsoNormal><span lang=EN-GB>Pharyngitis</span></p>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Sepsis<sup>b</sup></span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Dermo-hypodermitis</span></p>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=81 valign=top style='width:61.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=102 valign=top style='width:76.3pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Blood and
  lymphatic system disorders</span></p>
  </td>
  <td width=104 valign=top style='width:78.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Neutropenia</span></p>
  <p class=MsoNormal><span lang=EN-GB>Leukopenia</span></p>
  <p class=MsoNormal><span lang=EN-GB>Haemoglobin decreased</span></p>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Febrile
  neutropenia</span></p>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Platelet
  count decreased</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Pancytopenia</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Autoimmune
  haemolytic anaemia</span></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=81 valign=top style='width:61.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=102 valign=top style='width:76.3pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Immune
  System disorders</span></p>
  </td>
  <td width=104 valign=top style='width:78.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Hypersensiti-vity</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'>&nbsp;</p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Anaphylactic
  shock</span></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=81 valign=top style='width:61.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=102 valign=top style='width:76.3pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Metabolism</span></p>
  <p class=MsoNormal><span lang=EN-GB>and nutrition</span></p>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>disorders</span></p>
  </td>
  <td width=104 valign=top style='width:78.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Dehydration</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=81 valign=top style='width:61.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=102 valign=top style='width:76.3pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Nervous
  system disorders</span></p>
  </td>
  <td width=104 valign=top style='width:78.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><sup><span lang=EN-GB>&nbsp;</span></sup></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Taste
  disorder</span></p>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Peripheral
  motor neuropathy</span></p>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Peripheral
  sensory neuropathy</span></p>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Dizziness</span></p>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Cerebrovascular
  accident</span></p>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Ischaemic
  stroke</span></p>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Haemorrhage
  intracranial </span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=81 valign=top style='width:61.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=102 valign=top style='width:76.3pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Eye
  disorders</span></p>
  </td>
  <td width=104 valign=top style='width:78.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Conjunctivitis</span></p>
  <p class=MsoNormal><span lang=EN-GB>Dry eye</span></p>
  <p class=MsoNormal><span lang=EN-GB>Lacrimation increased</span></p>
  <p class=MsoNormal><span lang=EN-GB>Keratoconjunctivitis sicca</span></p>
  <p class=MsoNormal><span lang=EN-GB>Eyelid oedema</span></p>
  <p class=MsoNormal><span lang=EN-GB>Ocular surface disease</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=81 valign=top style='width:61.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=102 valign=top style='width:76.3pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Cardiac
  disorders<sup> </sup></span></p>
  </td>
  <td width=104 valign=top style='width:78.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Cardiac
  failure</span></p>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Arrhythmia</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Angina</span></p>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Myocardial
  infarction</span></p>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Coronary
  artery disease</span></p>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Arrhythmia
  supraventricular</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=81 valign=top style='width:61.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=102 valign=top style='width:76.3pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Vascular
  disorders</span></p>
  </td>
  <td width=104 valign=top style='width:78.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'>Peripheral ischaemia<sup>c</sup></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=81 valign=top style='width:61.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=102 valign=top style='width:76.3pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Respiratory, thoracic and mediastinal
  disorders</span></p>
  </td>
  <td width=104 valign=top style='width:78.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Pulmonary
  embolism Interstitial pneumonitis<sup>b,d</sup></span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=81 valign=top style='width:61.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=102 valign=top style='width:76.3pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Gastrointes-tinal
  disorders</span></p>
  </td>
  <td width=104 valign=top style='width:78.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Stomatitis</span></p>
  <p class=MsoNormal><span lang=EN-GB>Anorexia</span></p>
  <p class=MsoNormal><span lang=EN-GB>Vomiting</span></p>
  <p class=MsoNormal><span lang=EN-GB>Diarrhoea</span></p>
  <p class=MsoNormal><span lang=EN-GB>Nausea</span></p>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=mdTblEntry style='page-break-after:auto'><span lang=EN-GB
  style='font-size:11.0pt'>Dyspepsia</span></p>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Constipation</span></p>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Abdominal
  pain</span></p>
  <p class=mdTblEntry style='page-break-after:auto'><span lang=EN-GB
  style='font-size:11.0pt'></span></p>
  <p class=mdTblEntry style='page-break-after:auto'><sup><span
  style='font-size:11.0pt'>&nbsp;</span></sup></p>
  <p class=mdTblEntry style='page-break-after:auto'><span style='font-size:
  11.0pt'>&nbsp;</span></p>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Rectal haemorrhage</span></p>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Gastrointestinal
  haemorrhage</span></p>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Intestinal
  perforation</span></p>
  <p class=Normal11pt style='page-break-after:auto'>Oesophagitis</p>
  <p class=Normal11pt style='page-break-after:auto'>Colitis<sup><span lang=DE>e</span></sup></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=81 valign=top style='width:61.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=102 valign=top style='width:76.3pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Hepatobiliary
  disorders</span></p>
  </td>
  <td width=104 valign=top style='width:78.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB></span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Alanine aminotransferase increased</span></p>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Aspartate
  aminotransferase increased</span></p>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Hepatitis</span></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=81 valign=top style='width:61.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=102 valign=top style='width:76.3pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Skin and
  subcutaneous tissue disorders</span></p>
  </td>
  <td width=104 valign=top style='width:78.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Rash</span></p>
  <p class=MsoNormal><span lang=EN-GB>Skin exfoliation </span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Hyperpigmentation</span></p>
  <p class=MsoNormal><span lang=EN-GB>Pruritus</span></p>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Erythema
  multiforme</span></p>
  <p class=MsoNormal><span lang=EN-GB>Alopecia</span></p>
  <p class=MsoNormal><span lang=EN-GB>Urticaria</span></p>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'>&nbsp;</p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Erythema</span></p>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Stevens-Johnson syndrome<sup>b</sup></span></p>
  <p class=MsoNormal><span lang=EN-GB>Toxic epidermal necrolysis<sup>b</sup></span></p>
  <p class=MsoNormal><span lang=EN-GB>Pemphigoid</span></p>
  <p class=MsoNormal><span lang=EN-GB>Dermatitis bullous</span></p>
  <p class=MsoNormal><span lang=EN-GB>Acquired epidermolysis bullosa</span></p>
  <p class=Normal11pt style='page-break-after:auto'><span lang=DE>Erythemato&#8209;us
  oedema<sup>f </sup></span></p>
  <p class=MsoNormal><span lang=DE>Pseudocell&#8209;ulitis</span></p>
  <p class=MsoNormal><span lang=DE>Dermatitis</span></p>
  <p class=MsoNormal><span lang=DE>Eczema</span></p>
  <p class=MsoNormal><span lang=EN-GB>Prurigo</span></p>
  </td>
  <td width=81 valign=top style='width:61.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  <p class=Normal11pt style='page-break-after:auto'><sup><span lang=EN-GB>&nbsp;</span></sup></p>
  </td>
 </tr>
 <tr>
  <td width=102 valign=top style='width:76.3pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Renal and
  urinary disorders</span></p>
  </td>
  <td width=104 valign=top style='width:78.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Creatinine clearance decreased</span></p>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Blood creatinine
  increased<sup>e</sup></span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Renal
  failure</span></p>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Glomerular
  filtration rate decreased</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><sup>&nbsp;</sup></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=81 valign=top style='width:61.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><a name="_Hlk29467431"><span
  lang=EN-GB>Nephroge&#8209;nic diabetes insipidus</span></a></p>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Renal
  tubular necrosis</span></p>
  </td>
 </tr>
 <tr>
  <td width=102 valign=top style='width:76.3pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>General
  disorders and administration site conditions</span></p>
  </td>
  <td width=104 valign=top style='width:78.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Fatigue</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Pyrexia</span></p>
  <p class=MsoNormal><span lang=EN-GB>Pain</span></p>
  <p class=MsoNormal><span lang=EN-GB>Oedema</span></p>
  <p class=MsoNormal><span lang=EN-GB>Chest pain</span></p>
  <p class=MsoNormal><span lang=EN-GB>Mucosal inflammation</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'>&nbsp;</p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=81 valign=top style='width:61.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=102 valign=top style='width:76.3pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Investigations</span></p>
  </td>
  <td width=104 valign=top style='width:78.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Gamma-glutamyltransferase
  increased</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'>&nbsp;</p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=81 valign=top style='width:61.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=102 valign=top style='width:76.3pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Injury,
  poisoning and procedural complications</span></p>
  </td>
  <td width=104 valign=top style='width:78.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'>Radiation oesophagitis</p>
  <p class=Normal11pt style='page-break-after:auto'>Radiation pneumonitis</p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Recall
  pheno-menon</span></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=81 valign=top style='width:61.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
</table>

<p class=xnormal11pt><sup><span lang=EN-GB>a</span></sup><span lang=EN-GB> with
and without neutropenia </span></p>

<p class=xnormal11pt><sup><span lang=EN-GB>b</span></sup><span lang=EN-GB
style='color:black'> </span><span style='color:black'>in some cases fatal </span></p>

<p class=xnormal11pt><sup><span lang=EN-GB>c</span></sup><span lang=EN-GB>
sometimes leading to extremity necrosis </span></p>

<p class=xnormal11pt><sup><span lang=EN-GB>d</span></sup><span lang=EN-GB> </span>with
respiratory insufficiency</p>

<p class=MsoNormal style='line-height:normal'><sup><span lang=EN-GB>e</span></sup><span
lang=EN-GB> seen only in combination with cisplatin <br>
<sup>f</sup><span style='color:black'> </span>mainly of the lower limbs</span></p>

<p class=MsoNormal style='text-autospace:none'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='text-autospace:none'><u><span lang=EN-GB>Reporting of
suspected adverse reactions</span></u></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Reporting
suspected adverse reactions after authorisation of the medicinal product is
important. It allows continued monitoring of the benefit/risk balance of the
medicinal product. Healthcare professionals are asked to report any suspected
adverse reactions via <span style='background:lightgrey'>the national reporting
system listed in </span></span><span lang=EN-GB><a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span
style='background:lightgrey'>Appendix V</span></a></span><span lang=EN-GB>.<span
style='color:navy'> </span></span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>4.9 Overdose</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Reported
symptoms of overdose include neutropenia, anaemia, thrombocytopenia, mucositis,
sensory polyneuropathy, and rash. Anticipated complications of overdose include
bone marrow suppression as manifested by neutropenia, thrombocytopenia, and
anaemia. In addition, infection with or without fever, diarrhoea, and/or
mucositis may be seen. In the event of suspected overdose, patients should be
monitored with blood counts and should receive supportive therapy as necessary.
The use of calcium folinate/folinic acid in the management of pemetrexed
overdose should be considered.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>5. PHARMACOLOGICAL PROPERTIES</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>5.1  Pharmacodynamic properties</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Pharmacotherapeutic
group:</span><span lang=EN-GB> antineoplastic agents, folic acid analogues. ATC
code: L01BA04. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Pemetrexed </span><span
lang=EN-GB>is a multi-targeted anti-cancer antifolate agent that exerts its
action by disrupting crucial folate-dependent metabolic processes essential for
cell replication. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>In vitro</span></i><span
lang=EN-GB> studies have shown that pemetrexed behaves as a multi-targeted
antifolate by inhibiting thymidylate synthase (TS), dihydrofolate reductase
(DHFR), and glycinamide ribonucleotide formyltransferase (GARFT), which are key
folate-dependent enzymes for the <i>de novo</i> biosynthesis of thymidine and
purine nucleotides. Pemetrexed is transported into cells by both the reduced
folate carrier and membrane folate binding protein transport systems. Once in
the cell, pemetrexed is rapidly and efficiently converted to polyglutamate
forms by the enzyme folylpolyglutamate synthetase. The polyglutamate forms are
retained in cells and are even more potent inhibitors of TS and GARFT.
Polyglutamation is a time- and concentration-dependent process that occurs in
tumour cells and, to a lesser extent, in normal tissues. Polyglutamated
metabolites have an increased intracellular half-life resulting in prolonged
drug action in malignant cells. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The European
Medicines Agency has waived the obligation to submit the results of studies
with the reference medicinal product containing pemetrexed in all subsets of
the paediatric population for the granted indications (see section 4.2 for
information on paediatric use).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Clinical
efficacy</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><u><span lang=EN-GB>Mesothelioma</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EMPHACIS, a
multi-centre, randomised, single-blind Phase 3 study of pemetrexed plus
cisplatin versus cisplatin in chemonaive patients with malignant pleural
mesothelioma, has shown that patients treated with pemetrexed and cisplatin had
a clinically meaningful 2.8&#8209;month median survival advantage over patients
receiving cisplatin alone. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>During the
study, low-dose folic acid and vitamin B<sub>12</sub> supplementation was
introduced to patients' therapy to reduce toxicity. The primary analysis of
this study was performed on the population of all patients randomly assigned to
a treatment arm who received study drug (randomised and treated). A subgroup
analysis was performed on patients who received folic acid and vitamin B<sub>12</sub>
supplementation during the entire course of study therapy (fully supplemented).
The results of these analyses of efficacy are summarised in the table below. </span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Table 5. Efficacy
of pemetrexed plus cisplatin vs. cisplatin in malignant pleural mesothelioma</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse;border:none'>
 <tr>
  <td width="28%" valign=top style='width:28.0%;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="36%" colspan=2 valign=top style='width:36.0%;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Randomised
  and treated patients</span></b></p>
  </td>
  <td width="36%" colspan=2 valign=top style='width:36.0%;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Fully supplemented
  patients</span></b></p>
  </td>
 </tr>
 <tr>
  <td width="28%" valign=top style='width:28.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Efficacy
  parameter</span></b></p>
  </td>
  <td width="18%" valign=top style='width:18.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Pemetrexed /
  Cisplatin</span></b></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>(N = 226)</span></b></p>
  </td>
  <td width="18%" valign=top style='width:18.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Cisplatin</span></b></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>(N = 222)</span></b></p>
  </td>
  <td width="18%" valign=top style='width:18.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Pemetrexed /
  Cisplatin</span></b></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>(N = 168)</span></b></p>
  </td>
  <td width="18%" valign=top style='width:18.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Cisplatin</span></b></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>(N = 163)</span></b></p>
  </td>
 </tr>
 <tr>
  <td width="28%" valign=top style='width:28.0%;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Median overall
  survival (months) </span></p>
  </td>
  <td width="18%" valign=top style='width:18.0%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>12.1 </span></p>
  </td>
  <td width="18%" valign=top style='width:18.0%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>9.3 </span></p>
  </td>
  <td width="18%" valign=top style='width:18.0%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>13.3 </span></p>
  </td>
  <td width="18%" valign=top style='width:18.0%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>10.0 </span></p>
  </td>
 </tr>
 <tr>
  <td width="28%" valign=top style='width:28.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(95% CI) </span></p>
  </td>
  <td width="18%" valign=top style='width:18.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(10.0&#8209;14.4)
  </span></p>
  </td>
  <td width="18%" valign=top style='width:18.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(7.8&#8209;10.7)
  </span></p>
  </td>
  <td width="18%" valign=top style='width:18.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(11.4&#8209;14.9)
  </span></p>
  </td>
  <td width="18%" valign=top style='width:18.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(8.4&#8209;11.9)
  </span></p>
  </td>
 </tr>
 <tr>
  <td width="28%" valign=top style='width:28.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Log rank <i>p</i>-value<sup>a</sup>*
  </span></p>
  </td>
  <td width="36%" colspan=2 valign=top style='width:36.0%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>0.020 </span></p>
  </td>
  <td width="36%" colspan=2 valign=top style='width:36.0%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>0.051 </span></p>
  </td>
 </tr>
 <tr>
  <td width="28%" valign=top style='width:28.0%;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Median time to
  tumour progression (months) </span></p>
  </td>
  <td width="18%" valign=top style='width:18.0%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>5.7 </span></p>
  </td>
  <td width="18%" valign=top style='width:18.0%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>3.9 </span></p>
  </td>
  <td width="18%" valign=top style='width:18.0%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>6.1 </span></p>
  </td>
  <td width="18%" valign=top style='width:18.0%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>3.9 </span></p>
  </td>
 </tr>
 <tr>
  <td width="28%" valign=top style='width:28.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(95% CI) </span></p>
  </td>
  <td width="18%" valign=top style='width:18.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(4.9&#8209;6.5)
  </span></p>
  </td>
  <td width="18%" valign=top style='width:18.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(2.8&#8209;4.4)
  </span></p>
  </td>
  <td width="18%" valign=top style='width:18.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(5.3&#8209;7.0)
  </span></p>
  </td>
  <td width="18%" valign=top style='width:18.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(2.8&#8209;4.5)
  </span></p>
  </td>
 </tr>
 <tr>
  <td width="28%" valign=top style='width:28.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Log rank <i>p</i>-value<sup>a</sup>*
  </span></p>
  </td>
  <td width="36%" colspan=2 valign=top style='width:36.0%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>0.001</span></p>
  </td>
  <td width="36%" colspan=2 valign=top style='width:36.0%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>0.008</span></p>
  </td>
 </tr>
 <tr>
  <td width="28%" valign=top style='width:28.0%;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Time to
  treatment failure (months) </span></p>
  </td>
  <td width="18%" valign=top style='width:18.0%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>4.5 </span></p>
  </td>
  <td width="18%" valign=top style='width:18.0%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>2.7 </span></p>
  </td>
  <td width="18%" valign=top style='width:18.0%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>4.7 </span></p>
  </td>
  <td width="18%" valign=top style='width:18.0%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>2.7 </span></p>
  </td>
 </tr>
 <tr>
  <td width="28%" valign=top style='width:28.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(95% CI) </span></p>
  </td>
  <td width="18%" valign=top style='width:18.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(3.9&#8209;4.9)
  </span></p>
  </td>
  <td width="18%" valign=top style='width:18.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(2.1&#8209;2.9)
  </span></p>
  </td>
  <td width="18%" valign=top style='width:18.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(4.3&#8209;5.6)
  </span></p>
  </td>
  <td width="18%" valign=top style='width:18.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(2.2&#8209;3.1)
  </span></p>
  </td>
 </tr>
 <tr>
  <td width="28%" valign=top style='width:28.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Log rank <i>p</i>-value<sup>a</sup>*
  </span></p>
  </td>
  <td width="36%" colspan=2 valign=top style='width:36.0%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>0.001 </span></p>
  </td>
  <td width="36%" colspan=2 valign=top style='width:36.0%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>0.001 </span></p>
  </td>
 </tr>
 <tr>
  <td width="28%" valign=top style='width:28.0%;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Overall
  response rate<sup>b</sup>** </span></p>
  </td>
  <td width="18%" valign=top style='width:18.0%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>41.3% </span></p>
  </td>
  <td width="18%" valign=top style='width:18.0%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>16.7% </span></p>
  </td>
  <td width="18%" valign=top style='width:18.0%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>45.5% </span></p>
  </td>
  <td width="18%" valign=top style='width:18.0%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>19.6% </span></p>
  </td>
 </tr>
 <tr>
  <td width="28%" valign=top style='width:28.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(95% CI) </span></p>
  </td>
  <td width="18%" valign=top style='width:18.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(34.8&#8209;48.1)
  </span></p>
  </td>
  <td width="18%" valign=top style='width:18.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(12.0&#8209;22.2)
  </span></p>
  </td>
  <td width="18%" valign=top style='width:18.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(37.8&#8209;53.4)
  </span></p>
  </td>
  <td width="18%" valign=top style='width:18.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(13.8&#8209;26.6)
  </span></p>
  </td>
 </tr>
 <tr>
  <td width="28%" valign=top style='width:28.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Fisher's exact
  <i>p</i>-value<sup>a</sup>* </span></p>
  </td>
  <td width="36%" colspan=2 valign=top style='width:36.0%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>&lt;0.001 </span></p>
  </td>
  <td width="36%" colspan=2 valign=top style='width:36.0%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>&lt;0.001 </span></p>
  </td>
 </tr>
 <tr>
  <td width="100%" colspan=5 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Abbreviation:
  CI = confidence interval. </span></p>
  <p class=MsoNormal style='line-height:normal'><sup><span lang=EN-GB>a</span></sup><span
  lang=EN-GB>*<i>p</i>-value refers to comparison between arms. </span></p>
  <p class=MsoNormal style='line-height:normal'><sup><span lang=EN-GB>b</span></sup><span
  lang=EN-GB>**In the pemetrexed /cisplatin arm, randomised and treated (N=225)
  and fully supplemented (N=167). </span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>A statistically
significant improvement of the clinically relevant symptoms (pain and dyspnoea)
associated with malignant pleural mesothelioma in the pemetrexed /cisplatin arm
(212&nbsp;patients) versus the cisplatin arm alone (218&nbsp;patients) was
demonstrated using the Lung Cancer Symptom Scale. Statistically significant
differences in pulmonary function tests were also observed. The separation
between the treatment arms was achieved by improvement in lung function in the pemetrexed
/cisplatin arm and deterioration of lung function over time in the control arm.
</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>There are
limited data in patients with malignant pleural mesothelioma treated with pemetrexed
alone. Pemetrexed at a dose of 500&nbsp;mg/m<sup>2</sup> was studied as a
single agent in 64 chemonaive patients with malignant pleural mesothelioma. The
overall response rate was 14.1%. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><u><span lang=EN-GB>NSCLC,
second-line treatment</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>A multi-centre,
randomised, open-label Phase-3 study of pemetrexed versus docetaxel in patients
with locally advanced or metastatic NSCLC after prior chemotherapy has shown
median survival times of 8.3&nbsp;months for patients treated with pemetrexed
(Intent-To-Treat [ITT] population N = 283) and 7.9&nbsp;months for patients
treated with docetaxel (ITT N = 288). Prior chemotherapy did not include pemetrexed.
An analysis of the impact of NSCLC histology on the treatment effect on overall
survival was in favour of pemetrexed versus docetaxel for other than
predominantly squamous histologies (N&nbsp;=&nbsp;399, 9.3 versus 8.0&nbsp;months,
adjusted hazard ratio (HR) = 0.78; 95% CI = 0.61&#8209;1.00, p = 0.047) and was
in favour of docetaxel for squamous cell carcinoma histology (N =172, 6.2
versus 7.4&nbsp;months, adjusted HR = 1.56; 95% CI = 1.08&#8209;2.26, p =
0.018). There were no clinically relevant differences observed for the safety
profile of pemetrexed within the histology subgroups. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Limited clinical
data from a separate randomised, Phase&#8209;3, controlled trial, suggest that
efficacy data (overall survival, progression-free survival) for pemetrexed are
similar between patients previously pre-treated with docetaxel (N = 41) and
patients who did not receive previous docetaxel treatment (N&nbsp;=&nbsp;540). </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Table 6. Efficacy
of </span></b><b><span lang=EN-GB>pemetrexed </span></b><b><span lang=EN-GB>vs.
docetaxel in NSCLC - ITT population</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse;border:none'>
 <tr>
  <td width="48%" valign=top style='width:48.0%;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="26%" valign=top style='width:26.0%;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Pemetrexed</span></b></p>
  </td>
  <td width="26%" valign=top style='width:26.0%;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Docetaxel</span></b></p>
  </td>
 </tr>
 <tr>
  <td width="48%" rowspan=2 valign=top style='width:48.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Survival
  time (months)</span></b><span lang=EN-GB> </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB> Median (m) </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=IT> 95% CI for
  median </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=IT> HR </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=IT> 95% CI for HR </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=IT> Non-inferiority
  <i>p</i>-value (HR) </span></p>
  </td>
  <td width="26%" valign=top style='width:26.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(N = 283) </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>8.3 </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(7.0&#8209;9.4)
  </span></p>
  </td>
  <td width="26%" valign=top style='width:26.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(N = 288) </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>7.9 </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(6.3&#8209;9.2)
  </span></p>
  </td>
 </tr>
 <tr>
  <td width="100%" colspan=2 valign=top style='width:100.0%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>0.99</span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>(0.82&#8209;1.20)</span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>0.226 </span></p>
  </td>
 </tr>
 <tr>
  <td width="48%" rowspan=2 valign=top style='width:48.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Progression-free
  survival (months)</span></b><span lang=EN-GB> </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB> Median </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB> HR (95% CI) </span></p>
  </td>
  <td width="26%" valign=top style='width:26.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(N = 283) </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>2.9 </span></p>
  </td>
  <td width="26%" valign=top style='width:26.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(N = 288) </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>2.9 </span></p>
  </td>
 </tr>
 <tr>
  <td width="100%" colspan=2 valign=top style='width:100.0%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>0.97 (0.82&#8209;1.16)
  </span></p>
  </td>
 </tr>
 <tr>
  <td width="48%" rowspan=2 valign=top style='width:48.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Time to
  treatment failure (TTTF - months)</span></b><span lang=EN-GB> </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB> Median </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB> HR (95% CI) </span></p>
  </td>
  <td width="26%" valign=top style='width:26.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(N = 283) </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>2.3 </span></p>
  </td>
  <td width="26%" valign=top style='width:26.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(N = 288) </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>2.1 </span></p>
  </td>
 </tr>
 <tr>
  <td width="100%" colspan=2 valign=top style='width:100.0%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>0.84 (0.71&#8209;0.997)
  </span></p>
  </td>
 </tr>
 <tr>
  <td width="48%" valign=top style='width:48.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Response</span></b><span
  lang=EN-GB> (n: qualified for response) </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB> Response
  rate (%) (95% CI) </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB> Stable
  disease (%) </span></p>
  </td>
  <td width="26%" valign=top style='width:26.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(N = 264) </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>9.1 (5.9&#8209;13.2)
  </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>45.8 </span></p>
  </td>
  <td width="26%" valign=top style='width:26.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(N = 274) </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>8.8 (5.7&#8209;12.8)
  </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>46.4 </span></p>
  </td>
 </tr>
 <tr>
  <td width="100%" colspan=3 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Abbreviations:
  CI = confidence interval; HR = hazard ratio; ITT = intent-to-treat; N = total
  population size. </span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><i><u><span lang=EN-GB>NSCLC,
first-line treatment</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>A multi-centre,
randomised, open-label, Phase-3 study of pemetrexed plus cisplatin versus
gemcitabine plus cisplatin in chemonaive patients with locally advanced or
metastatic (Stage IIIb or IV) non-small cell lung cancer (NSCLC) showed that pemetrexed
plus cisplatin (Intent-To-Treat [ITT] population N = 862) met its primary
endpoint and showed similar clinical efficacy as gemcitabine plus cisplatin
(ITT N = 863) in overall survival (adjusted hazard ratio (HR) 0.94; 95% CI=
0.84&#8209;1.05). All patients included in this study had an ECOG performance
status 0 or 1. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The primary efficacy
analysis was based on the ITT population. Sensitivity analyses of main efficacy
endpoints were also assessed on the Protocol Qualified (PQ) population. The
efficacy analyses using PQ population are consistent with the analyses for the
ITT population and support the non-inferiority of AC versus GC. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Progression-free
survival (PFS) and overall response rate were similar between treatment arms:
median PFS was 4.8&nbsp;months for pemetrexed plus cisplatin versus 5.1&nbsp;months
for gemcitabine plus cisplatin (adjusted hazard ratio (HR) 1.04; 95% CI= 0.94&#8209;1.15),
and overall response rate was 30.6% (95% CI= 27.3&#8209; 33.9) for pemetrexed
plus cisplatin versus 28.2% (95% CI= 25.0&#8209;31.4) for gemcitabine plus
cisplatin. PFS data were partially confirmed by an independent review (400/1725&nbsp;patients
were randomly selected for review). </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The analysis of
the impact of NSCLC histology on overall survival demonstrated clinically
relevant differences in survival according to histology, see table below. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Table 7. Efficacy
of </span></b><b><span lang=EN-GB>pemetrexed </span></b><b><span lang=EN-GB>+
cisplatin vs. gemcitabine + cisplatin in first-line non-small cell lung cancer
 ITT population and histology subgroups</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%"
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width="18%" rowspan=2 valign=top style='width:18.02%;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>ITT
  population and histology subgroups</span></b></p>
  </td>
  <td width="52%" colspan=4 valign=top style='width:52.0%;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Median
  overall survival in months</span></b></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>(95% CI)</span></b></p>
  </td>
  <td width="18%" rowspan=2 valign=top style='width:18.84%;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Adjusted
  hazard ratio (HR)</span></b></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>(95% CI)</span></b></p>
  </td>
  <td width="11%" rowspan=2 valign=top style='width:11.16%;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Superiority
  <i>p</i>-value</span></b></p>
  </td>
 </tr>
 <tr>
  <td width="26%" colspan=2 valign=top style='width:26.0%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Pemetrexed </span></b><b><span
  lang=EN-GB>+ Cisplatin</span></b></p>
  </td>
  <td width="26%" colspan=2 valign=top style='width:26.0%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Gemcitabine
  + Cisplatin</span></b></p>
  </td>
 </tr>
 <tr>
  <td width="18%" valign=top style='width:18.02%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ITT population
  </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(N = 1725) </span></p>
  </td>
  <td width="15%" valign=top style='width:15.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>10.3 </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(9.8  11.2) </span></p>
  </td>
  <td width="11%" valign=top style='width:11.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>N = 862 </span></p>
  </td>
  <td width="15%" valign=top style='width:15.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>10.3 </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(9.6  10.9) </span></p>
  </td>
  <td width="11%" valign=top style='width:11.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>N = 863 </span></p>
  </td>
  <td width="18%" valign=top style='width:18.84%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>0.94<sup>a</sup>
  </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(0.84  1.05) </span></p>
  </td>
  <td width="11%" valign=top style='width:11.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>0.259 </span></p>
  </td>
 </tr>
 <tr>
  <td width="18%" valign=top style='width:18.02%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Adenocarcinoma
  </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(N = 847) </span></p>
  </td>
  <td width="15%" valign=top style='width:15.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>12.6 </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(10.7  13.6) </span></p>
  </td>
  <td width="11%" valign=top style='width:11.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>N = 436 </span></p>
  </td>
  <td width="15%" valign=top style='width:15.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>10.9 </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(10.2 11.9) </span></p>
  </td>
  <td width="11%" valign=top style='width:11.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>N = 411 </span></p>
  </td>
  <td width="18%" valign=top style='width:18.84%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>0.84 </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(0.710.99) </span></p>
  </td>
  <td width="11%" valign=top style='width:11.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>0.033 </span></p>
  </td>
 </tr>
 <tr>
  <td width="18%" valign=top style='width:18.02%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Large cell </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(N = 153) </span></p>
  </td>
  <td width="15%" valign=top style='width:15.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>10.4 </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(8.6  14.1) </span></p>
  </td>
  <td width="11%" valign=top style='width:11.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>N = 76 </span></p>
  </td>
  <td width="15%" valign=top style='width:15.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>6.7 </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(5.5  9.0) </span></p>
  </td>
  <td width="11%" valign=top style='width:11.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>N = 77 </span></p>
  </td>
  <td width="18%" valign=top style='width:18.84%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>0.67 </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(0.480.96) </span></p>
  </td>
  <td width="11%" valign=top style='width:11.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>0.027 </span></p>
  </td>
 </tr>
 <tr>
  <td width="18%" valign=top style='width:18.02%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Other </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(N = 252) </span></p>
  </td>
  <td width="15%" valign=top style='width:15.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>8.6 </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(6.8  10.2) </span></p>
  </td>
  <td width="11%" valign=top style='width:11.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>N = 106 </span></p>
  </td>
  <td width="15%" valign=top style='width:15.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>9.2 </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(8.1  10.6) </span></p>
  </td>
  <td width="11%" valign=top style='width:11.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>N = 146 </span></p>
  </td>
  <td width="18%" valign=top style='width:18.84%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>1.08 </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(0.811.45) </span></p>
  </td>
  <td width="11%" valign=top style='width:11.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>0.586 </span></p>
  </td>
 </tr>
 <tr>
  <td width="18%" valign=top style='width:18.02%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Squamous cell </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(N = 473) </span></p>
  </td>
  <td width="15%" valign=top style='width:15.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>9.4 </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(8.4  10.2) </span></p>
  </td>
  <td width="11%" valign=top style='width:11.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>N = 244 </span></p>
  </td>
  <td width="15%" valign=top style='width:15.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>10.8 </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(9.5  12.1) </span></p>
  </td>
  <td width="11%" valign=top style='width:11.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>N = 229 </span></p>
  </td>
  <td width="18%" valign=top style='width:18.84%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>1.23 </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(1.001.51) </span></p>
  </td>
  <td width="11%" valign=top style='width:11.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>0.050 </span></p>
  </td>
 </tr>
 <tr>
  <td width="100%" colspan=7 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Abbreviations:
  CI = confidence interval; ITT = intent-to-treat; N = total population size. </span></p>
  </td>
 </tr>
 <tr>
  <td width="100%" colspan=7 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><sup><span lang=EN-GB>a</span></sup><span
  lang=EN-GB> Statistically significant for non-inferiority, with the entire
  confidence interval for HR well below the 1.17645 non-inferiority margin (<i>p</i>
  &lt; 0.001). </span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Kaplan-Meier
plots of overall survival by histology</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span style='position:absolute;
z-index:251657216;margin-left:243px;margin-top:39px;width:330px;height:47px'><img
width=330 height=47 src="PemetrexedHospira_files/image001.png"></span><img
border=0 width=576 height=232 src="PemetrexedHospira_files/image002.png"
alt=IMAGE002></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>There were no
clinically relevant differences observed for the safety profile of pemetrexed plus
cisplatin within the histology subgroups. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Patients treated
with pemetrexed and cisplatin required fewer transfusions (16.4% versus 28.9%,
p&nbsp;&lt;&nbsp;0.001), red blood cell transfusions (16.1% versus 27.3%, p
&lt; 0.001) and platelet transfusions (1.8% versus 4.5%, p = 0.002). Patients
also required lower administration of erythropoietin/darbopoietin (10.4% versus
18.1%, p &lt; 0.001), G-CSF/GM-CSF (3.1% versus 6.1%, p&nbsp;= 0.004), and iron
preparations (4.3% versus 7.0%, p = 0.021). </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><u><span lang=EN-GB>NSCLC,
maintenance treatment</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>JMEN</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>A multi-centre,
randomised, double-blind, placebo-controlled Phase-3 study (JMEN), compared the
efficacy and safety of maintenance treatment with pemetrexed plus best
supportive care (BSC) (N&nbsp;=&nbsp;441) with that of placebo plus BSC (N =
222) in patients with locally advanced (Stage IIIB) or metastatic (Stage IV)
Non-Small Cell Lung Cancer (NSCLC) who did not progress after 4 cycles of
first-line doublet therapy containing cisplatin or carboplatin in combination
with gemcitabine, paclitaxel, or docetaxel. First-line doublet therapy
containing pemetrexed was not included. All patients included in this study had
an ECOG performance status 0 or 1. Patients received maintenance treatment
until disease progression. Efficacy and safety were measured from the time of
randomisation after completion of first-line (induction) therapy. Patients
received a median of 5&nbsp;cycles of maintenance treatment with pemetrexed and
3.</span><span lang=EN-GB>5&nbsp;cycles</span><span lang=EN-GB> of placebo. A
total of 213&nbsp;patients (48.3%) completed &#8805; 6&nbsp;cycles and a total
of 103&nbsp;patients (23.4%) completed &#8805; 10&nbsp;cycles of treatment with
pemetrexed. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The study met
its primary endpoint and showed a statistically significant improvement in PFS
in the pemetrexed arm over the placebo arm (N = 581, independently reviewed
population; median of 4.0&nbsp;months and 2.0&nbsp;months, respectively)
(hazard ratio = 0.60, 95% CI = 0.49&#8209;0.73, p &lt; 0.00001). The
independent review of patient scans confirmed the findings of the investigator
assessment of PFS. The median OS for the overall population (N = 663) was
13.4&nbsp;months for the pemetrexed arm and 10.6&nbsp;months for the placebo
arm, hazard ratio = 0.79 (95% CI= 0.65&#8209;0.95, p = 0.01192). </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Consistent with
other pemetrexed studies, a difference in efficacy according to NSCLC histology
was observed in JMEN. For patients with NSCLC other than predominantly squamous
cell histology (N&nbsp;=&nbsp;430, independently reviewed population) median
PFS was 4.4&nbsp;months for the pemetrexed arm and 1.8&nbsp;months for the
placebo arm, hazard ratio = 0.47 (95% CI = 0.37&#8209;0.60, p = 0.00001). The
median OS for patients with NSCLC other than predominantly squamous cell
histology (N = 481) was 15.5&nbsp;months for the pemetrexed arm and 10.3&nbsp;months
for the placebo arm, hazard ratio = 0.70 (95% CI&nbsp;= 0.56&#8209;0.88, p =
0.002). Including the induction phase, the median OS for patients with NSCLC
other than predominantly squamous cell histology was 18.6&nbsp;months for the pemetrexed
arm and 13.6&nbsp;months for the placebo arm, hazard ratio = 0.71 (95% CI =
0.56&#8209;0.88, p = 0.002). </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The PFS and OS
results in patients with squamous cell histology suggested no advantage for pemetrexed
over placebo. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>There were no
clinically relevant differences observed for the safety profile of pemetrexed within
the histology subgroups. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>JMEN:
Kaplan-Meier plots of progression-free survival (PFS) and overall survival p</span></b><b><span
lang=EN-GB>emetrexed </span></b><b><span lang=EN-GB>versus placebo in patients
with NSCLC other than predominantly squamous cell histology</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><img border=0 width=583
height=250 src="PemetrexedHospira_files/image003.png" alt=90502A></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>PARAMOUNT</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>A multi-centre,
randomised, double-blind, placebo-controlled Phase-3 study (PARAMOUNT),
compared the efficacy and safety of continuation maintenance treatment with pemetrexed
plus BSC (N&nbsp;= 359) with that of placebo plus BSC (N = 180) in patients
with locally advanced (Stage IIIB) or metastatic (Stage IV) NSCLC other than
predominantly squamous cell histology who did not progress after 4&nbsp;cycles
of first-line doublet therapy of pemetrexed in combination with cisplatin. Of
the 939&nbsp;patients treated with pemetrexed plus cisplatin induction, </span><span
lang=EN-GB>539&nbsp;patients</span><span lang=EN-GB> were randomised to
maintenance treatment with pemetrexed or placebo. Of the randomised patients,
44.9% had a complete/partial response and 51.9% had a response of stable
disease to pemetrexed plus cisplatin induction. Patients randomised to
maintenance treatment were required to have an ECOG performance status 0 or 1.
The median time from the start of pemetrexed plus cisplatin induction therapy
to the start of maintenance treatment was 2.96&nbsp;months on both the
pemetrexed arm and the placebo arm. Randomised patients received maintenance
treatment until disease progression. Efficacy and safety were measured from the
time of randomisation after completion of first-line (induction) therapy. Patients
received a median of 4&nbsp;cycles of maintenance treatment with pemetrexed and
4&nbsp;cycles of placebo. A total of </span><span lang=EN-GB>169&nbsp;patients</span><span
lang=EN-GB> (47.1%) completed &#8805; 6 cycles maintenance treatment with pemetrexed,
representing at least 10 total cycles of pemetrexed. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The study met
its primary endpoint and showed a statistically significant improvement in PFS
in the pemetrexed arm over the placebo arm (N = 472, independently reviewed
population; median of 3.9&nbsp;months and 2.6&nbsp;months, respectively)
(hazard ratio = 0.64, 95% CI = 0.51&#8209;0.81, p = 0.0002). The independent
review of patient scans confirmed the findings of the investigator assessment
of PFS. For randomised patients, as measured from the start of pemetrexed plus
cisplatin first-line induction treatment, the median investigator-assessed PFS
was 6.9&nbsp;months for the pemetrexed arm and 5.6&nbsp;months for the placebo
arm (hazard ratio = 0.59, 95% CI = 0.47&#8209;0.74). </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Following pemetrexed
plus cisplatin induction (4&nbsp;cycles), treatment with pemetrexed was
statistically superior to placebo for OS (median 13.9&nbsp;months versus 11.0&nbsp;months,
hazard ratio = 0.78, 95% CI=0.64&#8209;0.96, p=0.0195). At the time of this
final survival analysis, 28.7% of patients were alive or lost to follow up on
the pemetrexed arm versus 21.7% on the placebo arm. The relative treatment
effect of pemetrexed was internally consistent across subgroups (including
disease stage, induction response, ECOG PS, smoking status, gender, histology
and age) and similar to that observed in the unadjusted OS and PFS analyses. The
1&nbsp;year and 2&nbsp;year survival rates for patients on pemetrexed were 58%
and 32% respectively, compared to 45% and 21% for patients on placebo. From the
start of pemetrexed plus cisplatin first-line induction treatment, the median
OS of patients was 16.9&nbsp;months for the pemetrexed arm and 14.0&nbsp;months
for the placebo arm (hazard ratio= 0.78, 95% CI= 0.64&#8209;0.96). The
percentage of patients that received post-study treatment was 64.3% for pemetrexed
and 71.7% for placebo. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>PARAMOUNT: Kaplan-Meier plot of progression-free survival (PFS) and
Overall Survival (OS) for continuation p</span></b><b><span lang=EN-GB>emetrexed
</span></b><b><span lang=EN-GB>maintenance versus placebo in patients with
NSCLC other than predominantly squamous cell histology (measured from
randomisation)</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><img border=0 width=584
height=279 src="PemetrexedHospira_files/image004.png" alt=90502B></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The pemetrexed maintenance
safety profiles from the two studies JMEN and PARAMOUNT were similar.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;page-break-after:
avoid'><b><span lang=EN-GB>5.2 Pharmacokinetic properties</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The
pharmacokinetic properties of pemetrexed following single-agent administration
have been evaluated in 426 cancer patients with a variety of solid tumours at
doses ranging from 0.2 to 838&nbsp;mg/m<sup>2</sup> infused over a 10&nbsp;minute
period. Pemetrexed has a steady-state volume of distribution of 9&nbsp;l/m<sup>2</sup>.
<i>In vitro</i> studies indicate that pemetrexed is approximately 81% bound to
plasma proteins. Binding was not notably affected by varying degrees of renal
impairment. Pemetrexed undergoes limited hepatic metabolism. Pemetrexed is
primarily eliminated in the urine, with 70% to 90% of the administered dose
being recovered unchanged in urine within the first 24&nbsp;hours following
administration. <i>In vitro</i> studies indicate that pemetrexed is actively
secreted by OAT3 (organic anion transporter). </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Pemetrexed total
systemic clearance is 91.8&nbsp;ml/min and the elimination half-life from
plasma is 3.5&nbsp;hours in patients with normal renal function (creatinine
clearance of 90&nbsp;ml/min). Between-patient variability in clearance is
moderate at 19.3%. Pemetrexed total systemic exposure (AUC) and maximum plasma
concentration increase proportionally with dose. The pharmacokinetics of
pemetrexed are consistent over multiple treatment cycles. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The
pharmacokinetic properties of pemetrexed are not influenced by concurrently
administered cisplatin. Oral folic acid and intramuscular vitamin B<sub>12</sub>
supplementation do not affect the pharmacokinetics of pemetrexed.</span></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>5.3 Preclinical safety data</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Administration of pemetrexed to pregnant
mice resulted in decreased foetal viability, decreased foetal weight,
incomplete ossification of some skeletal structures, and cleft palate.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Administration
of pemetrexed to male mice resulted in reproductive toxicity characterised by
reduced fertility rates and testicular atrophy. In a study conducted in beagle
dog by intravenous bolus injection for 9&nbsp;months, testicular findings
(degeneration/necrosis of the seminiferous epithelium) have been observed. This
suggests that pemetrexed may impair male fertility. Female fertility was not
investigated. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Pemetrexed was
not mutagenic in either the <i>in vitro</i> chromosome aberration test in
Chinese hamster ovary cells, or the Ames test. Pemetrexed has been shown to be
clastogenic in the <i>in vivo</i> micronucleus test in the mouse. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Studies to assess the carcinogenic
potential of pemetrexed have not been conducted.</span></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>6. PHARMACEUTICAL PARTICULARS</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>6.1 List of excipients</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Mannitol (E421)</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Hydrochloric
acid (for pH adjustment) </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Sodium hydroxide
(for pH adjustment)</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>6.2 Incompatibilities</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Pemetrexed is
physically incompatible with diluents containing calcium, including lactated
Ringer's injection and Ringer's injection. In the absence of other
compatibility studies this medicinal product must not be mixed with other
medicinal products.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>6.3 Shelf life</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Unopened vial</span></u></p>

<p class=MsoNormal><span lang=EN-GB>3&nbsp;years</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Reconstituted
and infusion solutions </span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Chemical and
physical in-use stability of reconstituted and infusion solutions of Pemetrexed
Hospira powder for concentrate for solution for infusion has been demonstrated
for up to 24&nbsp;hours after reconstitution of the original vial when stored
below 25C. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>From a microbiological point of view, the product should be used
immediately. If not used immediately, in-use storage times and conditions prior
to use are the responsibility of the user and would normally not be longer than
24 hours at 2</span><span lang=EN-GB></span><span lang=EN-GB>C to 8</span><span
lang=EN-GB></span><span lang=EN-GB>C.</span></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>6.4 Special precautions for storage</span></b></p>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>This medicinal
product does not require any special storage conditions.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>For storage
conditions after reconstitution of the medicinal product, see section 6.3.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.5pt;text-indent:-28.5pt'><b><span
lang=EN-GB>6.5<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></b><b><span lang=EN-GB>Nature and contents of container</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Pemetrexed
Hospira 100&nbsp;mg powder for concentrate for solution for infusion </span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Type I glass vial
with rubber stopper containing 100 mg of pemetrexed (as pemetrexed disodium
hemipentahydrate).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Pack of 1 vial.</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Pemetrexed
Hospira 500&nbsp;mg powder for concentrate for solution for infusion </span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Type I glass
vial with rubber stopper containing 500 mg of pemetrexed (as pemetrexed disodium
hemipentahydrate).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Pack of 1 vial.</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Pemetrexed
Hospira 1,000&nbsp;mg powder for concentrate for solution for infusion </span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Type I glass
vial with rubber stopper containing 1,000 mg of pemetrexed (as pemetrexed
disodium hemipentahydrate).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Pack of 1 vial.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>6.6 Special precautions for disposal and other handling</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:9.0pt;text-indent:-9.0pt;line-height:
normal'><span lang=EN-GB>1. Use aseptic technique during the reconstitution and
further dilution of pemetrexed for intravenous infusion administration. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:9.0pt;text-indent:-9.0pt;line-height:
normal'><span lang=EN-GB>2. Calculate the dose and the number of Pemetrexed
Hospira vials needed. Each vial contains an excess of pemetrexed to facilitate
delivery of label amount. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:9.0pt;text-indent:-9.0pt;line-height:
normal'><span lang=EN-GB>3. Reconstitute 100&nbsp;mg vials with 4.2&nbsp;ml of
sodium chloride 9&nbsp;mg/ml (0.9%) solution for injection, without
preservative. Reconstitute 500&nbsp;mg vials with 20&nbsp;ml of sodium chloride
9&nbsp;mg/ml (0.9%) solution for injection, without preservative. Reconstitute
1,000&nbsp;mg vials with 40&nbsp;ml of sodium chloride 9&nbsp;mg/ml (0.9%)
solution for injection, without preservative. The resulting solution contains
25&nbsp;mg/ml pemetrexed. Gently swirl each vial until the powder is completely
dissolved. The resulting solution is clear and ranges in colour from colourless
to yellow or green-yellow without adversely affecting product quality. The pH
of the reconstituted solution is between 6.6 and 7.8. <b>Further dilution is
required.</b> </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:9.0pt;text-indent:-9.0pt;line-height:
normal'><span lang=EN-GB>4. The appropriate volume of reconstituted pemetrexed
solution must be further diluted to 100&nbsp;ml with sodium chloride 9&nbsp;mg/ml
(0.9%) solution for injection, without preservative, and administered as an
intravenous infusion over 10&nbsp;minutes. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:9.0pt;text-indent:-9.0pt;line-height:
normal'><span lang=EN-GB>5. Pemetrexed infusion solutions prepared as directed
above are compatible with polyvinyl chloride- and polyolefin-lined
administration sets and infusion bags. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:9.0pt;text-indent:-9.0pt;line-height:
normal'><span lang=EN-GB>6. Parenteral medicinal products must be inspected
visually for particulate matter and discolouration prior to administration. If
particulate matter is observed, do not administer. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>7. Pemetrexed
solutions are for single use only. Any unused medicinal product or waste
material must be disposed of in accordance with local requirements. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Preparation
and administration precautions</span></u><u><span lang=EN-GB> </span></u></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>As with other
potentially toxic anti-cancer agents, care should be exercised in the handling
and preparation of pemetrexed infusion solutions. The use of gloves is
recommended. If a pemetrexed solution contacts the skin, wash the skin
immediately and thoroughly with soap and water. If pemetrexed solutions contact
the mucous membranes, flush thoroughly with water. Pemetrexed is not a
vesicant. There is not a specific antidote for extravasation of pemetrexed.
There have been few reported cases of pemetrexed extravasation, which were not
assessed as serious by the investigator. Extravasation should be managed by
local standard practice as with other non-vesicants.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=FR>7. MARKETING AUTHORISATION HOLDER</span></b></p>

<p class=MsoNormal><span lang=FR>&nbsp;</span></p>

<p style='margin:0in'><span lang=FR style='font-size:11.0pt'>Pfizer Europe MA
EEIG</span></p>

<p style='margin:0in'><span lang=FR style='font-size:11.0pt'>Boulevard de la
Plaine 17</span></p>

<p style='margin:0in'><span lang=EN-GB style='font-size:11.0pt'>1050 Bruxelles</span></p>

<p style='margin:0in'><span lang=EN-GB style='font-size:11.0pt'>Belgium</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>8. MARKETING AUTHORISATION NUMBER(S) </span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>EU/1/15/1057/001</span></p>

<p class=MsoNormal><span lang=EN-GB>EU/1/15/1057/002</span></p>

<p class=MsoNormal><span lang=EN-GB>EU/1/15/1057/003</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Date of initial authorisation: 20 November
2015</span></p>

<p class=MsoNormal><span lang=EN-GB>Date of latest renewal: 10 August 2020</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>10. DATE OF REVISION OF THE TEXT</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Detailed information on this medicinal product
is available on the website of the European Medicines Agency (EMA) </span><span
lang=EN-GB><a href="http://www.ema.europa.eu"><span class=FooterChar><span
style='font-size:8.0pt;color:windowtext;text-decoration:none'>http://www.ema.europa.eu</span></span></a></span><span
lang=EN-GB>.<br clear=all style='page-break-before:always'>
1. <b>NAME OF THE MEDICINAL PRODUCT</b></span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Pemetrexed
Hospira 25 mg/ml concentrate for solution for infusion. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>2. QUALITATIVE AND QUANTITATIVE
COMPOSITION</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>One ml of
concentrate contains pemetrexed disodium equivalent to 25&nbsp;mg of pemetrexed.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>One vial of 4 ml
concentrate contains pemetrexed disodium equivalent to 100&nbsp;mg of
pemetrexed. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>One vial of 20
ml concentrate contains pemetrexed disodium equivalent to 500&nbsp;mg of
pemetrexed. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>One vial of 40
ml concentrate contains pemetrexed disodium equivalent to 1,000&nbsp;mg of
pemetrexed.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Excipient
with known effect</span></u><span lang=EN-GB> </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>One vial of 20
ml concentrate contains approximately 54&nbsp;mg sodium.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>One vial of 40
ml concentrate contains approximately 108&nbsp;mg sodium.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>For the full
list of excipients, see section 6.1.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>3. PHARMACEUTICAL <span style='text-transform:uppercase'>form</span></span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Concentrate for
solution for infusion (sterile concentrate). </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The concentrate
is a clear, colourless to pale yellow or green yellow solution practically free
from visible particulates.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The pH is between 7.3 to 8.3.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB style='text-transform:uppercase'>4. Clinical particulars</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>4.1 Therapeutic indications</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Malignant
pleural mesothelioma</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Pemetrexed
Hospira in combination with cisplatin is indicated for the treatment of
chemotherapy naive patients with unresectable malignant pleural mesothelioma. </span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Non-small cell lung cancer</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Pemetrexed Hospira</span><span lang=EN-GB> in combination with
cisplatin is indicated for the first-line treatment of patients with locally
advanced or metastatic non-small cell lung cancer other than predominantly
squamous cell histology (see section 5.1). </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Pemetrexed
Hospira</span><span lang=EN-GB> is indicated as monotherapy for the maintenance
treatment of locally advanced or metastatic non-small cell lung cancer other
than predominantly squamous cell histology in patients whose disease has not
progressed immediately following platinum-based chemotherapy (see section&nbsp;5.1).
</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Pemetrexed
Hospira</span><span lang=EN-GB> is indicated as monotherapy for the second-line
treatment of patients with locally advanced or metastatic non-small cell lung
cancer other than predominantly squamous cell histology (see section 5.1).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;page-break-after:
avoid'><b><span lang=EN-GB>4.2 Posology and method of administration</span></b></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Pemetrexed
Hospira</span><span lang=EN-GB> must only be administered under the supervision
of a physician qualified in the use of anti-cancer chemotherapy. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Posology</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Pemetrexed Hospira</span></u></i><i><u><span lang=EN-GB> in
combination with cisplatin</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The recommended
dose of Pemetrexed Hospira is 500&nbsp;mg/m<sup>2</sup> of body surface area
(BSA) administered as an intravenous infusion over 10&nbsp;minutes on the first
day of each 21&#8209;day cycle. The recommended dose of cisplatin is 75&nbsp;mg/m<sup>2
</sup>BSA infused over two hours approximately 30&nbsp;minutes after completion
of the pemetrexed infusion on the first day of each 21&#8209;day cycle. <u>Patients
must receive adequate anti&#8209;emetic treatment and appropriate hydration
prior to and/or after receiving cisplatin</u> (see also cisplatin Summary of
Product Characteristics for specific dosing advice). </span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><i><u><span lang=EN-GB>Pemetrexed
Hospira </span></u></i><i><u><span lang=EN-GB>as single agent</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In patients
treated for non-small cell lung cancer after prior chemotherapy, the
recommended dose of Pemetrexed Hospira is 500&nbsp;mg/m<sup>2</sup> BSA
administered as an intravenous infusion over 10&nbsp;minutes on the first day
of each 21&#8209;day cycle. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><u><span lang=EN-GB>Pre-medication
regimen</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>To reduce the
incidence and severity of skin reactions, a corticosteroid should be given the
day prior to, on the day of, and the day after pemetrexed administration. The
corticosteroid should be equivalent to 4&nbsp;mg of dexamethasone administered
orally twice a day (see section 4.4). </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>To reduce
toxicity, patients treated with pemetrexed must also receive vitamin
supplementation (see section 4.4). Patients must take oral folic acid or a
multivitamin containing folic acid (350 to 1,000&nbsp;micrograms) on a daily
basis. At least five doses of folic acid must be taken during the seven days
preceding the first dose of pemetrexed, and dosing must continue during the full
course of therapy and for 21 days after the last dose of pemetrexed. Patients
must also receive an intramuscular injection of vitamin B<sub>12</sub>
(1,000&nbsp;micrograms) in the week preceding the first dose of pemetrexed and
once every three cycles thereafter. Subsequent vitamin B<sub>12</sub>
injections may be given on the same day as pemetrexed. </span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><i><u><span lang=EN-GB>Monitoring</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Patients
receiving pemetrexed should be monitored before each dose with a complete blood
count, including a differential white cell count (WCC) and platelet count.
Prior to each chemotherapy administration, blood chemistry tests should be
collected to evaluate renal and hepatic function. Before the start of any cycle
of chemotherapy, patients are required to have the following: absolute
neutrophil count (ANC) should be &#8805; 1,500&nbsp;cells/mm<sup>3</sup> and
platelets should be &#8805; 100,000&nbsp;cells/mm<sup>3</sup>. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Creatinine
clearance should be &#8805; 45&nbsp;ml/min. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The total bilirubin
should be &#8804; 1.5&#8209;times upper limit of normal. Alkaline phosphatase
(ALP), aspartate aminotransferase (AST or SGOT), and alanine aminotransferase
(ALT or SGPT) should be &#8804; 3&#8209;times upper limit of normal. Alkaline
phosphatase, AST, and ALT &#8804; 5&#8209;times upper limit of normal is
acceptable if liver has tumour involvement. </span></p>

<p class=MsoNormal style='line-height:normal'><i><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Dose adjustments</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Dose adjustments
at the start of a subsequent cycle should be based on nadir haematologic counts
or maximum non-haematologic toxicity from the preceding cycle of therapy.
Treatment may be delayed to allow sufficient time for recovery. Upon recovery,
patients should be re-treated using the guidelines in Tables 1, 2, and 3, which
are applicable for Pemetrexed Hospira used as a single agent or in combination
with cisplatin. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse;border:none'>
 <tr>
  <td width="100%" colspan=2 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><b><span lang=EN-GB>Table 1. Dose modification table
  for </span></b><b><span lang=EN-GB>Pemetrexed Hospira</span></b><b><span
  lang=EN-GB> (as single agent or in combination) and cisplatin - Haematologic toxicities</span></b></p>
  </td>
 </tr>
 <tr>
  <td width="55%" valign=top style='width:55.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>Nadir ANC &lt; 500/mm<sup>3</sup> and nadir platelets &#8805;
  50,000/mm<sup>3</sup></span></p>
  </td>
  <td width="45%" valign=top style='width:45.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>75% of previous dose (both Pemetrexed Hospira and cisplatin) </span></p>
  </td>
 </tr>
 <tr>
  <td width="55%" valign=top style='width:55.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>Nadir platelets &lt; 50,000/mm<sup>3 </sup>regardless of nadir ANC
  </span></p>
  </td>
  <td width="45%" valign=top style='width:45.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>75% of previous dose (both Pemetrexed Hospira and cisplatin) </span></p>
  </td>
 </tr>
 <tr>
  <td width="55%" valign=top style='width:55.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>Nadir platelets &lt; 50,000/mm<sup>3</sup> with bleeding<sup>a</sup>,
  regardless of nadir ANC </span></p>
  </td>
  <td width="45%" valign=top style='width:45.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>50% of previous dose (both Pemetrexed Hospira and cisplatin) </span></p>
  </td>
 </tr>
 <tr>
  <td width="100%" colspan=2 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><sup><span
  lang=EN-GB>a</span></sup><span lang=EN-GB> These criteria meet the National
  Cancer Institute Common Toxicity Criteria (CTC v2.0; NCI 1998) definition of
  &#8805; CTC Grade 2 bleeding. </span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>If patients
develop non-haematologic toxicities &#8805; Grade 3 (excluding neurotoxicity), Pemetrexed
Hospira should be withheld until resolution to less than or equal to the
patient's pre-therapy value. Treatment should be resumed according to the
guidelines in Table 2. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse;border:none'>
 <tr>
  <td width="100%" colspan=3 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
  lang=EN-GB>Table 2. Dose modification table for </span></b><b><span
  lang=EN-GB>Pemetrexed Hospira</span></b><b><span lang=EN-GB> (as single agent
  or in combination) and cisplatin - Non-haematologic toxicities </span></b><sup><span
  lang=EN-GB>a, b</span></sup></p>
  </td>
 </tr>
 <tr>
  <td width="40%" valign=top style='width:40.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="30%" valign=top style='width:30.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Dose of </span></b><b><span
  lang=EN-GB>Pemetrexed Hospira</span></b><b><span lang=EN-GB> (mg/m<sup>2</sup>)</span></b></p>
  </td>
  <td width="30%" valign=top style='width:30.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Dose for cisplatin
  (mg/m<sup>2</sup>)</span></b></p>
  </td>
 </tr>
 <tr>
  <td width="40%" valign=top style='width:40.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Any Grade 3 or
  4 toxicities except mucositis </span></p>
  </td>
  <td width="30%" valign=top style='width:30.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>75% of
  previous dose </span></p>
  </td>
  <td width="30%" valign=top style='width:30.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>75% of
  previous dose </span></p>
  </td>
 </tr>
 <tr>
  <td width="40%" valign=top style='width:40.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Any diarrhoea
  requiring hospitalisation (irrespective of grade) or Grade 3 or 4 diarrhoea </span></p>
  </td>
  <td width="30%" valign=top style='width:30.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>75% of
  previous dose </span></p>
  </td>
  <td width="30%" valign=top style='width:30.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>75% of
  previous dose </span></p>
  </td>
 </tr>
 <tr>
  <td width="40%" valign=top style='width:40.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Grade 3 or 4
  mucositis </span></p>
  </td>
  <td width="30%" valign=top style='width:30.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>50% of
  previous dose </span></p>
  </td>
  <td width="30%" valign=top style='width:30.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>100% of
  previous dose </span></p>
  </td>
 </tr>
 <tr>
  <td width="100%" colspan=3 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><sup><span lang=EN-GB>a </span></sup><span
  lang=EN-GB>National Cancer Institute Common Toxicity Criteria (CTC v2.0; NCI
  1998) </span></p>
  <p class=MsoNormal style='line-height:normal'><sup><span lang=EN-GB>b </span></sup><span
  lang=EN-GB>Excluding neurotoxicity </span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In the event of
neurotoxicity, the recommended dose adjustment for Pemetrexed Hospira and
cisplatin is documented in Table 3. Patients should discontinue therapy if
Grade 3 or 4 neurotoxicity is observed. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse;border:none'>
 <tr>
  <td width="100%" colspan=3 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
  lang=EN-GB>Table 3. Dose modification table for </span></b><b><span
  lang=EN-GB>Pemetrexed Hospira</span></b><b><span lang=EN-GB> (as single agent
  or in combination) and cisplatin - Neurotoxicity</span></b></p>
  </td>
 </tr>
 <tr>
  <td width="20%" valign=top style='width:20.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>CTC</span></b><sup><span
  lang=EN-GB> a</span></sup><b><span lang=EN-GB> Grade</span></b></p>
  </td>
  <td width="40%" valign=top style='width:40.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Dose of </span></b><b><span
  lang=EN-GB>Pemetrexed Hospira</span></b><b><span lang=EN-GB> (mg/m<sup>2</sup>)</span></b></p>
  </td>
  <td width="40%" valign=top style='width:40.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Dose for cisplatin
  (mg/m<sup>2</sup>)</span></b></p>
  </td>
 </tr>
 <tr>
  <td width="20%" valign=top style='width:20.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>0&#8209;1 </span></p>
  </td>
  <td width="40%" valign=top style='width:40.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>100% of
  previous dose </span></p>
  </td>
  <td width="40%" valign=top style='width:40.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>100% of
  previous dose </span></p>
  </td>
 </tr>
 <tr>
  <td width="20%" valign=top style='width:20.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>2 </span></p>
  </td>
  <td width="40%" valign=top style='width:40.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>100% of
  previous dose </span></p>
  </td>
  <td width="40%" valign=top style='width:40.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>50% of
  previous dose </span></p>
  </td>
 </tr>
 <tr>
  <td width="100%" colspan=3 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><sup><span lang=EN-GB>a </span></sup><span
  lang=EN-GB>National Cancer Institute Common Toxicity Criteria (CTC v2.0; NCI
  1998) </span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Treatment with Pemetrexed
Hospira should be discontinued if a patient experiences any haematologic or
non-haematologic Grade 3 or 4 toxicity after 2 dose reductions or immediately
if Grade 3 or 4 neurotoxicity is observed. </span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><i><u><span lang=EN-GB>Special
populations</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Elderly</span></i><span
lang=EN-GB> </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In clinical
studies, there has been no indication that patients 65&nbsp;years of age or
older are at increased risk of adverse reactions compared to patients younger
than 65&nbsp;years old. No dose reductions other than those recommended for all
patients are necessary. </span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>Paediatric population</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>There is no
relevant use of pemetrexed in the paediatric population in malignant pleural
mesothelioma and non-small cell lung cancer. </span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Patients with
renal impairment </span></i><span lang=EN-GB>(Standard Cockcroft and Gault
formula or glomerular filtration rate measured Tc99m DPTA serum clearance
method)</span><span lang=EN-GB> </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Pemetrexed is
primarily eliminated unchanged by renal excretion. In clinical studies,
patients with creatinine clearance of &#8805; 45&nbsp;ml/min required no dose
adjustments other than those recommended for all patients. There are
insufficient data on the use of pemetrexed in patients with creatinine
clearance below 45&nbsp;ml/min; therefore, the use of pemetrexed is not
recommended (see section 4.4). </span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Patients with
hepatic impairment</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>No relationships
between AST (SGOT), ALT (SGPT), or total bilirubin and pemetrexed
pharmacokinetics were identified. However, patients with hepatic impairment,
such as bilirubin &gt;&nbsp;1.5&#8209;times the upper limit of normal and/or
aminotransferase &gt; 3.0&#8209;times the upper limit of normal (hepatic
metastases absent) or &gt; 5.0&#8209;times the upper limit of normal (hepatic
metastases present), have not been specifically studied.</span></p>

<p class=MsoNormal style='text-align:justify;line-height:normal;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Method of
administration </span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>Pemetrexed Hospira
is for intravenous use. It should be administered as an intravenous infusion
over 10&nbsp;minutes on the first day of each 21&#8209;day cycle.</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>For precautions
to be taken before handling or administering Pemetrexed Hospira and for
instructions on dilution of Pemetrexed Hospira before administration, see
section 6.6.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>4.3 Contraindications</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Hypersensitivity
to the active substance or to any of the excipients listed in section 6.1. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Breast-feeding
(see section 4.6). </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Concomitant
yellow fever vaccine (see section 4.5).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>4.4 Special warnings and precautions for use</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Pemetrexed can
suppress bone marrow function as manifested by neutropenia, thrombocytopenia,
and anaemia (or pancytopenia) (see section 4.8). Myelosuppression is usually
the dose-limiting toxicity. Patients should be monitored for myelosuppression
during therapy and pemetrexed should not be given to patients until absolute
neutrophil count (ANC) returns to &#8805; 1,500&nbsp;cells/mm<sup>3</sup> and
platelet count returns to &#8805; 100,000&nbsp;cells/mm<sup>3</sup>. Dose
reductions for subsequent cycles are based on nadir ANC, platelet count, and
maximum non-haematologic toxicity seen from the previous cycle (see section
4.2). </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Less toxicity
and reduction in Grade 3/4 haematologic and non-haematologic toxicities, such
as neutropenia, febrile neutropenia, and infection with Grade 3/4 neutropenia,
were reported when pre&#8209;treatment with folic acid and vitamin B<sub>12</sub>
was administered. Therefore, all patients treated with pemetrexed must be
instructed to take folic acid and vitamin B<sub>12</sub> as a prophylactic
measure to reduce treatment-related toxicity (see section 4.2). </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Skin reactions
have been reported in patients not pre-treated with a corticosteroid.
Pre-treatment with dexamethasone (or equivalent) can reduce the incidence and
severity of skin reactions (see section&nbsp;4.2). </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>An insufficient
number of patients have been studied with creatinine clearance of below 45&nbsp;ml/min.
Therefore, the use of pemetrexed in patients with creatinine clearance of
&lt;45&nbsp;ml/min is not recommended (see section 4.2). </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Patients with
mild to moderate renal insufficiency (creatinine clearance from 45 to 79&nbsp;ml/min)
should avoid taking non-steroidal anti-inflammatory drugs (NSAIDs), such as
ibuprofen, and acetylsalicylic acid (&gt;1.3&nbsp;g daily) for 2 days before,
on the day of, and 2&nbsp;days following pemetrexed administration (see section
4.5). </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In patients with
mild to moderate renal insufficiency eligible for pemetrexed therapy, NSAIDs
with long elimination half-lives should be interrupted for at least 5 days
prior to, on the day of, and at least 2&nbsp;days following pemetrexed
administration (see section 4.5). </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Serious renal
events, including acute renal failure, have been reported with pemetrexed alone
or in association with other chemotherapeutic agents. Many of the patients in
whom these occurred had underlying risk factors for the development of renal
events, including dehydration or pre-existing hypertension or diabetes.
Nephrogenic diabetes insipidus and renal tubular necrosis were also reported in
post marketing setting with pemetrexed alone or with other chemotherapeutic
agents. Most of these events resolved after pemetrexed withdrawal. Patients
should be regularly monitored for acute tubular necrosis, decreased renal
function and signs and symptoms of nephrogenic diabetes insipidus
(e.g.&nbsp;hypernatraemia). </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The effect of
third space fluid, such as pleural effusion or ascites, on pemetrexed is not
fully defined. A phase 2 study of pemetrexed in 31 solid tumour patients with
stable third space fluid demonstrated no difference in pemetrexed dose normalised
plasma concentrations or clearance compared to patients without third space
fluid collections. Thus, drainage of third space fluid collection prior to
pemetrexed treatment should be considered, but may not be necessary. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Due to the
gastrointestinal toxicity of pemetrexed given in combination with cisplatin,
severe dehydration has been observed. Therefore, patients should receive
adequate antiemetic treatment and appropriate hydration prior to and/or after
receiving treatment. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Serious
cardiovascular events, including myocardial infarction and cerebrovascular
events have been uncommonly reported during clinical studies with pemetrexed,
usually when given in combination with another cytotoxic agent. Most of the
patients in whom these events have been observed had preexisting cardiovascular
risk factors (see section 4.8). </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Immunodepressed
status is common in cancer patients. As a result, concomitant use of live
attenuated vaccines is not recommended (see section 4.3 and 4.5). </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Pemetrexed can
have genetically damaging effects. Sexually mature males are advised not to
father a child during the treatment and up to 6&nbsp;months thereafter.
Contraceptive measures or abstinence are recommended. Owing to the possibility
of pemetrexed treatment causing irreversible infertility, men are advised to
seek counselling on sperm storage before starting treatment. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Women of
childbearing potential must use effective contraception during treatment with
pemetrexed (see section 4.6). </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Cases of radiation
pneumonitis have been reported in patients treated with radiation either prior,
during, or subsequent to their pemetrexed therapy. Particular attention should
be paid to these patients, and caution exercised with use of other
radiosensitising agents. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Cases of
radiation recall have been reported in patients who received radiotherapy weeks
or years previously. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Excipients</span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>One vial of 4 ml
concentrate contains less than 1 mmol sodium (23 mg), that is to say
essentially sodium free.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>One vial of 20 ml
concentrate contains approximately 54&nbsp;mg sodium equivalent to 2.7% of the
WHO recommended maximum daily intake of 2 g sodium for an adult.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>One vial of 40
ml concentrate contains approximately 108&nbsp;mg sodium</span><span
lang=EN-GB> </span><span lang=EN-GB>equivalent to 5.4% of the WHO recommended
maximum daily intake of 2 g sodium for an adult.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>4.5 Interaction
with other medicinal products and other forms of interaction</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Pemetrexed is
mainly eliminated unchanged renally by tubular secretion and to a lesser extent
by glomerular filtration. Concomitant administration of nephrotoxic medicinal
products (e.g., aminoglycoside, loop diuretics, platinum compounds, ciclosporin)
could potentially result in delayed clearance of pemetrexed. This combination
should be used with caution. If necessary, creatinine clearance should be
closely monitored. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Concomitant
administration of substances that are also tubularly secreted (e.g.,
probenecid, penicillin) could potentially result in delayed clearance of
pemetrexed. Caution should be made when these medicinal products are combined
with pemetrexed. If necessary, creatinine clearance should be closely
monitored. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In patients with
normal renal function (creatinine clearance &#8805; 80&nbsp;ml/min), high doses
of non-steroidal anti-inflammatory drugs (NSAIDs, such as ibuprofen &gt; 1600&nbsp;mg/day)
and acetylsalicylic acid at higher doses (&#8805;&nbsp;1.3&nbsp;g daily) may
decrease pemetrexed elimination and, consequently, increase the occurrence of
pemetrexed adverse reactions. Therefore, caution should be made when
administering higher doses of NSAIDs or acetylsalicylic acid, concurrently with
pemetrexed to patients with normal function (creatinine clearance &#8805; 80&nbsp;ml/min).
</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In patients with
mild to moderate renal insufficiency (creatinine clearance from 45 to 79&nbsp;ml/min),
the concomitant administration of pemetrexed with NSAIDs (e.g., ibuprofen) or acetylsalicylic
acid at higher doses should be avoided for 2 days before, on the day of, and 2
days following pemetrexed administration (see section 4.4). </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In the absence
of data regarding potential interaction with NSAIDs having longer half-lives
such as piroxicam or rofecoxib, the concomitant administration with pemetrexed
in patients with mild to moderate renal insufficiency should be interrupted for
at least 5&nbsp;days prior to, on the day of, and at least 2&nbsp;days
following pemetrexed administration (see section 4.4). If concomitant
administration of NSAIDs is necessary, patients should be monitored closely for
toxicity, especially myelosuppression and gastrointestinal toxicity. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Pemetrexed
undergoes limited hepatic metabolism. Results from <i>in vitro</i> studies with
human liver microsomes indicated that pemetrexed would not be predicted to
cause clinically significant inhibition of the metabolic clearance of medicinal
products metabolised by CYP3A, CYP2D6, CYP2C9, and CYP1A2. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Interactions
common to all cytotoxics</span></u></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Due to the increased
thrombotic risk in patients with cancer, the use of anticoagulation treatment
is frequent. The high intra-individual variability of the coagulation status
during diseases and the possibility of interaction between oral anticoagulants
and anti-cancer chemotherapy require increased frequency of INR (International
Normalised Ratio) monitoring, if it is decided to treat the patient with oral
anticoagulants. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Concomitant use contraindicated:
<i>Yellow fever vaccine:</i> risk of fatal generalised vaccinale disease (see
section 4.3). </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Concomitant use not
recommended: <i>Live attenuated vaccines (except yellow fever, for which
concomitant use is contraindicated): </i>risk of systemic, possibly fatal,
disease. The risk is increased in subjects who are already immunosuppressed by
their underlying disease. Use an inactivated vaccine where it exists
(poliomyelitis) (see section 4.4).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>4.6 Fertility, pregnancy and lactation</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Women of childbearing potential/Contraception in males and females</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Women of childbearing potential must use effective contraception
during treatment with pemetrexed. Pemetrexed can have genetically damaging
effects. Sexually mature males are advised not to father a child during the
treatment, and up to 6 months thereafter. Contraceptive measures or abstinence
are recommended. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Pregnancy</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>There are no
data from the use of pemetrexed in pregnant women; but pemetrexed, like other
anti&#8209;metabolites, is suspected to cause serious birth defects when
administered during pregnancy. Animal studies have shown reproductive toxicity
(see section 5.3). Pemetrexed should not be used during pregnancy unless
clearly necessary, after a careful consideration of the needs of the mother and
the risk for the foetus (see section 4.4). </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Breast-feeding</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>It is unknown
whether pemetrexed is excreted in human milk, and adverse reactions on the breast-feeding
child cannot be excluded. Breast-feeding must be discontinued during pemetrexed
therapy (see section&nbsp;4.3). </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Fertility</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Owing to the
possibility of pemetrexed treatment causing irreversible infertility, men are
advised to seek counselling on sperm storage before starting treatment.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>4.7 Effects on ability to drive and use machines</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>No studies on
the effects on the ability to drive and use machines have been performed.
However, it has been reported that pemetrexed may cause fatigue. Therefore,
patients should be cautioned against driving or operating machines if this
event occurs.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:46.5pt;text-indent:-46.5pt'><b><span
lang=EN-GB>4.8<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></b><b><span lang=EN-GB>Undesirable effects</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Summary of
the safety profile</span></u></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The most
commonly reported undesirable effects related to pemetrexed, whether used as
monotherapy or in combination, are bone marrow suppression manifested as
anaemia, neutropenia, leucopenia, thrombocytopenia; and gastrointestinal
toxicities, manifested as anorexia, nausea, vomiting, diarrhoea, constipation,
pharyngitis, mucositis, and stomatitis. Other undesirable effects include renal
toxicities, increased aminotransferases, alopecia, fatigue, dehydration, rash,
infection/sepsis and neuropathy. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Rarely seen
events include Stevens-Johnson syndrome and Toxic epidermal necrolysis. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Tabulated
list of adverse reactions</span></u></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoEndnoteText><span style='color:black'>The table 4 lists the adverse
drug events regardless of causality associated with pemetrexed used either as a
monotherapy treatment or in combination with cisplatin from the pivotal
registration studies (</span><span lang=EN-GB>JMCH</span><span
style='color:black'>, </span><span lang=EN-GB>JMEI, JMBD, </span>JMEN and
PARAMOUNT)<span style='color:black'> and from the post marketing period<s>.</s></span></p>

<p class=MsoEndnoteText><s><span style='color:black'><span style='text-decoration:
 none'>&nbsp;</span></span></s></p>

<p class=MsoNormal style='line-height:normal'><span style='color:black'>ADRs
are listed by MedDRA body system organ class. The following convention has been
used for classification of frequency: </span><span lang=EN-GB>very common:
&#8805;&nbsp;1/10; common: &#8805;&nbsp;1/100 to &lt;&nbsp;1/10; uncommon:
&#8805;&nbsp;1/1,000 to &lt;&nbsp;1/100; rare: &#8805;&nbsp;1/10,000 to
&lt;&nbsp;1/1,000; very rare: &lt;&nbsp;1/10,000) <span style='color:black'>and
not known (cannot be estimated from the available data).</span></span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Table 4.
Frequencies of all grades adverse drug events regardless of causality from the
pivotal registration studies: JMEI (Pemetrexed vs Docetaxel), JMDB (Pemetrexed
and Cisplatin versus Gemcitabine and Cisplatin, JMCH (Pemetrexed plus Cisplatin
versus Cisplatin), JMEN and PARAMOUNT (Pemetrexed plus Best Supportive Care
versus Placebo plus Best Supportive Care) and from post-marketing period.</span></b></p>

<p class=Normal11pt><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=697
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=102 valign=top style='width:76.3pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><b>System Organ Class </b></p>
  <p class=Normal11pt style='page-break-after:auto'><b>(MedDRA)</b></p>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=85 valign=top style='width:64.1pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Very common</span></b></p>
  <p class=Normal11pt style='page-break-after:auto'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=126 valign=top style='width:94.5pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><b><span lang=EN-GB>Common</span></b></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><b><span lang=EN-GB>Uncommon</span></b></p>
  </td>
  <td width=94 valign=top style='width:70.55pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><b><span lang=EN-GB>Rare</span></b></p>
  </td>
  <td width=92 valign=top style='width:69.1pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><b><span lang=EN-GB>Very
  rare</span></b></p>
  </td>
  <td width=94 valign=top style='width:70.4pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><b><span lang=EN-GB>Not
  known</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=102 valign=top style='width:76.3pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Infections
  and infestations</span></p>
  </td>
  <td width=85 valign=top style='width:64.1pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Infection<sup>a</sup></span></p>
  <p class=MsoNormal><span lang=EN-GB>Pharyngitis</span></p>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=126 valign=top style='width:94.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Sepsis<sup>b</sup></span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=94 valign=top style='width:70.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=92 valign=top style='width:69.1pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Dermo-hypodermitis</span></p>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=94 valign=top style='width:70.4pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=102 valign=top style='width:76.3pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Blood and
  lymphatic system disorders</span></p>
  </td>
  <td width=85 valign=top style='width:64.1pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Neutropenia</span></p>
  <p class=MsoNormal><span lang=EN-GB>Leukopenia</span></p>
  <p class=MsoNormal><span lang=EN-GB>Haemoglobin decreased</span></p>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=126 valign=top style='width:94.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Febrile
  neutropenia</span></p>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Platelet
  count decreased</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Pancytopenia</span></p>
  </td>
  <td width=94 valign=top style='width:70.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Autoimmune
  haemolytic anaemia</span></p>
  </td>
  <td width=92 valign=top style='width:69.1pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=94 valign=top style='width:70.4pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=102 valign=top style='width:76.3pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Immune
  System disorders</span></p>
  </td>
  <td width=85 valign=top style='width:64.1pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=126 valign=top style='width:94.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Hypersensitivity</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'>&nbsp;</p>
  </td>
  <td width=94 valign=top style='width:70.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Anaphylactic
  shock</span></p>
  </td>
  <td width=92 valign=top style='width:69.1pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=94 valign=top style='width:70.4pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=102 valign=top style='width:76.3pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Metabolism</span></p>
  <p class=MsoNormal><span lang=EN-GB>and nutrition</span></p>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>disorders</span></p>
  </td>
  <td width=85 valign=top style='width:64.1pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=126 valign=top style='width:94.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Dehydration</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=94 valign=top style='width:70.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=92 valign=top style='width:69.1pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=94 valign=top style='width:70.4pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=102 valign=top style='width:76.3pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Nervous
  system disorders</span></p>
  </td>
  <td width=85 valign=top style='width:64.1pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><sup><span lang=EN-GB>&nbsp;</span></sup></p>
  </td>
  <td width=126 valign=top style='width:94.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Taste
  disorder</span></p>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Peripheral
  motor neuropathy</span></p>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Peripheral
  sensory neuropathy</span></p>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Dizziness</span></p>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='margin-right:-6.5pt;page-break-after:auto'><span
  lang=EN-GB>Cerebrovascular accident</span></p>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Ischaemic
  stroke</span></p>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Haemorrhage
  intracranial </span></p>
  </td>
  <td width=94 valign=top style='width:70.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=92 valign=top style='width:69.1pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=94 valign=top style='width:70.4pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=102 valign=top style='width:76.3pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Eye
  disorders</span></p>
  </td>
  <td width=85 valign=top style='width:64.1pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=126 valign=top style='width:94.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Conjunctivitis</span></p>
  <p class=MsoNormal><span lang=EN-GB>Dry eye</span></p>
  <p class=MsoNormal><span lang=EN-GB>Lacrimation increased</span></p>
  <p class=MsoNormal><span lang=EN-GB>Keratoconjunctivitis sicca</span></p>
  <p class=MsoNormal><span lang=EN-GB>Eyelid oedema</span></p>
  <p class=MsoNormal><span lang=EN-GB>Ocular surface disease</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=94 valign=top style='width:70.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=92 valign=top style='width:69.1pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=94 valign=top style='width:70.4pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=102 valign=top style='width:76.3pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Cardiac
  disorders<sup> </sup></span></p>
  </td>
  <td width=85 valign=top style='width:64.1pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=126 valign=top style='width:94.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Cardiac
  failure</span></p>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Arrhythmia</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Angina</span></p>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Myocardial
  infarction</span></p>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Coronary
  artery disease</span></p>
  <p class=Normal11pt style='margin-right:-6.5pt'><span lang=EN-GB>Arrhythmia
  supraventricular</span></p>
  </td>
  <td width=94 valign=top style='width:70.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=92 valign=top style='width:69.1pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=94 valign=top style='width:70.4pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=102 valign=top style='width:76.3pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Vascular
  disorders</span></p>
  </td>
  <td width=85 valign=top style='width:64.1pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=126 valign=top style='width:94.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'>Peripheral ischaemia<sup>c</sup></p>
  </td>
  <td width=94 valign=top style='width:70.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=92 valign=top style='width:69.1pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=94 valign=top style='width:70.4pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=102 valign=top style='width:76.3pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt><span lang=EN-GB>Respiratory, thoracic and mediastinal
  disorders</span></p>
  </td>
  <td width=85 valign=top style='width:64.1pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=126 valign=top style='width:94.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Pulmonary
  embolism Interstitial pneumonitis<sup>b,d</sup></span></p>
  </td>
  <td width=94 valign=top style='width:70.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=92 valign=top style='width:69.1pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=94 valign=top style='width:70.4pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=102 valign=top style='width:76.3pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Gastrointes-tinal
  disorders</span></p>
  </td>
  <td width=85 valign=top style='width:64.1pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Stomatitis</span></p>
  <p class=MsoNormal><span lang=EN-GB>Anorexia</span></p>
  <p class=MsoNormal><span lang=EN-GB>Vomiting</span></p>
  <p class=MsoNormal><span lang=EN-GB>Diarrhoea</span></p>
  <p class=MsoNormal><span lang=EN-GB>Nausea</span></p>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=126 valign=top style='width:94.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=mdTblEntry style='page-break-after:auto'><span lang=EN-GB
  style='font-size:11.0pt'>Dyspepsia</span></p>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Constipation</span></p>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Abdominal
  pain</span></p>
  <p class=mdTblEntry style='page-break-after:auto'><span lang=EN-GB
  style='font-size:11.0pt'></span></p>
  <p class=mdTblEntry style='page-break-after:auto'><sup><span
  style='font-size:11.0pt'>&nbsp;</span></sup></p>
  <p class=mdTblEntry style='page-break-after:auto'><span style='font-size:
  11.0pt'>&nbsp;</span></p>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Rectal
  haemorrhage</span></p>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Gastrointestinal
  haemorrhage</span></p>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Intestinal
  perforation</span></p>
  <p class=Normal11pt style='page-break-after:auto'>Oesophagitis</p>
  <p class=Normal11pt style='page-break-after:auto'>Colitis<sup><span lang=DE>e</span></sup></p>
  </td>
  <td width=94 valign=top style='width:70.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=92 valign=top style='width:69.1pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=94 valign=top style='width:70.4pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=102 valign=top style='width:76.3pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Hepatobiliary
  disorders</span></p>
  </td>
  <td width=85 valign=top style='width:64.1pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB></span></p>
  </td>
  <td width=126 valign=top style='width:94.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Alanine aminotransferase increased</span></p>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Aspartate aminotransferase
  increased</span></p>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=94 valign=top style='width:70.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Hepatitis</span></p>
  </td>
  <td width=92 valign=top style='width:69.1pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=94 valign=top style='width:70.4pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=102 valign=top style='width:76.3pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Skin and
  subcutaneous tissue disorders</span></p>
  </td>
  <td width=85 valign=top style='width:64.1pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Rash</span></p>
  <p class=MsoNormal><span lang=EN-GB>Skin exfoliation </span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=126 valign=top style='width:94.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Hyperpigmentation</span></p>
  <p class=MsoNormal><span lang=EN-GB>Pruritus</span></p>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Erythema
  multiforme</span></p>
  <p class=MsoNormal><span lang=EN-GB>Alopecia</span></p>
  <p class=MsoNormal><span lang=EN-GB>Urticaria</span></p>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'>&nbsp;</p>
  </td>
  <td width=94 valign=top style='width:70.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Erythema</span></p>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=92 valign=top style='width:69.1pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Stevens-Johnson syndrome<sup>b</sup></span></p>
  <p class=MsoNormal><span lang=EN-GB>Toxic epidermal necrolysis<sup>b</sup></span></p>
  <p class=MsoNormal><span lang=EN-GB>Pemphigoid</span></p>
  <p class=MsoNormal><span lang=EN-GB>Dermatitis bullous</span></p>
  <p class=MsoNormal><span lang=EN-GB>Acquired epidermolysis bullosa</span></p>
  <p class=Normal11pt style='page-break-after:auto'><span lang=DE>Erythemato&#8209;us
  oedema<sup>f </sup></span></p>
  <p class=MsoNormal><span lang=DE>Pseudocell&#8209;ulitis</span></p>
  <p class=MsoNormal><span lang=DE>Dermatitis</span></p>
  <p class=MsoNormal><span lang=DE>Eczema</span></p>
  <p class=MsoNormal><span lang=EN-GB>Prurigo</span></p>
  </td>
  <td width=94 valign=top style='width:70.4pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  <p class=Normal11pt style='page-break-after:auto'><sup><span lang=EN-GB>&nbsp;</span></sup></p>
  </td>
 </tr>
 <tr>
  <td width=102 valign=top style='width:76.3pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Renal and
  urinary disorders</span></p>
  </td>
  <td width=85 valign=top style='width:64.1pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Creatinine clearance decreased</span></p>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Blood
  creatinine increased<sup>e</sup></span></p>
  </td>
  <td width=126 valign=top style='width:94.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Renal
  failure</span></p>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Glomerular
  filtration rate decreased</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><sup>&nbsp;</sup></p>
  </td>
  <td width=94 valign=top style='width:70.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=92 valign=top style='width:69.1pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=94 valign=top style='width:70.4pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Nephrogenic
  diabetes insipidus</span></p>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Renal
  tubular necrosis</span></p>
  </td>
 </tr>
 <tr>
  <td width=102 valign=top style='width:76.3pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>General
  disorders and administration site conditions</span></p>
  </td>
  <td width=85 valign=top style='width:64.1pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Fatigue</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=126 valign=top style='width:94.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Pyrexia</span></p>
  <p class=MsoNormal><span lang=EN-GB>Pain</span></p>
  <p class=MsoNormal><span lang=EN-GB>Oedema</span></p>
  <p class=MsoNormal><span lang=EN-GB>Chest pain</span></p>
  <p class=MsoNormal><span lang=EN-GB>Mucosal inflammation</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'>&nbsp;</p>
  </td>
  <td width=94 valign=top style='width:70.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=92 valign=top style='width:69.1pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=94 valign=top style='width:70.4pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=102 valign=top style='width:76.3pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Investigations</span></p>
  </td>
  <td width=85 valign=top style='width:64.1pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=126 valign=top style='width:94.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Gamma-glutamyltransferase
  increased</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'>&nbsp;</p>
  </td>
  <td width=94 valign=top style='width:70.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=92 valign=top style='width:69.1pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=94 valign=top style='width:70.4pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=102 valign=top style='width:76.3pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Injury,
  poisoning and procedural complications</span></p>
  </td>
  <td width=85 valign=top style='width:64.1pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=126 valign=top style='width:94.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'>Radiation oesophagitis</p>
  <p class=Normal11pt style='page-break-after:auto'>Radiation pneumonitis</p>
  </td>
  <td width=94 valign=top style='width:70.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>Recall
  pheno-menon</span></p>
  </td>
  <td width=92 valign=top style='width:69.1pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=94 valign=top style='width:70.4pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:auto'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
</table>

<p class=xnormal11pt><sup><span lang=EN-GB>a</span></sup><span lang=EN-GB> with
and without neutropenia </span></p>

<p class=xnormal11pt><sup><span lang=EN-GB>b</span></sup><span lang=EN-GB
style='color:black'> </span><span style='color:black'>in some cases fatal </span></p>

<p class=xnormal11pt><sup><span lang=EN-GB>c</span></sup><span lang=EN-GB>
sometimes leading to extremity necrosis </span></p>

<p class=xnormal11pt><sup><span lang=EN-GB>d</span></sup><span lang=EN-GB> </span>with
respiratory insufficiency</p>

<p class=MsoNormal style='line-height:normal'><sup><span lang=EN-GB>e</span></sup><span
lang=EN-GB> seen only in combination with cisplatin <br>
<sup>f</sup><span style='color:black'> </span>mainly of the lower limbs</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='text-autospace:none'><u><span lang=EN-GB>Reporting of
suspected adverse reactions</span></u></p>

<p class=MsoNormal style='text-autospace:none'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Reporting
suspected adverse reactions after authorisation of the medicinal product is
important. It allows continued monitoring of the benefit/risk balance of the
medicinal product. Healthcare professionals are asked to report any suspected
adverse reactions via <span style='background:lightgrey'>the national reporting
system listed in </span></span><span lang=EN-GB><a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span
style='background:lightgrey'>Appendix V</span></a></span><span lang=EN-GB>.<span
style='color:navy'> </span></span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>4.9 Overdose</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Reported
symptoms of overdose include neutropenia, anaemia, thrombocytopenia, mucositis,
sensory polyneuropathy, and rash. Anticipated complications of overdose include
bone marrow suppression as manifested by neutropenia, thrombocytopenia, and
anaemia. In addition, infection with or without fever, diarrhoea, and/or
mucositis may be seen. In the event of suspected overdose, patients should be
monitored with blood counts and should receive supportive therapy as necessary.
The use of calcium folinate/folinic acid in the management of pemetrexed
overdose should be considered.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>5. PHARMACOLOGICAL PROPERTIES</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>5.1  Pharmacodynamic properties</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Pharmacotherapeutic
group:</span><span lang=EN-GB> antineoplastic agents, folic acid analogues. ATC
code: L01BA04. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Pemetrexed </span><span
lang=EN-GB>is a multi-targeted anti-cancer antifolate agent that exerts its
action by disrupting crucial folate-dependent metabolic processes essential for
cell replication. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>In vitro</span></i><span
lang=EN-GB> studies have shown that pemetrexed behaves as a multi-targeted
antifolate by inhibiting thymidylate synthase (TS), dihydrofolate reductase
(DHFR), and glycinamide ribonucleotide formyltransferase (GARFT), which are key
folate-dependent enzymes for the <i>de novo</i> biosynthesis of thymidine and
purine nucleotides. Pemetrexed is transported into cells by both the reduced
folate carrier and membrane folate binding protein transport systems. Once in
the cell, pemetrexed is rapidly and efficiently converted to polyglutamate
forms by the enzyme folylpolyglutamate synthetase. The polyglutamate forms are
retained in cells and are even more potent inhibitors of TS and GARFT.
Polyglutamation is a time- and concentration-dependent process that occurs in
tumour cells and, to a lesser extent, in normal tissues. Polyglutamated
metabolites have an increased intracellular half-life resulting in prolonged
drug action in malignant cells. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The European
Medicines Agency has waived the obligation to submit the results of studies
with the reference medicinal product containing pemetrexed in all subsets of
the paediatric population for the granted indications (see section 4.2 for
information on paediatric use).</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Clinical
efficacy</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><u><span lang=EN-GB>Mesothelioma</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EMPHACIS, a
multi-centre, randomised, single-blind Phase 3 study of pemetrexed plus
cisplatin versus cisplatin in chemonaive patients with malignant pleural
mesothelioma, has shown that patients treated with pemetrexed and cisplatin had
a clinically meaningful 2.8&#8209;month median survival advantage over patients
receiving cisplatin alone. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>During the
study, low-dose folic acid and vitamin B<sub>12</sub> supplementation was
introduced to patients' therapy to reduce toxicity. The primary analysis of
this study was performed on the population of all patients randomly assigned to
a treatment arm who received study drug (randomised and treated). A subgroup
analysis was performed on patients who received folic acid and vitamin B<sub>12</sub>
supplementation during the entire course of study therapy (fully supplemented).
The results of these analyses of efficacy are summarised in the table below. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Table 5. Efficacy
of pemetrexed plus cisplatin vs. cisplatin in malignant pleural mesothelioma</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse;border:none'>
 <tr>
  <td width="28%" valign=top style='width:28.0%;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="36%" colspan=2 valign=top style='width:36.0%;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Randomised
  and treated patients</span></b></p>
  </td>
  <td width="36%" colspan=2 valign=top style='width:36.0%;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Fully
  supplemented patients</span></b></p>
  </td>
 </tr>
 <tr>
  <td width="28%" valign=top style='width:28.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Efficacy
  parameter</span></b></p>
  </td>
  <td width="18%" valign=top style='width:18.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Pemetrexed
  / Cisplatin</span></b></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>(N = 226)</span></b></p>
  </td>
  <td width="18%" valign=top style='width:18.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Cisplatin</span></b></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>(N = 222)</span></b></p>
  </td>
  <td width="18%" valign=top style='width:18.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Pemetrexed
  / Cisplatin</span></b></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>(N = 168)</span></b></p>
  </td>
  <td width="18%" valign=top style='width:18.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Cisplatin</span></b></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>(N = 163)</span></b></p>
  </td>
 </tr>
 <tr>
  <td width="28%" valign=top style='width:28.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Median overall
  survival (months) </span></p>
  </td>
  <td width="18%" valign=top style='width:18.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>12.1 </span></p>
  </td>
  <td width="18%" valign=top style='width:18.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>9.3 </span></p>
  </td>
  <td width="18%" valign=top style='width:18.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>13.3 </span></p>
  </td>
  <td width="18%" valign=top style='width:18.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>10.0 </span></p>
  </td>
 </tr>
 <tr>
  <td width="28%" valign=top style='width:28.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(95% CI) </span></p>
  </td>
  <td width="18%" valign=top style='width:18.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(10.0&#8209;14.4)
  </span></p>
  </td>
  <td width="18%" valign=top style='width:18.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(7.8&#8209;10.7)
  </span></p>
  </td>
  <td width="18%" valign=top style='width:18.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(11.4&#8209;14.9)
  </span></p>
  </td>
  <td width="18%" valign=top style='width:18.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(8.4&#8209;11.9)
  </span></p>
  </td>
 </tr>
 <tr>
  <td width="28%" valign=top style='width:28.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Log rank <i>p</i>-value*
  </span></p>
  </td>
  <td width="36%" colspan=2 valign=top style='width:36.0%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>0.020 </span></p>
  </td>
  <td width="36%" colspan=2 valign=top style='width:36.0%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>0.051 </span></p>
  </td>
 </tr>
 <tr>
  <td width="28%" valign=top style='width:28.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Median time to
  tumour progression (months) </span></p>
  </td>
  <td width="18%" valign=top style='width:18.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>5.7 </span></p>
  </td>
  <td width="18%" valign=top style='width:18.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>3.9 </span></p>
  </td>
  <td width="18%" valign=top style='width:18.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>6.1 </span></p>
  </td>
  <td width="18%" valign=top style='width:18.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>3.9 </span></p>
  </td>
 </tr>
 <tr>
  <td width="28%" valign=top style='width:28.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(95% CI) </span></p>
  </td>
  <td width="18%" valign=top style='width:18.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(4.9&#8209;6.5)
  </span></p>
  </td>
  <td width="18%" valign=top style='width:18.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(2.8&#8209;4.4)
  </span></p>
  </td>
  <td width="18%" valign=top style='width:18.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(5.3&#8209;7.0)
  </span></p>
  </td>
  <td width="18%" valign=top style='width:18.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(2.8&#8209;4.5)
  </span></p>
  </td>
 </tr>
 <tr>
  <td width="28%" valign=top style='width:28.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Log rank <i>p</i>-value*
  </span></p>
  </td>
  <td width="36%" colspan=2 valign=top style='width:36.0%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>0.001 </span></p>
  </td>
  <td width="36%" colspan=2 valign=top style='width:36.0%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>0.008 </span></p>
  </td>
 </tr>
 <tr>
  <td width="28%" valign=top style='width:28.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Time to
  treatment failure (months) </span></p>
  </td>
  <td width="18%" valign=top style='width:18.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>4.5 </span></p>
  </td>
  <td width="18%" valign=top style='width:18.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>2.7 </span></p>
  </td>
  <td width="18%" valign=top style='width:18.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>4.7 </span></p>
  </td>
  <td width="18%" valign=top style='width:18.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>2.7 </span></p>
  </td>
 </tr>
 <tr>
  <td width="28%" valign=top style='width:28.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(95% CI) </span></p>
  </td>
  <td width="18%" valign=top style='width:18.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(3.9&#8209;4.9)
  </span></p>
  </td>
  <td width="18%" valign=top style='width:18.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(2.1&#8209;2.9)
  </span></p>
  </td>
  <td width="18%" valign=top style='width:18.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(4.3&#8209;5.6)
  </span></p>
  </td>
  <td width="18%" valign=top style='width:18.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(2.2&#8209;3.1)
  </span></p>
  </td>
 </tr>
 <tr>
  <td width="28%" valign=top style='width:28.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Log rank <i>p</i>-value*
  </span></p>
  </td>
  <td width="36%" colspan=2 valign=top style='width:36.0%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>0.001 </span></p>
  </td>
  <td width="36%" colspan=2 valign=top style='width:36.0%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>0.001 </span></p>
  </td>
 </tr>
 <tr>
  <td width="28%" valign=top style='width:28.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Overall
  response rate** </span></p>
  </td>
  <td width="18%" valign=top style='width:18.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>41.3% </span></p>
  </td>
  <td width="18%" valign=top style='width:18.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>16.7% </span></p>
  </td>
  <td width="18%" valign=top style='width:18.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>45.5% </span></p>
  </td>
  <td width="18%" valign=top style='width:18.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>19.6% </span></p>
  </td>
 </tr>
 <tr>
  <td width="28%" valign=top style='width:28.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(95% CI) </span></p>
  </td>
  <td width="18%" valign=top style='width:18.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(34.8&#8209;48.1)
  </span></p>
  </td>
  <td width="18%" valign=top style='width:18.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(12.0&#8209;22.2)
  </span></p>
  </td>
  <td width="18%" valign=top style='width:18.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(37.8&#8209;53.4)
  </span></p>
  </td>
  <td width="18%" valign=top style='width:18.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(13.8&#8209;26.6)
  </span></p>
  </td>
 </tr>
 <tr>
  <td width="28%" valign=top style='width:28.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Fisher's exact
  <i>p</i>-value* </span></p>
  </td>
  <td width="36%" colspan=2 valign=top style='width:36.0%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&lt;0.001 </span></p>
  </td>
  <td width="36%" colspan=2 valign=top style='width:36.0%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&lt;0.001 </span></p>
  </td>
 </tr>
 <tr>
  <td width="100%" colspan=5 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Abbreviation:
  CI = confidence interval. </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>*<i>p</i>-value
  refers to comparison between arms. </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>**In the
  pemetrexed /cisplatin arm, randomised and treated (N=225) and fully
  supplemented (N=167). </span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>A statistically
significant improvement of the clinically relevant symptoms (pain and dyspnoea)
associated with malignant pleural mesothelioma in the pemetrexed /cisplatin arm
(212&nbsp;patients) versus the cisplatin arm alone (218&nbsp;patients) was
demonstrated using the Lung Cancer Symptom Scale. Statistically significant
differences in pulmonary function tests were also observed. The separation
between the treatment arms was achieved by improvement in lung function in the
pemetrexed /cisplatin arm and deterioration of lung function over time in the
control arm. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>There are
limited data in patients with malignant pleural mesothelioma treated with
pemetrexed alone. Pemetrexed at a dose of 500&nbsp;mg/m<sup>2</sup> was studied
as a single agent in 64 chemonaive patients with malignant pleural
mesothelioma. The overall response rate was 14.1%. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><u><span lang=EN-GB>NSCLC,
second-line treatment</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>A multi-centre,
randomised, open-label Phase-3 study of pemetrexed versus docetaxel in patients
with locally advanced or metastatic NSCLC after prior chemotherapy has shown
median survival times of 8.3&nbsp;months for patients treated with pemetrexed
(Intent-To-Treat [ITT] population N = 283) and 7.9&nbsp;months for patients
treated with docetaxel (ITT N = 288). Prior chemotherapy did not include
pemetrexed. An analysis of the impact of NSCLC histology on the treatment
effect on overall survival was in favour of pemetrexed versus docetaxel for
other than predominantly squamous histologies (N&nbsp;=&nbsp;399, 9.3 versus
8.0&nbsp;months, adjusted hazard ratio (HR) = 0.78; 95% CI = 0.61&#8209;1.00, p
= 0.047) and was in favour of docetaxel for squamous cell carcinoma histology
(N =172, 6.2 versus 7.4&nbsp;months, adjusted HR = 1.56; 95% CI = 1.08&#8209;2.26,
p = 0.018). There were no clinically relevant differences observed for the
safety profile of pemetrexed within the histology subgroups. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Limited clinical
data from a separate randomised, Phase&#8209;3, controlled trial, suggest that
efficacy data (overall survival, progression-free survival) for pemetrexed are
similar between patients previously pre-treated with docetaxel (N = 41) and
patients who did not receive previous docetaxel treatment (N&nbsp;=&nbsp;540). </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Table 6. Efficacy
of </span></b><b><span lang=EN-GB>pemetrexed </span></b><b><span lang=EN-GB>vs.
docetaxel in NSCLC - ITT population</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse;border:none'>
 <tr>
  <td width="48%" valign=top style='width:48.0%;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="26%" valign=top style='width:26.0%;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Pemetrexed</span></b></p>
  </td>
  <td width="26%" valign=top style='width:26.0%;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Docetaxel</span></b></p>
  </td>
 </tr>
 <tr>
  <td width="48%" rowspan=2 valign=top style='width:48.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Survival
  time (months)</span></b><span lang=EN-GB> </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB> Median (m) </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB> 95% CI for
  median </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB> HR </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB> 95% CI for
  HR </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>
  Non-inferiority <i>p</i>-value (HR) </span></p>
  </td>
  <td width="26%" valign=top style='width:26.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(N = 283) </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>8.3 </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(7.0&#8209;9.4)
  </span></p>
  </td>
  <td width="26%" valign=top style='width:26.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(N = 288) </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>7.9 </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(6.3&#8209;9.2)
  </span></p>
  </td>
 </tr>
 <tr>
  <td width="100%" colspan=2 valign=top style='width:100.0%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>0.99 </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(0.82&#8209;1.20)
  </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>0.226 </span></p>
  </td>
 </tr>
 <tr>
  <td width="48%" rowspan=2 valign=top style='width:48.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Progression-free
  survival (months)</span></b><span lang=EN-GB> </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB> Median </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB> HR (95% CI) </span></p>
  </td>
  <td width="26%" valign=top style='width:26.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(N = 283) </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>2.9 </span></p>
  </td>
  <td width="26%" valign=top style='width:26.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(N = 288) </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>2.9 </span></p>
  </td>
 </tr>
 <tr>
  <td width="100%" colspan=2 valign=top style='width:100.0%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>0.97 (0.82&#8209;1.16)
  </span></p>
  </td>
 </tr>
 <tr>
  <td width="48%" rowspan=2 valign=top style='width:48.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Time to
  treatment failure (TTTF - months)</span></b><span lang=EN-GB> </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB> Median </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB> HR (95% CI) </span></p>
  </td>
  <td width="26%" valign=top style='width:26.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(N = 283) </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>2.3 </span></p>
  </td>
  <td width="26%" valign=top style='width:26.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(N = 288) </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>2.1 </span></p>
  </td>
 </tr>
 <tr>
  <td width="100%" colspan=2 valign=top style='width:100.0%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>0.84 (0.71&#8209;0.997)
  </span></p>
  </td>
 </tr>
 <tr>
  <td width="48%" valign=top style='width:48.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Response</span></b><span
  lang=EN-GB> (n: qualified for response) </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB> Response
  rate (%) (95% CI) </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB> Stable
  disease (%) </span></p>
  </td>
  <td width="26%" valign=top style='width:26.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(N = 264) </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>9.1 (5.9&#8209;13.2)
  </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>45.8 </span></p>
  </td>
  <td width="26%" valign=top style='width:26.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(N = 274) </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>8.8 (5.7&#8209;12.8)
  </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>46.4 </span></p>
  </td>
 </tr>
 <tr>
  <td width="100%" colspan=3 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Abbreviations:
  CI = confidence interval; HR = hazard ratio; ITT = intent-to-treat; N = total
  population size. </span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><i><u><span lang=EN-GB>NSCLC,
first-line treatment</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>A multi-centre,
randomised, open-label, Phase-3 study of pemetrexed plus cisplatin versus
gemcitabine plus cisplatin in chemonaive patients with locally advanced or
metastatic (Stage IIIb or IV) non-small cell lung cancer (NSCLC) showed that pemetrexed
plus cisplatin (Intent-To-Treat [ITT] population N = 862) met its primary
endpoint and showed similar clinical efficacy as gemcitabine plus cisplatin
(ITT N = 863) in overall survival (adjusted hazard ratio (HR) 0.94; 95% CI=
0.84&#8209;1.05). All patients included in this study had an ECOG performance
status 0 or 1. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The primary
efficacy analysis was based on the ITT population. Sensitivity analyses of main
efficacy endpoints were also assessed on the Protocol Qualified (PQ)
population. The efficacy analyses using PQ population are consistent with the
analyses for the ITT population and support the non-inferiority of AC versus
GC. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Progression-free
survival (PFS) and overall response rate were similar between treatment arms:
median PFS was 4.8&nbsp;months for pemetrexed plus cisplatin versus 5.1&nbsp;months
for gemcitabine plus cisplatin (adjusted hazard ratio (HR) 1.04; 95% CI= 0.94&#8209;1.15),
and overall response rate was 30.6% (95% CI= 27.3&#8209; 33.9) for pemetrexed
plus cisplatin versus 28.2% (95% CI= 25.0&#8209;31.4) for gemcitabine plus
cisplatin. PFS data were partially confirmed by an independent review (400/1725&nbsp;patients
were randomly selected for review). </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The analysis of
the impact of NSCLC histology on overall survival demonstrated clinically
relevant differences in survival according to histology, see table below. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Table 7. Efficacy
of </span></b><b><span lang=EN-GB>pemetrexed </span></b><b><span lang=EN-GB>+
cisplatin vs. gemcitabine + cisplatin in first-line non-small cell lung cancer
 ITT population and histology subgroups</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%"
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width="18%" rowspan=2 valign=top style='width:18.02%;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>ITT
  population and histology subgroups</span></b></p>
  </td>
  <td width="52%" colspan=4 valign=top style='width:52.0%;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Median
  overall survival in months</span></b></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>(95% CI)</span></b></p>
  </td>
  <td width="18%" rowspan=2 valign=top style='width:18.84%;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Adjusted
  hazard ratio (HR)</span></b></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>(95% CI)</span></b></p>
  </td>
  <td width="11%" rowspan=2 valign=top style='width:11.16%;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Superiority
  <i>p</i>-value</span></b></p>
  </td>
 </tr>
 <tr>
  <td width="26%" colspan=2 valign=top style='width:26.0%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Pemetrexed </span></b><b><span
  lang=EN-GB>+ Cisplatin</span></b></p>
  </td>
  <td width="26%" colspan=2 valign=top style='width:26.0%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Gemcitabine
  + Cisplatin</span></b></p>
  </td>
 </tr>
 <tr>
  <td width="18%" valign=top style='width:18.02%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ITT population
  </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(N = 1725) </span></p>
  </td>
  <td width="15%" valign=top style='width:15.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>10.3 </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(9.8  11.2) </span></p>
  </td>
  <td width="11%" valign=top style='width:11.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>N = 862 </span></p>
  </td>
  <td width="15%" valign=top style='width:15.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>10.3 </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(9.6  10.9) </span></p>
  </td>
  <td width="11%" valign=top style='width:11.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>N = 863 </span></p>
  </td>
  <td width="18%" valign=top style='width:18.84%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>0.94<sup>a</sup>
  </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(0.84  1.05) </span></p>
  </td>
  <td width="11%" valign=top style='width:11.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>0.259 </span></p>
  </td>
 </tr>
 <tr>
  <td width="18%" valign=top style='width:18.02%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Adenocarcinoma
  </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(N = 847) </span></p>
  </td>
  <td width="15%" valign=top style='width:15.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>12.6 </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(10.7  13.6) </span></p>
  </td>
  <td width="11%" valign=top style='width:11.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>N = 436 </span></p>
  </td>
  <td width="15%" valign=top style='width:15.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>10.9 </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(10.2 11.9) </span></p>
  </td>
  <td width="11%" valign=top style='width:11.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>N = 411 </span></p>
  </td>
  <td width="18%" valign=top style='width:18.84%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>0.84 </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(0.710.99) </span></p>
  </td>
  <td width="11%" valign=top style='width:11.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>0.033 </span></p>
  </td>
 </tr>
 <tr>
  <td width="18%" valign=top style='width:18.02%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Large cell </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(N = 153) </span></p>
  </td>
  <td width="15%" valign=top style='width:15.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>10.4 </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(8.6  14.1) </span></p>
  </td>
  <td width="11%" valign=top style='width:11.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>N = 76 </span></p>
  </td>
  <td width="15%" valign=top style='width:15.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>6.7 </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(5.5  9.0) </span></p>
  </td>
  <td width="11%" valign=top style='width:11.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>N = 77 </span></p>
  </td>
  <td width="18%" valign=top style='width:18.84%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>0.67 </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(0.480.96) </span></p>
  </td>
  <td width="11%" valign=top style='width:11.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>0.027 </span></p>
  </td>
 </tr>
 <tr>
  <td width="18%" valign=top style='width:18.02%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Other </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(N = 252) </span></p>
  </td>
  <td width="15%" valign=top style='width:15.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>8.6 </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(6.8  10.2) </span></p>
  </td>
  <td width="11%" valign=top style='width:11.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>N = 106 </span></p>
  </td>
  <td width="15%" valign=top style='width:15.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>9.2 </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(8.1  10.6) </span></p>
  </td>
  <td width="11%" valign=top style='width:11.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>N = 146 </span></p>
  </td>
  <td width="18%" valign=top style='width:18.84%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>1.08 </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(0.811.45) </span></p>
  </td>
  <td width="11%" valign=top style='width:11.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>0.586 </span></p>
  </td>
 </tr>
 <tr>
  <td width="18%" valign=top style='width:18.02%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Squamous cell </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(N = 473) </span></p>
  </td>
  <td width="15%" valign=top style='width:15.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>9.4 </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(8.4  10.2) </span></p>
  </td>
  <td width="11%" valign=top style='width:11.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>N = 244 </span></p>
  </td>
  <td width="15%" valign=top style='width:15.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>10.8 </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(9.5  12.1) </span></p>
  </td>
  <td width="11%" valign=top style='width:11.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>N = 229 </span></p>
  </td>
  <td width="18%" valign=top style='width:18.84%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>1.23 </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(1.001.51) </span></p>
  </td>
  <td width="11%" valign=top style='width:11.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>0.050 </span></p>
  </td>
 </tr>
 <tr>
  <td width="100%" colspan=7 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Abbreviations:
  CI = confidence interval; ITT = intent-to-treat; N = total population size. </span></p>
  </td>
 </tr>
 <tr>
  <td width="100%" colspan=7 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><sup><span lang=EN-GB>a</span></sup><span
  lang=EN-GB> Statistically significant for non-inferiority, with the entire
  confidence interval for HR well below the 1.17645 non-inferiority margin (<i>p</i>
  &lt; 0.001). </span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Kaplan-Meier
plots of overall survival by histology</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span style='position:absolute;
z-index:251658240;margin-left:243px;margin-top:39px;width:330px;height:47px'><img
width=330 height=47 src="PemetrexedHospira_files/image005.png"></span><img
border=0 width=576 height=232 id="Picture 2"
src="PemetrexedHospira_files/image002.png" alt=IMAGE002></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>There were no
clinically relevant differences observed for the safety profile of pemetrexed plus
cisplatin within the histology subgroups. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Patients treated
with pemetrexed and cisplatin required fewer transfusions (16.4% versus 28.9%,
p&nbsp;&lt;&nbsp;0.001), red blood cell transfusions (16.1% versus 27.3%, p
&lt; 0.001) and platelet transfusions (1.8% versus 4.5%, p = 0.002). Patients
also required lower administration of erythropoietin/darbopoietin (10.4% versus
18.1%, p &lt; 0.001), G-CSF/GM-CSF (3.1% versus 6.1%, p&nbsp;= 0.004), and iron
preparations (4.3% versus 7.0%, p = 0.021). </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><u><span lang=EN-GB>NSCLC,
maintenance treatment</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>JMEN</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>A multi-centre,
randomised, double-blind, placebo-controlled Phase-3 study (JMEN), compared the
efficacy and safety of maintenance treatment with pemetrexed plus best
supportive care (BSC) (N&nbsp;=&nbsp;441) with that of placebo plus BSC (N =
222) in patients with locally advanced (Stage IIIB) or metastatic (Stage IV)
Non-Small Cell Lung Cancer (NSCLC) who did not progress after 4 cycles of
first-line doublet therapy containing cisplatin or carboplatin in combination
with gemcitabine, paclitaxel, or docetaxel. First-line doublet therapy
containing pemetrexed was not included. All patients included in this study had
an ECOG performance status 0 or 1. Patients received maintenance treatment
until disease progression. Efficacy and safety were measured from the time of
randomisation after completion of first-line (induction) therapy. Patients
received a median of 5&nbsp;cycles of maintenance treatment with pemetrexed and
3.</span><span lang=EN-GB>5&nbsp;cycles</span><span lang=EN-GB> of placebo. A
total of 213&nbsp;patients (48.3%) completed &#8805; 6&nbsp;cycles and a total
of 103&nbsp;patients (23.4%) completed &#8805; 10&nbsp;cycles of treatment with
pemetrexed. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The study met
its primary endpoint and showed a statistically significant improvement in PFS
in the pemetrexed arm over the placebo arm (N = 581, independently reviewed
population; median of 4.0&nbsp;months and 2.0&nbsp;months, respectively)
(hazard ratio = 0.60, 95% CI = 0.49&#8209;0.73, p &lt; 0.00001). The
independent review of patient scans confirmed the findings of the investigator
assessment of PFS. The median OS for the overall population (N = 663) was
13.4&nbsp;months for the pemetrexed arm and 10.6&nbsp;months for the placebo
arm, hazard ratio = 0.79 (95% CI= 0.65&#8209;0.95, p = 0.01192). </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Consistent with
other pemetrexed studies, a difference in efficacy according to NSCLC histology
was observed in JMEN. For patients with NSCLC other than predominantly squamous
cell histology (N&nbsp;=&nbsp;430, independently reviewed population) median
PFS was 4.4&nbsp;months for the pemetrexed arm and 1.8&nbsp;months for the
placebo arm, hazard ratio = 0.47 (95% CI = 0.37&#8209;0.60, p = 0.00001). The
median OS for patients with NSCLC other than predominantly squamous cell
histology (N = 481) was 15.5 months for the pemetrexed arm and 10.3&nbsp;months
for the placebo arm, hazard ratio = 0.70 (95% CI&nbsp;= 0.56&#8209;0.88, p =
0.002). Including the induction phase, the median OS for patients with NSCLC
other than predominantly squamous cell histology was 18.6&nbsp;months for the pemetrexed
arm and 13.6&nbsp;months for the placebo arm, hazard ratio = 0.71 (95% CI =
0.56&#8209;0.88, p = 0.002). </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The PFS and OS
results in patients with squamous cell histology suggested no advantage for pemetrexed
over placebo. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>There were no
clinically relevant differences observed for the safety profile of pemetrexed within
the histology subgroups. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>JMEN:
Kaplan-Meier plots of progression-free survival (PFS) and overall survival p</span></b><b><span
lang=EN-GB>emetrexed </span></b><b><span lang=EN-GB>versus placebo in patients
with NSCLC other than predominantly squamous cell histology</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><img border=0 width=583
height=250 id="Picture 3" src="PemetrexedHospira_files/image003.png"
alt=90502A></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>PARAMOUNT</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>A multi-centre,
randomised, double-blind, placebo-controlled Phase-3 study (PARAMOUNT),
compared the efficacy and safety of continuation maintenance treatment with pemetrexed
plus BSC (N&nbsp;= 359) with that of placebo plus BSC (N = 180) in patients
with locally advanced (Stage IIIB) or metastatic (Stage IV) NSCLC other than
predominantly squamous cell histology who did not progress after 4&nbsp;cycles
of first-line doublet therapy of pemetrexed in combination with cisplatin. Of
the 939&nbsp;patients treated with pemetrexed plus cisplatin induction, </span><span
lang=EN-GB>539&nbsp;patients</span><span lang=EN-GB> were randomised to
maintenance treatment with pemetrexed or placebo. Of the randomised patients,
44.9% had a complete/partial response and 51.9% had a response of stable
disease to pemetrexed plus cisplatin induction. Patients randomised to
maintenance treatment were required to have an ECOG performance status 0 or 1.
The median time from the start of pemetrexed plus cisplatin induction therapy
to the start of maintenance treatment was 2.96&nbsp;months on both the pemetrexed
arm and the placebo arm. Randomised patients received maintenance treatment
until disease progression. Efficacy and safety were measured from the time of
randomisation after completion of first-line (induction) therapy. Patients
received a median of 4&nbsp;cycles of maintenance treatment with pemetrexed and
4&nbsp;cycles of placebo. A total of </span><span lang=EN-GB>169&nbsp;patients</span><span
lang=EN-GB> (47.1%) completed &#8805; 6 cycles maintenance treatment with pemetrexed,
representing at least 10 total cycles of pemetrexed. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The study met
its primary endpoint and showed a statistically significant improvement in PFS
in the pemetrexed arm over the placebo arm (N = 472, independently reviewed
population; median of 3.9&nbsp;months and 2.6&nbsp;months, respectively)
(hazard ratio = 0.64, 95% CI = 0.51&#8209;0.81, p = 0.0002). The independent
review of patient scans confirmed the findings of the investigator assessment
of PFS. For randomised patients, as measured from the start of pemetrexed plus
cisplatin first-line induction treatment, the median investigator-assessed PFS
was 6.9&nbsp;months for the pemetrexed arm and 5.6&nbsp;months for the placebo
arm (hazard ratio = 0.59, 95% CI = 0.47&#8209;0.74). </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Following pemetrexed
plus cisplatin induction (4&nbsp;cycles), treatment with pemetrexed was
statistically superior to placebo for OS (median 13.9&nbsp;months versus 11.0&nbsp;months,
hazard ratio = 0.78, 95% CI=0.64&#8209;0.96, p=0.0195). At the time of this
final survival analysis, 28.7% of patients were alive or lost to follow up on
the pemetrexed arm versus 21.7% on the placebo arm. The relative treatment
effect of pemetrexed was internally consistent across subgroups (including
disease stage, induction response, ECOG PS, smoking status, gender, histology
and age) and similar to that observed in the unadjusted OS and PFS analyses.
The 1&nbsp;year and 2&nbsp;year survival rates for patients on pemetrexed were
58% and 32% respectively, compared to 45% and 21% for patients on placebo. From
the start of pemetrexed plus cisplatin first-line induction treatment, the
median OS of patients was 16.9&nbsp;months for the pemetrexed arm and
14.0&nbsp;months for the placebo arm (hazard ratio= 0.78, 95% CI= 0.64&#8209;0.96).
The percentage of patients that received post-study treatment was 64.3% for pemetrexed
and 71.7% for placebo. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>PARAMOUNT: Kaplan-Meier plot of progression-free survival (PFS) and
Overall Survival (OS) for continuation p</span></b><b><span lang=EN-GB>emetrexed
</span></b><b><span lang=EN-GB>maintenance versus placebo in patients with
NSCLC other than predominantly squamous cell histology (measured from
randomisation)</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><img border=0 width=584
height=279 id="Picture 4" src="PemetrexedHospira_files/image004.png"
alt=90502B></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The pemetrexed maintenance
safety profiles from the two studies JMEN and PARAMOUNT were similar.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>5.2 Pharmacokinetic properties</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>The pharmacokinetic properties of pemetrexed following single-agent
administration have been evaluated in 426 cancer patients with a variety of
solid tumours at doses ranging from 0.2 to 838&nbsp;mg/m<sup>2</sup> infused
over a 10&nbsp;minute period. Pemetrexed has a steady-state volume of
distribution of 9&nbsp;l/m<sup>2</sup>. <i>In vitro</i> studies indicate that
pemetrexed is approximately 81% bound to plasma proteins. Binding was not
notably affected by varying degrees of renal impairment. Pemetrexed undergoes
limited hepatic metabolism. Pemetrexed is primarily eliminated in the urine,
with 70% to 90% of the administered dose being recovered unchanged in urine
within the first 24&nbsp;hours following administration. <i>In vitro</i>
studies indicate that pemetrexed is actively secreted by OAT3 (organic anion
transporter). </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Pemetrexed total
systemic clearance is 91.8&nbsp;ml/min and the elimination half-life from
plasma is 3.5&nbsp;hours in patients with normal renal function (creatinine
clearance of 90&nbsp;ml/min). Between-patient variability in clearance is
moderate at 19.3%. Pemetrexed total systemic exposure (AUC) and maximum plasma
concentration increase proportionally with dose. The pharmacokinetics of
pemetrexed are consistent over multiple treatment cycles. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The
pharmacokinetic properties of pemetrexed are not influenced by concurrently
administered cisplatin. Oral folic acid and intramuscular vitamin B<sub>12</sub>
supplementation do not affect the pharmacokinetics of pemetrexed.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>5.3 Preclinical safety data</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Administration of pemetrexed to pregnant
mice resulted in decreased foetal viability, decreased foetal weight,
incomplete ossification of some skeletal structures, and cleft palate.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Administration
of pemetrexed to male mice resulted in reproductive toxicity characterised by
reduced fertility rates and testicular atrophy. In a study conducted in beagle
dog by intravenous bolus injection for 9&nbsp;months, testicular findings
(degeneration/necrosis of the seminiferous epithelium) have been observed. This
suggests that pemetrexed may impair male fertility. Female fertility was not
investigated. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Pemetrexed was
not mutagenic in either the <i>in vitro</i> chromosome aberration test in
Chinese hamster ovary cells, or the Ames test. Pemetrexed has been shown to be
clastogenic in the <i>in vivo</i> micronucleus test in the mouse. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Studies to assess the carcinogenic
potential of pemetrexed have not been conducted.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>6. PHARMACEUTICAL PARTICULARS</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>6.1 List of excipients</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Monothioglycerol</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Sodium hydroxide
(for pH adjustment)</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Water for
injections</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>6.2 Incompatibilities</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Pemetrexed is
physically incompatible with diluents containing calcium, including lactated
Ringer's injection and Ringer's injection. In the absence of other
compatibility studies this medicinal product must not be mixed with other
medicinal products.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>6.3 Shelf life</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Unopened
vial</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>2&nbsp;years</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Diluted
solution </span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Chemical and
physical in-use stability of infusion solution of pemetrexed has been
demonstrated for 24&nbsp;hours at 2C to 8C. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>From a microbiological point of view, the product should be used
immediately. If not used immediately, in-use storage times and conditions prior
to use are the responsibility of the user and would normally not be longer than
24 hours at 2</span><span lang=EN-GB></span><span lang=EN-GB>C to 8</span><span
lang=EN-GB></span><span lang=EN-GB>C.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>6.4 Special precautions for storage</span></b></p>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>This medicinal
product does not require any special storage conditions.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>For storage
conditions after dilution of the medicinal product, see section 6.3.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:74.5pt;text-indent:-74.5pt'><b><span
lang=EN-GB>6.5<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></b><b><span lang=EN-GB>Nature and contents of container</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>A clear, type I silicon dioxide inner
coated glass vial with bromobutyl rubber stopper and an aluminium seal with a
plastic flip-off top. The vials may be sheathed in protective ONCO-TAIN
sleeves.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>One vial contains either 4 ml, 20 ml or 40
ml of the concentrate.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Pack sizes</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>1 x 4 ml vial
(100 mg/4 ml)</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>1 x 20 ml vial
(500 mg/20 ml)</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>1 x 40 ml vial
(1,000 mg/40 ml)</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Not all pack
sizes may be marketed. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>6.6 Special precautions for disposal and other handling</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:9.0pt;text-indent:-9.0pt;line-height:
normal'><span lang=EN-GB>1. Use aseptic technique during dilution of pemetrexed
for intravenous infusion administration. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:9.0pt;text-indent:-9.0pt;line-height:
normal'><span lang=EN-GB>2. Calculate the dose and the number of Pemetrexed
Hospira vials needed. Each vial contains an excess of pemetrexed to facilitate
delivery of label amount.</span></p>

<p class=MsoNormal style='margin-left:9.0pt;text-indent:-9.0pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:9.0pt;text-indent:-9.0pt;line-height:
normal'><span lang=EN-GB>3. The appropriate volume of pemetrexed concentrate
must be diluted to 100&nbsp;ml with sodium chloride 9&nbsp;mg/ml (0.9%)
solution for injection, without preservative, and administered as an
intravenous infusion over 10&nbsp;minutes. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:9.0pt;text-indent:-9.0pt;line-height:
normal'><span lang=EN-GB>4. Pemetrexed infusion solution prepared as directed
above are compatible with polyvinyl chloride&#8209; and polyolefin-lined
administration sets and infusion bags. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:9.0pt;text-indent:-9.0pt;line-height:
normal'><span lang=EN-GB>5. Parenteral medicinal products must be inspected
visually for particulate matter and discolouration prior to administration. If
particulate matter is observed, do not administer. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>6. Pemetrexed
solutions are for single use only. Any unused medicinal product or waste
material must be disposed of in accordance with local requirements. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Preparation and administration precautions</span></u><u><span
lang=EN-GB> </span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>As with other potentially toxic anti-cancer agents, care should be
exercised in the handling and preparation of pemetrexed infusion solution. The
use of gloves is recommended. If a pemetrexed solution contacts the skin, wash
the skin immediately and thoroughly with soap and water. If pemetrexed
solutions contact the mucous membranes, flush thoroughly with water. Pemetrexed
is not a vesicant. There is not a specific antidote for extravasation of
pemetrexed. There have been few reported cases of pemetrexed extravasation, which
were not assessed as serious by the investigator. Extravasation should be
managed by local standard practice as with other non-vesicants.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>7. MARKETING AUTHORISATION HOLDER</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p style='margin:0in'><span lang=DE style='font-size:11.0pt'>Pfizer Europe MA
EEIG</span></p>

<p style='margin:0in'><span lang=DE style='font-size:11.0pt'>Boulevard de la
Plaine 17</span></p>

<p style='margin:0in'><span lang=DE style='font-size:11.0pt'>1050 Bruxelles</span></p>

<p style='margin:0in'><span lang=DE style='font-size:11.0pt'>Belgium</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>8. MARKETING AUTHORISATION NUMBER(S) </span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EU/1/15/1057/004
</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EU/1/15/1057/005</span><span
lang=EN-GB> </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EU/1/15/1057/006</span><span
lang=EN-GB> </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Date of initial authorisation: 20 November
2015</span></p>

<p class=MsoNormal><span lang=EN-GB>Date of latest renewal: 10 August 2020</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>10. DATE OF REVISION OF THE TEXT</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Detailed information on this medicinal product is available on the
website of the European Medicines Agency (EMA) </span><span lang=EN-GB><a
href="http://www.ema.europa.eu">http://www.ema.europa.eu</a></span><span
lang=EN-GB>.</span></p>

<p class=MsoNormal align=center style='margin-right:6.0pt;text-align:center;
line-height:normal;page-break-after:avoid;text-autospace:none'><b><span
lang=EN-GB style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='margin-right:6.0pt;text-align:center;
line-height:normal;page-break-after:avoid;text-autospace:none'><b><span
lang=EN-GB style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='margin-right:6.0pt;text-align:center;
line-height:normal;page-break-after:avoid;text-autospace:none'><b><span
lang=EN-GB style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='margin-right:6.0pt;text-align:center;
line-height:normal;page-break-after:avoid;text-autospace:none'><b><span
lang=EN-GB style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='margin-right:6.0pt;text-align:center;
line-height:normal;page-break-after:avoid;text-autospace:none'><b><span
lang=EN-GB style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='margin-right:6.0pt;text-align:center;
line-height:normal;page-break-after:avoid;text-autospace:none'><b><span
lang=EN-GB style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='margin-right:6.0pt;text-align:center;
line-height:normal;page-break-after:avoid;text-autospace:none'><b><span
lang=EN-GB style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='margin-right:6.0pt;text-align:center;
line-height:normal;page-break-after:avoid;text-autospace:none'><b><span
lang=EN-GB style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='margin-right:6.0pt;text-align:center;
line-height:normal;page-break-after:avoid;text-autospace:none'><b><span
lang=EN-GB style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='margin-right:6.0pt;text-align:center;
line-height:normal;page-break-after:avoid;text-autospace:none'><b><span
lang=EN-GB style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='margin-right:6.0pt;text-align:center;
line-height:normal;page-break-after:avoid;text-autospace:none'><b><span
lang=EN-GB style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='margin-right:6.0pt;text-align:center;
line-height:normal;page-break-after:avoid;text-autospace:none'><b><span
lang=EN-GB style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='margin-right:6.0pt;text-align:center;
line-height:normal;page-break-after:avoid;text-autospace:none'><b><span
lang=EN-GB style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='margin-right:6.0pt;text-align:center;
line-height:normal;page-break-after:avoid;text-autospace:none'><b><span
lang=EN-GB style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='margin-right:6.0pt;text-align:center;
line-height:normal;page-break-after:avoid;text-autospace:none'><b><span
lang=EN-GB style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='margin-right:6.0pt;text-align:center;
line-height:normal;page-break-after:avoid;text-autospace:none'><b><span
lang=EN-GB style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='margin-right:6.0pt;text-align:center;
line-height:normal;page-break-after:avoid;text-autospace:none'><b><span
lang=EN-GB style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='margin-right:6.0pt;text-align:center;
line-height:normal;page-break-after:avoid;text-autospace:none'><b><span
lang=EN-GB style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='margin-right:6.0pt;text-align:center;
line-height:normal;page-break-after:avoid;text-autospace:none'><b><span
lang=EN-GB style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='margin-right:6.0pt;text-align:center;
line-height:normal;page-break-after:avoid;text-autospace:none'><b><span
lang=EN-GB style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='margin-right:6.0pt;text-align:center;
line-height:normal;page-break-after:avoid;text-autospace:none'><b><span
lang=EN-GB style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='margin-right:6.0pt;text-align:center;
line-height:normal;page-break-after:avoid;text-autospace:none'><b><span
lang=EN-GB style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='margin-right:6.0pt;text-align:center;
line-height:normal;page-break-after:avoid;text-autospace:none'><b><span
lang=EN-GB style='color:black'>ANNEX II</span></b></p>

<p class=MsoNormal align=center style='margin-right:6.0pt;text-align:center;
line-height:normal;page-break-after:avoid;text-autospace:none'><b><span
lang=EN-GB style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.0pt;margin-bottom:0in;
margin-left:40.5pt;margin-bottom:.0001pt;text-indent:-9.0pt;line-height:normal;
page-break-after:avoid;text-autospace:none'><b><span lang=EN-GB
style='color:black'>A. MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.0pt;margin-bottom:0in;
margin-left:40.5pt;margin-bottom:.0001pt;text-indent:-9.0pt;line-height:normal;
page-break-after:avoid;text-autospace:none'><b><span lang=EN-GB
style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.0pt;margin-bottom:0in;
margin-left:40.5pt;margin-bottom:.0001pt;text-indent:-9.0pt;line-height:normal;
page-break-after:avoid;text-autospace:none'><b><span lang=EN-GB
style='color:black'>B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.0pt;margin-bottom:0in;
margin-left:40.5pt;margin-bottom:.0001pt;text-indent:-9.0pt;line-height:normal;
text-autospace:none'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.0pt;margin-bottom:0in;
margin-left:58.5pt;margin-bottom:.0001pt;text-indent:-27.0pt;line-height:normal;
page-break-after:avoid;text-autospace:none'><b><span lang=EN-GB
style='color:black'>C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING
AUTHORISATION</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.0pt;margin-bottom:0in;
margin-left:40.5pt;margin-bottom:.0001pt;text-indent:-9.0pt;line-height:normal;
text-autospace:none'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.0pt;margin-bottom:0in;
margin-left:58.5pt;margin-bottom:.0001pt;text-indent:-27.0pt;line-height:normal;
page-break-after:avoid;text-autospace:none'><b><span lang=EN-GB
style='color:black'>D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE
AND EFFECTIVE USE OF THE MEDICINAL PRODUCT</span></b></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'><br clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal align=center style='margin-right:1.6in;text-align:center;
line-height:normal;page-break-after:avoid;text-autospace:none'><b><span
lang=EN-GB style='color:black'>A. MANUFACTURER(S) RESPONSIBLE FOR BATCH
RELEASE</span></b></p>

<p class=MsoNormal style='margin-right:6.0pt;line-height:normal;text-autospace:
none'><u><span lang=EN-GB style='color:black'><span style='text-decoration:
 none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='margin-right:6.0pt;line-height:normal;text-autospace:
none'><u><span lang=EN-GB style='color:black'>Name and address of the
manufacturer(s) responsible for batch release</span></u></p>

<p class=MsoNormal style='margin-right:6.0pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:6.0pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='color:black'>Pfizer Service Company BVBA</span></p>

<p class=MsoNormal style='margin-right:6.0pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='color:black'>Hoge Wei 10</span></p>

<p class=MsoNormal style='margin-right:6.0pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='color:black'>1930 Zaventem</span></p>

<p class=MsoNormal style='margin-right:6.0pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='color:black'>Belgium</span></p>

<p class=MsoNormal style='margin-right:6.0pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:6.0pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.75pt;line-height:normal;page-break-after:
avoid;text-autospace:none'><b><span lang=EN-GB style='color:black'>B. CONDITIONS
OR RESTRICTIONS REGARDING SUPPLY AND USE</span></b></p>

<p class=MsoNormal style='margin-right:6.0pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:6.0pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='color:black'>Medicinal product subject to
restricted medical prescription (see Annex I: Summary of Product
Characteristics, section 4.2).</span></p>

<p class=MsoNormal style='margin-right:5.75pt;line-height:normal;page-break-after:
avoid;text-autospace:none'><b><span lang=EN-GB style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:5.75pt;line-height:normal;page-break-after:
avoid;text-autospace:none'><b><span lang=EN-GB style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:5.75pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;text-autospace:none'><b><span lang=EN-GB
style='color:black'>C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING
AUTHORISATION </span></b></p>

<p class=MsoNormal style='margin-right:5.75pt;line-height:normal;page-break-after:
avoid;text-autospace:none'><b><span lang=EN-GB style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:0in;text-indent:0in;line-height:normal;
text-autospace:none'><span lang=EN-GB style='font-size:12.0pt;font-family:Symbol;
color:black'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB style='color:black'>Periodic safety update
reports (PSURs) </span></b></p>

<p class=MsoNormal style='margin-right:6.0pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:6.0pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='color:black'>The requirements for submission of PSURs
for this medicinal product are set out in the list of Union reference dates
(EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any
subsequent updates published on the European medicines web-portal.</span></p>

<p class=MsoNormal style='margin-right:6.0pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:6.0pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.0pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;text-autospace:none'><b><span lang=EN-GB
style='color:black'>D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE
AND EFFECTIVE USE OF THE MEDICINAL PRODUCT</span></b></p>

<p class=MsoNormal style='margin-right:6.0pt;line-height:normal;page-break-after:
avoid;text-autospace:none'><b><span lang=EN-GB style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:0in;text-indent:0in;line-height:normal;
text-autospace:none'><span lang=EN-GB style='font-size:12.0pt;font-family:Symbol;
color:black'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB style='color:black'>Risk management plan
(RMP)</span></b></p>

<p class=MsoNormal style='margin-right:6.0pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:6.0pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='color:black'>The marketing authorisation holder (MAH)
shall perform the required pharmacovigilance activities and interventions
detailed in the agreed RMP presented in Module 1.8.2 of the marketing authorisation
and any agreed subsequent updates of the RMP.</span></p>

<p class=MsoNormal style='margin-right:6.0pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:6.0pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='color:black'>An updated RMP should be submitted:</span></p>

<p class=MsoNormal style='margin-left:0in;text-indent:0in;line-height:normal;
text-autospace:none'><span lang=EN-GB style='font-size:12.0pt;font-family:Symbol;
color:black'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>At the request of the
European Medicines Agency;</span></p>

<p class=MsoNormal style='margin-left:0in;text-indent:0in;line-height:normal;
text-autospace:none'><span lang=EN-GB style='font-size:12.0pt;font-family:Symbol;
color:black'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>Whenever the risk management
system is modified, especially as the result of new information being received
that may lead to a significant change to the benefit/risk profile or as the
result of an important (pharmacovigilance or risk minimisation) milestone being
reached. </span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>ANNEX
III</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>LABELLING
AND PACKAGE LEAFLET</span></b></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=TitleA><span lang=EN-GB>A. LABELLING</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'><br clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='background:white'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>PARTICULARS
TO APPEAR ON THE OUTER PACKAGING</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>OUTER
CARTON 100&nbsp;mg presentation</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>1. NAME OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Pemetrexed
Hospira 100&nbsp;mg powder for concentrate for solution for infusion</span></p>

<p class=MsoNormal><span lang=EN-GB>pemetrexed</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>2. STATEMENT OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Each vial contains 100&nbsp;mg of
pemetrexed (as pemetrexed disodium hemipentahydrate).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>After reconstitution</span><span
lang=EN-GB>, each vial contains 25&nbsp;mg/ml of pemetrexed.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>3. LIST OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Excipients: m</span><span
lang=EN-GB>annitol, hydrochloric acid concentrated, sodium hydroxide. <span
style='background:lightgrey'>(see package leaflet for further information)</span></span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>4. PHARMACEUTICAL FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:lightgrey'>Powder for concentrate for solution for infusion</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>1&nbsp;vial</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:lightgrey'>ONCO-TAIN</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>5. METHOD AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>For intravenous use </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Reconstitute and dilute before use.</span></p>

<p class=MsoNormal><span lang=EN-GB>Single use only.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Read the package leaflet before use.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>6. SPECIAL WARNING THAT THE MEDICINAL
PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Keep out of the sight and reach of children.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>7. OTHER SPECIAL
WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Cytotoxic</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>8. EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:lightgrey'>Read the
package leaflet for the shelf life of the reconstituted product</span><span
lang=EN-GB>.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>9. SPECIAL STORAGE
CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>10. SPECIAL PRECAUTIONS FOR DISPOSAL OF
UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL
PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Discard unused contents appropriately.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>11. NAME
AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p style='margin:0in'><span lang=FR style='font-size:11.0pt'>Pfizer Europe MA
EEIG</span></p>

<p style='margin:0in'><span lang=FR style='font-size:11.0pt'>Boulevard de la
Plaine 17</span></p>

<p style='margin:0in'><span lang=EN-GB style='font-size:11.0pt'>1050 Bruxelles</span></p>

<p style='margin:0in'><span lang=EN-GB style='font-size:11.0pt'>Belgium</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>12. MARKETING
AUTHORISATION NUMBER(S) </span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>EU/1/15/1057/001</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>13. BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>14. GENERAL
CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:2.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>15. INSTRUCTIONS
ON USE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>16. INFORMATION
IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black;background:#CCCCCC'>Justification
for not including Braille accepted.</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:#CCCCCC'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:#CCCCCC'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>17. </span><span lang=EN-GB>UNIQUE
IDENTIFIER  2D BARCODE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='background:lightgrey'>2D barcode carrying the unique
identifier included.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>18. </span><span lang=EN-GB>UNIQUE
IDENTIFIER  HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
lang=EN-GB>PC </span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
lang=EN-GB>SN </span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>NN </span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='background:#CCCCCC'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:#CCCCCC'>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black;background:#CCCCCC'><br clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>MINIMUM
PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS</span></b></p>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>VIAL
LABEL 100&nbsp;mg presentation</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>1. NAME
OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Pemetrexed
Hospira 100&nbsp;mg powder for concentrate for solution for infusion</span></p>

<p class=MsoNormal><span lang=EN-GB>pemetrexed</span></p>

<p class=MsoNormal><span lang=EN-GB>Intravenous use</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>2. METHOD
OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Reconstitute and dilute before use.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>3. EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>4. BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>5. CONTENTS
BY WEIGHT, BY VOLUME OR BY UNIT</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>100&nbsp;mg</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>6. OTHER</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>PARTICULARS
TO APPEAR ON THE OUTER PACKAGING</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>OUTER CARTON
500&nbsp;mg presentation</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>1. NAME OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Pemetrexed
Hospira 500&nbsp;mg powder for concentrate for solution for infusion</span></p>

<p class=MsoNormal><span lang=EN-GB>pemetrexed </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>2. STATEMENT OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Each vial contains 500&nbsp;mg of
pemetrexed (as pemetrexed disodium hemipentahydrate).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>After reconstitution</span><span
lang=EN-GB>, each vial contains 25&nbsp;mg/ml of pemetrexed.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>3. LIST OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Excipients: m</span><span
lang=EN-GB>annitol, hydrochloric acid concentrated, sodium hydroxide. <span
style='background:lightgrey'>(see package leaflet for further information)</span></span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>4. PHARMACEUTICAL FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:lightgrey'>Powder for concentrate for solution for infusion</span><span
lang=EN-GB>.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>1&nbsp;vial</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:lightgrey'>ONCO-TAIN</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>5. METHOD AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>For intravenous use </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Reconstitute and dilute before use.</span></p>

<p class=MsoNormal><span lang=EN-GB>Single use only.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Read the package leaflet before use.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>6. SPECIAL WARNING THAT THE MEDICINAL
PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Keep out of the sight and reach of children.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>7. OTHER SPECIAL
WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Cytotoxic</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>8. EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:lightgrey'>Read the
package leaflet for the shelf life of the reconstituted product</span><span
lang=EN-GB>.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>9. SPECIAL STORAGE
CONDITIONS</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>10. SPECIAL PRECAUTIONS FOR DISPOSAL OF
UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL
PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Discard unused contents appropriately.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>11. NAME
AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p style='margin:0in'><span lang=FR style='font-size:11.0pt'>Pfizer Europe MA
EEIG</span></p>

<p style='margin:0in'><span lang=FR style='font-size:11.0pt'>Boulevard de la
Plaine 17</span></p>

<p style='margin:0in'><span lang=EN-GB style='font-size:11.0pt'>1050 Bruxelles</span></p>

<p style='margin:0in'><span lang=EN-GB style='font-size:11.0pt'>Belgium</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>12. MARKETING
AUTHORISATION NUMBER(S) </span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>EU/1/15/1057/002</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>13. BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>14. GENERAL
CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:2.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>15. INSTRUCTIONS
ON USE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>16. INFORMATION
IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black;background:lightgrey'>Justification
for not including Braille accepted</span><span lang=EN-GB style='color:black;
background:#CCCCCC'>.</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:#CCCCCC'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:#CCCCCC'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>17. </span><span lang=EN-GB>UNIQUE IDENTIFIER  2D BARCODE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:lightgrey'>2D barcode carrying the unique identifier
included.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>18. </span><span lang=EN-GB>UNIQUE
IDENTIFIER  HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
lang=EN-GB>PC </span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
lang=EN-GB>SN </span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>NN </span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='background:#CCCCCC'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:#CCCCCC'>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black;background:#CCCCCC'><br clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>MINIMUM
PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS</span></b></p>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>Vial
label 500&nbsp;mg presentation</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>1. NAME
OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Pemetrexed
Hospira 500&nbsp;mg powder for concentrate for solution for infusion</span></p>

<p class=MsoNormal><span lang=EN-GB>pemetrexed</span></p>

<p class=MsoNormal><span lang=EN-GB>Intravenous use</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>2. METHOD
OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Reconstitute and dilute before use.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>3. EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>4. BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>5. CONTENTS
BY WEIGHT, BY VOLUME OR BY UNIT</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>500&nbsp;mg</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>6. OTHER</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>PARTICULARS
TO APPEAR ON THE OUTER PACKAGING</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>Outer
carton 1,000&nbsp;mg presentation</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>1. NAME OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Pemetrexed
Hospira 1,000&nbsp;mg powder for concentrate for solution for infusion</span></p>

<p class=MsoNormal><span lang=EN-GB>pemetrexed</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>2. STATEMENT OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Each vial contains 1,000&nbsp;mg of
pemetrexed (as pemetrexed disodium hemipentahydrate).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>After reconstitution, each vial contains 25&nbsp;mg/ml
of pemetrexed.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>3. LIST OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Excipients: m</span><span
lang=EN-GB>annitol, hydrochloric acid concentrated, sodium hydroxide. <span
style='background:lightgrey'>(see package leaflet for further information)</span></span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>4. PHARMACEUTICAL FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:lightgrey'>Powder for concentrate for solution for infusion</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>1&nbsp;vial</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:lightgrey'>ONCO-TAIN</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>5. METHOD AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>For intravenous use </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Reconstitute and dilute before use.</span></p>

<p class=MsoNormal><span lang=EN-GB>Single use only.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Read the package leaflet before use.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>6. SPECIAL WARNING THAT THE MEDICINAL
PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Keep out of the sight and reach of children.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>7. OTHER SPECIAL
WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Cytotoxic</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>8. EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:lightgrey'>Read the
package leaflet for the shelf life of the reconstituted product</span><span
lang=EN-GB>.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>9. SPECIAL STORAGE
CONDITIONS</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>10. SPECIAL PRECAUTIONS FOR DISPOSAL OF
UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL
PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Discard unused contents appropriately.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>11. NAME
AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p style='margin:0in'><span lang=FR style='font-size:11.0pt'>Pfizer Europe MA
EEIG</span></p>

<p style='margin:0in'><span lang=FR style='font-size:11.0pt'>Boulevard de la Plaine
17</span></p>

<p style='margin:0in'><span lang=EN-GB style='font-size:11.0pt'>1050 Bruxelles</span></p>

<p style='margin:0in'><span lang=EN-GB style='font-size:11.0pt'>Belgium</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>12. MARKETING
AUTHORISATION NUMBER(S) </span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>EU/1/15/1057/003</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>13. BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>14. GENERAL
CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:2.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>15. INSTRUCTIONS
ON USE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>16. INFORMATION
IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black;background:lightgrey'>Justification
for not including Braille accepted</span><span lang=EN-GB style='color:black;
background:#CCCCCC'>.</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:#CCCCCC'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:#CCCCCC'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>17. </span><span lang=EN-GB>UNIQUE
IDENTIFIER  2D BARCODE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='background:lightgrey'>2D barcode carrying the unique
identifier included.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>18. </span><span lang=EN-GB>UNIQUE IDENTIFIER  HUMAN READABLE
DATA</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>PC </span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>SN </span></p>

<p class=MsoNormal><span lang=EN-GB>NN </span></p>

<p class=MsoNormal><span lang=EN-GB style='background:#CCCCCC'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:#CCCCCC'>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black;background:#CCCCCC'><br clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>MINIMUM
PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS</span></b></p>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>Vial
label 1,000&nbsp;mg presentation</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>1. NAME
OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Pemetrexed
Hospira 1,000&nbsp;mg powder for concentrate for solution for infusion</span></p>

<p class=MsoNormal><span lang=EN-GB>pemetrexed</span></p>

<p class=MsoNormal><span lang=EN-GB>Intravenous use</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>2. METHOD
OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Reconstitute and dilute before use.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>3. EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>4. BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>5. CONTENTS
BY WEIGHT, BY VOLUME OR BY UNIT</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>1,000&nbsp;mg</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>6. OTHER</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'><br clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='background:white'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>PARTICULARS
TO APPEAR ON THE OUTER PACKAGING</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>OUTER
CARTON </span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>1. NAME OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Pemetrexed
Hospira 25&nbsp;mg/ml concentrate for solution for infusion</span></p>

<p class=MsoNormal><span lang=EN-GB>pemetrexed</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>2. STATEMENT OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>One ml contains pemetrexed disodium
equivalent to 25 mg of pemetrexed.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>One vial of 4 ml contains <a
name="_Hlk35436174">pemetrexed disodium equivalent </a>to 100&nbsp;mg of
pemetrexed.</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:lightgrey'>One vial of 20
ml contains pemetrexed disodium equivalent to 500 mg of pemetrexed.</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:lightgrey'>One vial of 40
ml contains pemetrexed disodium equivalent to 1,000 mg of pemetrexed </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>3. LIST OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Excipients: monothioglycerol</span><span
lang=EN-GB>, sodium hydroxide and water for injections <span style='background:
lightgrey'>(see package leaflet for further information)</span></span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>4. PHARMACEUTICAL FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:lightgrey'>Concentrate for solution for infusion</span></p>

<p class=MsoNormal><span lang=EN-GB>100 mg/4 ml</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:lightgrey'>500 mg/20 ml</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:lightgrey'>1,000 mg/40 ml</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>1 vial</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:lightgrey'>ONCO-TAIN</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>5. METHOD AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Intravenous use. Dilute before use. </span></p>

<p class=MsoNormal><span lang=EN-GB>Single use only</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Read the package leaflet before use.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>6. SPECIAL WARNING THAT THE MEDICINAL
PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:lightgrey'>Keep out of
the sight and reach of children.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>7. OTHER SPECIAL
WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Cytotoxic</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>8. EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>9. SPECIAL STORAGE
CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>10. SPECIAL PRECAUTIONS FOR DISPOSAL OF
UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL
PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>11. NAME
AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p style='margin:0in'><span lang=DE style='font-size:11.0pt'>Pfizer Europe MA
EEIG</span></p>

<p style='margin:0in'><span lang=DE style='font-size:11.0pt'>Boulevard de la
Plaine 17</span></p>

<p style='margin:0in'><span lang=DE style='font-size:11.0pt'>1050 Bruxelles</span></p>

<p style='margin:0in'><span lang=DE style='font-size:11.0pt'>Belgium</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>12. MARKETING
AUTHORISATION NUMBER(S) </span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'>EU/1/15/1057/004 <span
lang=EN-GB style='background:lightgrey'>100 mg/4 ml vial</span></p>

<p class=MsoNormal style='line-height:normal'><span style='background:lightgrey'>EU/1/15/1057/005</span><span
style='background:lightgrey'> <span lang=EN-GB>500 mg/20 ml vial</span></span></p>

<p class=MsoNormal style='line-height:normal'><span style='background:lightgrey'>EU/1/15/1057/006</span><span
style='background:lightgrey'> <span lang=EN-GB>1,000 mg/40 ml vial</span></span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>13. BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>14. GENERAL
CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:2.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>15. INSTRUCTIONS
ON USE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>16. INFORMATION
IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black;background:#CCCCCC'>Justification
for not including Braille accepted</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:#CCCCCC'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:#CCCCCC'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>17. </span><span lang=EN-GB>UNIQUE
IDENTIFIER  2D BARCODE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='background:lightgrey'>2D barcode carrying the unique
identifier included.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>18. </span><span lang=EN-GB>UNIQUE
IDENTIFIER  HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
lang=EN-GB>PC </span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
lang=EN-GB>SN </span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>NN</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='background:#CCCCCC'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:#CCCCCC'>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black;background:#CCCCCC'><br clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>MINIMUM
PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS</span></b></p>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>VIAL
LABEL </span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>1. NAME
OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Pemetrexed
Hospira 25&nbsp;mg/ml sterile concentrate</span></p>

<p class=MsoNormal><span lang=EN-GB>pemetrexed</span></p>

<p class=MsoNormal><span lang=EN-GB>IV</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>2. METHOD
OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Dilute before use</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>3. EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>4. BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>5. CONTENTS
BY WEIGHT, BY VOLUME OR BY UNIT</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>100&nbsp;mg/4
ml</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='background:lightgrey'>500 mg/20 ml</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB
style='background:lightgrey'>1,000 mg/40 ml</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>6. OTHER</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=TitleA><span lang=EN-GB>B. PACKAGE LEAFLET</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>Package leaflet: Information for the user</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal;
background:white'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>Pemetrexed Hospira 100&nbsp;mg powder for concentrate for solution
for infusion</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>Pemetrexed Hospira 500&nbsp;mg powder for concentrate for solution
for infusion</span></b><span lang=EN-GB> </span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>Pemetrexed Hospira 1,000&nbsp;mg powder for concentrate for solution
for infusion</span></b><span lang=EN-GB> </span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>pemetrexed</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Read all of
this leaflet carefully before you start receiving this medicine because it
contains important information for you.</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Keep this leaflet. You may need to read it
again. </span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you have any further questions, ask your
doctor or pharmacist</span><span lang=EN-GB> </span>or nurse.</p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>- If you get any side effects, talk to your
doctor or pharmacist</span> or nurse<span lang=EN-GB>. </span><span lang=EN-GB>This
includes any possible side effects not listed in this leaflet. See section 4.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><b><span lang=EN-GB>What is in this leaflet</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>1. What Pemetrexed Hospira is and what it is used for </span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>2. What you need to know before you use Pemetrexed Hospira</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>3. How to use Pemetrexed Hospira</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>4. Possible side effects </span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>5. How to store Pemetrexed Hospira</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>6. Contents of the pack and other information</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>1. What Pemetrexed Hospira is and what it is used for</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Pemetrexed Hospira</span><span lang=EN-GB style='color:black'> is a
medicine used in the treatment of cancer.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Pemetrexed Hospira</span><span lang=EN-GB style='color:black'> is
given in combination with cisplatin, another anti-cancer medicine, as treatment
for malignant pleural mesothelioma, a form of cancer that affects the lining of
the lung, to patients who have not received prior chemotherapy.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Pemetrexed Hospira</span><span lang=EN-GB style='color:black'> is
also given in combination with cisplatin for the initial treatment of patients
with advanced stage of lung cancer.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Pemetrexed Hospira</span><span lang=EN-GB style='color:black'> can
be prescribed to you if you have lung cancer at an advanced stage if your
disease has responded to treatment or it remains largely unchanged after
initial chemotherapy.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Pemetrexed Hospira</span><span lang=EN-GB style='color:black'> is
also a treatment for patients with advanced stage of lung cancer whose disease
has progressed after other initial chemotherapy has been used.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>2. What you need to know before you use Pemetrexed Hospira</span></b></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Do not use
Pemetrexed Hospira</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>- if you are allergic (hypersensitive) to
pemetrexed or any of the other ingredients of this medicine (listed in section
6).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='color:black'>-  if
you are breast-feeding; you must discontinue breast-feeding during treatment
with </span><span lang=EN-GB>Pemetrexed Hospira</span><span lang=EN-GB
style='color:black'>.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB style='color:black'>-  if you have recently received or are
about to receive a vaccine against yellow fever.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Warnings and
precautions </span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Talk to your doctor or hospital pharmacist before receiving
Pemetrexed Hospira.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>If you currently have or have previously had problems with your
kidneys, talk to your doctor or hospital pharmacist as you may not be able to
receive Pemetrexed Hospira.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Before each infusion you will have samples of your blood taken to
evaluate if you have sufficient kidney and liver function and to check that you
have enough blood cells to receive Pemetrexed Hospira. Your doctor may decide
to change the dose or delay treating you depending on your general condition
and if your blood cell counts are too low. If you are also receiving cisplatin,
your doctor will make sure that you are properly hydrated and receive
appropriate treatment before and after receiving cisplatin to prevent vomiting.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>If you have had or are going to have radiation therapy, please tell
your doctor, as there may be an early or late radiation reaction with
Pemetrexed Hospira.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>If you have been recently vaccinated, please tell your doctor, as
this can possibly cause bad effects with Pemetrexed Hospira.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>If you have heart disease or a history of heart disease, please tell
your doctor.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>If you have an accumulation of fluid around your lungs, your doctor
may decide to remove the fluid before giving you Pemetrexed Hospira.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>Children and adolescents</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>This medicine
should not be used in children or adolescents, since there is no experience
with this medicine in children and adolescents under 18&nbsp;years of age.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>Other medicines and Pemetrexed Hospira</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Please tell your doctor if you are taking any medicine for pain or
inflammation (swelling), such as medicines called nonsteroidal
anti-inflammatory drugs (NSAIDs), including medicines purchased without a
doctors prescription (such as ibuprofen). There are many sorts of NSAIDs with
different durations of activity. Based on the planned date of your infusion of
pemetrexed and/or on the status of your kidney function, your doctor needs to
advise you on which medicines you can take and when you can take them. If you
are unsure, ask your doctor or pharmacist if any of your medicines are NSAIDs.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Please tell your doctor or hospital pharmacist if you are taking or
have recently taken any other medicines, including medicines obtained without a
prescription.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>Pregnancy</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>If you are pregnant, think you may be pregnant or are planning to
have a baby, tell your doctor. </span><span lang=EN-GB>The use of pemetrexed
should be avoided during pregnancy. Your doctor will discuss with you the
potential risk of taking pemetrexed during pregnancy. Women must use effective
contraception during treatment with pemetrexed.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>Breast-feeding</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>If you are breast-feeding, tell your doctor. </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Breast-feeding must be discontinued during treatment with pemetrexed.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>Fertility</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Men are advised not to father a child during and up to 6&nbsp;months
following treatment with pemetrexed and should therefore use effective
contraception during treatment with pemetrexed and for up to 6&nbsp;months
afterwards. If you would like to father a child during the treatment or in the
6&nbsp;months following receipt of treatment, seek advice from your doctor or
pharmacist. You may want to seek counselling on sperm storage before starting
your therapy.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><b><span lang=EN-GB>Driving and using machines</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Pemetrexed Hospira may make you feel tired. Be careful when driving
a car or using machines.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><b><span lang=EN-GB>Pemetrexed Hospira contains sodium</span></b><span
lang=EN-GB><br>
<br>
</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><i><u><span lang=EN-GB>Pemetrexed Hospira 100&nbsp;mg </span></u></i><i><u><span
lang=EN-GB>powder for concentrate for solution for infusion</span></u></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>This medicine contains less than 1&nbsp;mmol sodium (23&nbsp;mg) per
vial, that is to say essentially sodium&#8209; free. </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><u><span
lang=EN-GB>Pemetrexed Hospira 500&nbsp;mg </span></u></i><i><u><span
lang=EN-GB>powder for concentrate for solution for infusion</span></u></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>This medicine contains 54&nbsp;mg sodium (main component of
cooking/table salt) in each vial. </span><span lang=EN-GB>This is equivalent to
2.7</span><span lang=EN-GB>&nbsp;</span><span lang=EN-GB>% of the recommended
maximum daily dietary intake of sodium for an adult.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><u><span
lang=EN-GB>Pemetrexed Hospira 1,000&nbsp;mg </span></u></i><i><u><span
lang=EN-GB>powder for concentrate for solution for infusion</span></u></i><span
lang=EN-GB> </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>This medicine contains 108&nbsp;mg sodium (main component of
cooking/table salt) in each vial. </span><span lang=EN-GB>This is equivalent to
5.4</span><span lang=EN-GB>&nbsp;</span><span lang=EN-GB>% of the recommended
maximum daily dietary intake of sodium for an adult.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>3. How to use Pemetrexed Hospira</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>The dose of Pemetrexed Hospira is 500&nbsp;milligrams for every
square metre of your bodys surface area. Your height and weight are measured
to work out the surface area of your body. Your doctor will use this body
surface area to work out the right dose for you. This dose may be adjusted, or
treatment may be delayed depending on your blood cell counts and on your
general condition. A hospital pharmacist, nurse or doctor will have mixed the
Pemetrexed Hospira powder with 9&nbsp;mg/ml (0.9 %) sodium chloride solution
for injection before it is given to you.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>You will always receive Pemetrexed Hospira by infusion into one of
your veins. The infusion will last approximately 10&nbsp;minutes.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>When using Pemetrexed Hospira in combination with cisplatin:</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>The doctor or hospital pharmacist will work out the dose you need
based on your height and weight. Cisplatin is also given by infusion into one
of your veins, and is given approximately 30&nbsp;minutes after the infusion of
Pemetrexed Hospira has finished. The infusion of cisplatin will last
approximately 2&nbsp;hours.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>You should usually receive your infusion once every 3&nbsp;weeks.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Additional medicines:</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Corticosteroids: your doctor will prescribe you steroid tablets
(equivalent to 4&nbsp;milligram of dexamethasone twice a day) that you will
need to take on the day before, on the day of, and the day after Pemetrexed
Hospira treatment. This medicine is given to you to reduce the frequency and
severity of skin reactions that you may experience during your anticancer treatment.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Vitamin supplementation: your doctor will prescribe you oral folic
acid (vitamin) or a multivitamin containing folic acid (350 to 1,000&nbsp;micrograms)
that you must take once a day while you are taking Pemetrexed Hospira. You must
take at least 5&nbsp;doses during the seven days before the first dose of
Pemetrexed Hospira. You must continue taking the folic acid for </span><span
lang=EN-GB>21&nbsp;days</span><span lang=EN-GB> after the last dose of
Pemetrexed Hospira. You will also receive an injection of vitamin B<sub>12</sub>
(1,000&nbsp;micrograms) in the week before administration of Pemetrexed Hospira
and then approximately every 9&nbsp;weeks (corresponding to 3 courses of
Pemetrexed Hospira treatment). Vitamin B<sub>12</sub> and folic acid are given
to you to reduce the possible toxic effects of the anticancer treatment.</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>If you have any further questions on the use of this medicine, ask
your doctor or pharmacist.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>4. Possible side effects</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB style='color:black'>Like all medicines, this medicine can cause side
effects, although not everybody gets them.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB style='color:black'>You must contact your doctor immediately if you
notice any of the following:</span></p>

<p class=MsoListParagraphCxSpFirst style='text-indent:-.25in;line-height:normal;
text-autospace:none'><span lang=EN-GB style='font-family:Symbol;color:black'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>Fever or infection (common):
if you have a temperature of 38C or greater, sweating or other signs of
infection (since you might have fewer white blood cells than normal which is
very common). Infection (sepsis) may be severe and could lead to death.</span></p>

<p class=MsoListParagraphCxSpMiddle style='text-indent:-.25in;line-height:normal;
text-autospace:none'><span lang=EN-GB style='font-family:Symbol;color:black'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>If you start feeling chest
pain (common) or having a fast heart rate (uncommon).</span></p>

<p class=MsoListParagraphCxSpMiddle style='text-indent:-.25in;line-height:normal;
text-autospace:none'><span lang=EN-GB style='font-family:Symbol;color:black'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>If you have pain, redness,
swelling or sores in your mouth (very common).</span></p>

<p class=MsoListParagraphCxSpMiddle style='text-indent:-.25in;line-height:normal;
text-autospace:none'><span lang=EN-GB style='font-family:Symbol;color:black'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>Allergic reaction: if you
develop skin rash (very common) / burning or prickling sensation (common), or
fever (common). Rarely, skin reactions may be severe and could lead to death</span><span
lang=EN-GB style='color:blue'>. </span><span lang=EN-GB style='color:black'>Contact
your doctor if you get a severe rash</span><span lang=EN-GB style='color:blue'>,
</span><span lang=EN-GB style='color:black'>or itching</span><span lang=EN-GB
style='color:blue'>, </span><span lang=EN-GB style='color:black'>or blistering
(Stevens-Johnson syndrome or toxic epidermal necrolysis).</span></p>

<p class=MsoListParagraphCxSpMiddle style='text-indent:-.25in;line-height:normal;
text-autospace:none'><span lang=EN-GB style='font-family:Symbol;color:black'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>If you experience tiredness,
feeling faint, becoming easily breathless or if you look pale (since you might
have less haemoglobin than normal which is very common).</span></p>

<p class=MsoListParagraphCxSpMiddle style='text-indent:-.25in;line-height:normal;
text-autospace:none'><span lang=EN-GB style='font-family:Symbol;color:black'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>If you experience bleeding
from the gums, nose or mouth or any bleeding that would not stop, reddish or
pinkish urine, unexpected bruising (since you might have fewer platelets than
normal which is very common).</span></p>

<p class=MsoListParagraphCxSpLast style='text-indent:-.25in;line-height:normal;
text-autospace:none'><span lang=EN-GB style='font-family:Symbol;color:black'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>If you experience sudden
breathlessness, intense chest pain or cough with bloody sputum (uncommon) (may
indicate a blood clot in the blood vessels of the lungs).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB style='color:black'>Side effects with pemetrexed may include:</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><span
lang=EN-GB style='color:black'>&nbsp;</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Very
common </span></i><i><span lang=EN-GB>(may affect more than 1 in 10 people)</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Infection</span></p>

<p class=MsoNormal><span lang=EN-GB>Pharyngitis (a sore throat)</span></p>

<p class=MsoNormal><span lang=EN-GB>Low number of neutrophil granulocytes (a
type of white blood cell)</span></p>

<p class=MsoNormal><span lang=EN-GB>Low white blood cells</span></p>

<p class=MsoNormal><span lang=EN-GB>Low haemoglobin level </span></p>

<p class=MsoNormal><span lang=EN-GB>Pain, redness, swelling or sores in your
mouth</span></p>

<p class=MsoNormal><span lang=EN-GB>Loss of appetite</span></p>

<p class=MsoNormal><span lang=EN-GB>Vomiting</span></p>

<p class=MsoNormal><span lang=EN-GB>Diarrhoea </span></p>

<p class=MsoNormal><span lang=EN-GB>Nausea<br>
Skin rash</span></p>

<p class=MsoNormal><span lang=EN-GB>Flaking skin</span></p>

<p class=MsoNormal><span lang=EN-GB>Abnormal blood tests showing reduced
functionality of kidneys <br>
Fatigue (tiredness)</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Common
(may affect up to 1 in 10 people)</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Blood infection</span></p>

<p class=MsoNormal><span lang=EN-GB>Fever with low number of neutrophil
granulocytes (a type of white blood cell)</span></p>

<p class=MsoNormal><span lang=EN-GB>Low platelet count</span></p>

<p class=MsoNormal><span lang=EN-GB>Allergic reaction</span></p>

<p class=MsoNormal><span lang=EN-GB>Loss of body fluids</span></p>

<p class=MsoNormal><span lang=EN-GB>Taste change</span></p>

<p class=MsoNormal><span lang=EN-GB>Damage to the motor nerves which may cause
muscle weakness and atrophy (wasting) primary in the arms and legs)</span></p>

<p class=MsoNormal><span lang=EN-GB>Damage to the sensory nerves that may cause
loss of sensation, burning pain and unsteady gait</span></p>

<p class=MsoNormal><span lang=EN-GB>Dizziness</span></p>

<p class=MsoNormal><span lang=EN-GB>Inflammation or swelling of the conjunctiva
(the membrane that lines the eyelids and covers the white of the eye</span></p>

<p class=MsoNormal><span lang=EN-GB>Dry eye</span></p>

<p class=MsoNormal><span lang=EN-GB>Watery eyes</span></p>

<p class=MsoNormal><span lang=EN-GB>Dryness of the conjunctiva (the membrane
that lines the eyelids and covers the white of the eye) and cornea (the clear
layer in front of the iris and pupil.</span></p>

<p class=MsoNormal><span lang=EN-GB>Swelling of the eyelids</span></p>

<p class=MsoNormal><span lang=EN-GB>Eye disorder with dryness, tearing,
irritation, and/or pain</span></p>

<p class=MsoNormal><span lang=EN-GB>Cardiac Failure (Condition that affects the
pumping power of your heart muscles)</span></p>

<p class=MsoNormal><span lang=EN-GB>Irregular heart rhythm</span></p>

<p class=MsoNormal><span lang=EN-GB>Indigestion</span></p>

<p class=MsoNormal><span lang=EN-GB>Constipation</span></p>

<p class=MsoNormal><span lang=EN-GB>Abdominal pain</span></p>

<p class=MsoNormal><span lang=EN-GB>Liver: increases in the chemicals in the
blood made by the liver </span></p>

<p class=MsoNormal><span lang=EN-GB>Increased skin pigmentation</span></p>

<p class=MsoNormal><span lang=EN-GB>Itchy skin</span></p>

<p class=MsoNormal><span lang=EN-GB>Rash on the body where each mark resembles
a bullseye</span></p>

<p class=MsoNormal><span lang=EN-GB>Hair loss</span></p>

<p class=MsoNormal><span lang=EN-GB>Hives</span></p>

<p class=MsoNormal><span lang=EN-GB>Kidney stop working</span></p>

<p class=MsoNormal><span lang=EN-GB>Reduced functionality of kidney </span></p>

<p class=MsoNormal><span lang=EN-GB>Fever</span></p>

<p class=MsoNormal><span lang=EN-GB>Pain</span></p>

<p class=MsoNormal><span lang=EN-GB>Excess fluid in body tissue, causing
swelling</span></p>

<p class=MsoNormal><span lang=EN-GB>Chest pain</span></p>

<p class=MsoNormal><span lang=EN-GB>Inflammation and ulceration of the mucous
membranes lining the digestive tract</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Uncommon
(may affect up to 1 in 100 people)</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Reduction in the number of red, white blood
cells and platelets</span></p>

<p class=MsoNormal><span lang=EN-GB>Stroke<br>
Type of stroke when an artery to the brain is blocked</span></p>

<p class=MsoNormal><span lang=EN-GB>Bleeding inside the skull</span></p>

<p class=MsoNormal><span lang=EN-GB>Angina (Chest pain caused by reduced blood
flow to the heart)</span></p>

<p class=MsoNormal><span lang=EN-GB>Heart attack</span></p>

<p class=MsoNormal><span lang=EN-GB>Narrowing or blockage of the coronary
arteries<br>
Abnormal heart rhythm<br>
Deficient blood distribution to the limbs</span></p>

<p class=MsoNormal><span lang=EN-GB>Blockage in one of the pulmonary arteries
in your lungs</span></p>

<p class=MsoNormal><span lang=EN-GB>Inflammation and scarring of the lining of
the lungs with breathing problems</span></p>

<p class=MsoNormal><span lang=EN-GB>Passage of bright red blood from the anus<br>
Bleeding in the gastrointestinal tract<br>
Ruptured bowel</span></p>

<p class=MsoNormal><span lang=EN-GB>Inflammation of the lining of the
oesophagus</span></p>

<p class=MsoNormal><span lang=EN-GB>Inflammation of the lining of the large
bowel, which may be accompanied by intestinal or rectal bleeding (seen only in
combination with cisplatin)<br>
Inflammation, edema, erythema, and erosion of the mucosal surface of the
esophagus caused by radiation therapy<br>
Inflammation of the lung caused by radiation therapy</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Rare (may
affect up to 1 in 1,000 people)</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Destruction of red blood cells<br>
Anaphylactic shock (severe allergic reaction)<br>
Inflammatory condition of the liver</span></p>

<p class=MsoNormal><span lang=EN-GB>Redness of the skin</span></p>

<p class=MsoNormal><span lang=EN-GB>Skin rash that develops throughout a
previously irradiated area</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Very rare (affect up to 1 of 10 000
people)<br>
</span></i><span lang=EN-GB>Infections of skin and soft tissues</span></p>

<p class=MsoNormal><span lang=EN-GB>Stevens-Johnson syndrome (a type of severe
skin and mucous membranes reaction that may be life threatening)</span></p>

<p class=MsoNormal><span lang=EN-GB>Toxic epidermal necrolysis (a type of
severe skin reaction that may be life threatening)</span></p>

<p class=MsoNormal><span lang=EN-GB>Autoimmune disorder that results in skin
rashes and blistering on the legs, arms, and abdomen</span></p>

<p class=MsoNormal><span lang=EN-GB>Inflammation of the skin characterized by
the presence of bullae which are filled with fluid</span></p>

<p class=MsoNormal><span lang=EN-GB>Skin fragility, blisters and erosions and
skin scarring</span></p>

<p class=MsoNormal><span lang=EN-GB>Redness, pain and swelling mainly of the
lower limbs</span></p>

<p class=MsoNormal><span lang=EN-GB>Inflammation of the skin and fat beneath
the skin (pseudocellulitis)</span></p>

<p class=MsoNormal><span lang=EN-GB>Inflammation of the skin (dermatitis)</span></p>

<p class=MsoNormal><span lang=EN-GB>Skin to become inflamed, itchy, red,
cracked, and rough</span></p>

<p class=MsoNormal><span lang=EN-GB>Intensely itchy spots </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Not known (frequency cannot be estimated
from the available data)</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Form of diabetes primarily due to pathology
of the kidney</span></p>

<p class=MsoNormal><span lang=EN-GB>Disorder of the kidneys involving the death
of tubular epithelial cells that form the renal tubules </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><span
lang=EN-GB style='color:black'>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>You might have any of these symptoms and/or
conditions. You must tell your doctor as soon as possible when you start
experiencing any of these side effects.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>If you are concerned about any side effects, talk to your doctor.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>Reporting of side effects</span></b></p>

<p class=MsoNormal><span lang=EN-GB>If you get any side effects, talk to your
doctor. </span><span lang=EN-GB>This includes any possible side effects not
listed in this leaflet. You can also report side effects directly via<span
style='color:navy'> </span><span style='background:lightgrey'>the national
reporting system listed in </span></span><span lang=EN-GB><a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span
style='background:lightgrey'>Appendix V</span></a></span><span lang=EN-GB>. By
reporting side effects you can help provide more information on the safety of this
medicine.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='background:yellow'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='background:yellow'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>5. How to store Pemetrexed Hospira</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Keep this medicine out of the sight and reach of children.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Do not use this medicine after the expiry date which is stated on
the carton and vial label after EXP. The expiry date refers to the last day of
that month.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>This medicine
does not require any special storage conditions.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Reconstituted and infusion solution: The product should be used
immediately. When prepared as directed<b>, </b>chemical and physical in-use
stability of reconstituted and infusion solutions of pemetrexed were
demonstrated for </span><span lang=EN-GB>24&nbsp;hours</span><span lang=EN-GB>
at refrigerated temperature (</span><span lang=EN-GB>2</span><span lang=EN-GB></span><span
lang=EN-GB>C to 8</span><span lang=EN-GB></span><span lang=EN-GB>C</span><span
lang=EN-GB>).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>The reconstituted solution is clear and ranges in colour from
colourless to yellow or green-yellow without adversely affecting product
quality. Parenteral medicines must be inspected visually for particulate matter
and discolouration prior to administration. If particulate matter is observed,
do not administer.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>This medicine is for single use only; any unused solution must be
disposed of in accordance with local requirements.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><b><span lang=EN-GB>6. Contents of the pack and other information</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><b><span lang=EN-GB>What Pemetrexed Hospira contains </span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>The active substance is pemetrexed. </span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Pemetrexed Hospira 100&nbsp;mg powder for concentrate for solution
for infusion: </span><span lang=EN-GB>Each vial contains 100&nbsp;milligrams of
pemetrexed (as pemetrexed disodium hemipentahydrate).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Pemetrexed Hospira 500&nbsp;mg powder for concentrate for solution
for infusion: </span><span lang=EN-GB>Each vial contains 500&nbsp;milligrams of
pemetrexed (as pemetrexed disodium hemipentahydrate).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>Pemetrexed Hospira 1,000&nbsp;mg powder for concentrate
for solution for infusion: Each vial contains 1,000&nbsp;milligrams of
pemetrexed (as pemetrexed disodium hemipentahydrate).</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>After reconstitution as directed, the solution contains 25&nbsp;mg/ml
of pemetrexed. Further dilution by a healthcare provider is required prior to
administration.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=Default><span style='font-size:11.0pt'>The other ingredients are
mannitol (E421), hydrochloric acid (for pH adjustment) and sodium hydroxide
(for pH adjustment). Refer to section 2 Pemetrexed Hospira contains sodium. </span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>What Pemetrexed Hospira looks like and contents of the pack</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Pemetrexed
Hospira is a powder for concentrate for solution for infusion in a glass vial.
It is a white to either light yellow or green-yellow lyophilised powder.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Each pack contains
one vial<b> </b>of 100&nbsp;mg, 500&nbsp;mg or 1,000&nbsp;mg pemetrexed as
(pemetrexed disodium hemipentahydrate).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=FR>Marketing Authorisation Holder</span></b></p>

<p style='margin:0in'><span lang=FR style='font-size:11.0pt'>Pfizer Europe MA
EEIG</span></p>

<p style='margin:0in'><span lang=FR style='font-size:11.0pt'>Boulevard de la
Plaine 17</span></p>

<p style='margin:0in'><span lang=EN-GB style='font-size:11.0pt'>1050 Bruxelles</span></p>

<p style='margin:0in'><span lang=EN-GB style='font-size:11.0pt'>Belgium</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Manufacturer</span></b></p>

<p class=MsoNormal style='margin-right:6.0pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='color:black'>Pfizer Service Company BVBA</span></p>

<p class=MsoNormal style='margin-right:6.0pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='color:black'>Hoge Wei 10</span></p>

<p class=MsoNormal style='margin-right:6.0pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='color:black'>1930 Zaventem</span></p>

<p class=MsoNormal style='margin-right:6.0pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='color:black'>Belgium</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>For any information about this medicine, please contact the local
representative of the Marketing Authorisation Holder:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=621
 style='border-collapse:collapse'>
 <tr style='page-break-inside:avoid'>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>BE</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Pfizer SA/NV</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tl/Tel: +32 2 554 62 11</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>LT</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Pfizer Luxembourg SARL filialas Lietuvoje</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel. + 370 52 51 4000</span></p>
  <p class=MsoNoSpacing><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNoSpacing><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>BG</span></b></p>
  <p class=MsoNoSpacing><span lang=EN-GB style='font-family:"Times New Roman",serif'>&#1055;&#1092;&#1072;&#1081;&#1079;&#1077;&#1088;
  &#1051;&#1102;&#1082;&#1089;&#1077;&#1084;&#1073;&#1091;&#1088;&#1075;
  &#1057;&#1040;&#1056;&#1051;, &#1050;&#1083;&#1086;&#1085;
  &#1041;&#1098;&#1083;&#1075;&#1072;&#1088;&#1080;&#1103;</span></p>
  <p class=MsoNoSpacing><span lang=EN-GB style='font-family:"Times New Roman",serif'>&#1058;&#1077;&#1083;.:
  +359 2 970 4333</span></p>
  <p class=MsoNoSpacing><b><span lang=DE style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>LU</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Pfizer SA/NV</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tl/Tel: +32 2 554 62 11</span></p>
  <p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNoSpacing><b><span lang=PT style='font-family:"Times New Roman",serif'>CZ</span></b></p>
  <p class=MsoNoSpacing><span lang=PT style='font-family:"Times New Roman",serif'>Pfizer,
  spol. s r.o.</span></p>
  <p class=MsoNoSpacing><span lang=PT style='font-family:"Times New Roman",serif'>Tel:
  +420-283-004-111</span></p>
  <p class=MsoNoSpacing><b><span lang=PT style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNoSpacing><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>HU</span></b></p>
  <p class=MsoNoSpacing><span lang=EN-GB style='font-family:"Times New Roman",serif'>Pfizer
  Kft.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: + 36 1 488 37 00</span></p>
  <p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNoSpacing><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>DK</span></b></p>
  <p class=MsoNoSpacing><span lang=EN-GB style='font-family:"Times New Roman",serif'>Pfizer
  ApS</span></p>
  <p class=MsoNoSpacing><span lang=EN-GB style='font-family:"Times New Roman",serif'>Tlf:
  + 45 44 20 11 00</span></p>
  <p class=MsoNoSpacing><b><span lang=DE style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNoSpacing><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>MT</span></b></p>
  <p class=MsoNoSpacing><span lang=SV style='font-family:"Times New Roman",serif'>Drugsales
  Ltd </span></p>
  <p class=MsoNoSpacing><span style='font-family:"Times New Roman",serif'>Tel.:
  + 356 21 419 070/1/2</span></p>
  <p class=MsoNoSpacing><b><span lang=DE style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNoSpacing><b><span lang=PT style='font-family:"Times New Roman",serif'>DE
  </span></b></p>
  <p class=MsoNoSpacing><span lang=PT style='font-family:"Times New Roman",serif'>PFIZER
  PHARMA GmbH </span></p>
  <p class=MsoNoSpacing><span lang=PT style='font-family:"Times New Roman",serif'>Tel:
  +49 (0)30 550055-51000</span></p>
  <p class=MsoNoSpacing><b><span lang=PT style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=CS>NL</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Pfizer bv</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +31 (0)10 406 43 01</span></p>
  <p class=MsoNoSpacing><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNoSpacing><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>EE</span></b></p>
  <p class=MsoNoSpacing><span lang=EN-GB style='font-family:"Times New Roman",serif'>Pfizer
  Luxembourg SARL Eesti filiaal</span></p>
  <p class=MsoNoSpacing><span lang=EN-GB style='font-family:"Times New Roman",serif'>Tel:
  +372 666 7500</span></p>
  <p class=MsoNoSpacing><b><span lang=DE style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNoSpacing><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>NO</span></b></p>
  <p class=MsoNoSpacing><span lang=EN-GB style='font-family:"Times New Roman",serif'>Pfizer
  AS</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tlf: +47 67 52 61 00</span></p>
  <p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNoSpacing><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>EL</span></b></p>
  <p class=MsoNoSpacing><span lang=EN-GB style='font-family:"Times New Roman",serif'>Pfizer
  </span><span lang=EL style='font-family:"Times New Roman",serif'>&#917;&#923;&#923;&#913;&#931;</span><span
  lang=EN-GB style='font-family:"Times New Roman",serif'> A</span><span
  style='font-family:"Times New Roman",serif'>.</span><span lang=EN-GB
  style='font-family:"Times New Roman",serif'>E</span><span style='font-family:
  "Times New Roman",serif'>.</span></p>
  <p class=MsoNoSpacing><span lang=EN-GB style='font-family:"Times New Roman",serif'>&#932;&#951;&#955;.:
  +30 210 6785 800</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNoSpacing><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>AT</span></b></p>
  <p class=MsoNoSpacing><span lang=EN-GB style='font-family:"Times New Roman",serif'>Pfizer
  Corporation Austria Ges.m.b.H.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +43 (0)1 521 15-0</span></p>
  <p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNoSpacing style='page-break-after:avoid'><b><span lang=DE
  style='font-family:"Times New Roman",serif'>ES</span></b></p>
  <p class=MsoNoSpacing style='page-break-after:avoid'><span lang=DE
  style='font-family:"Times New Roman",serif'>Pfizer, S.L.</span></p>
  <p class=MsoNoSpacing style='page-break-after:avoid'><span lang=DE
  style='font-family:"Times New Roman",serif'>Tel: +34 91 490 99 00</span></p>
  <p class=MsoNoSpacing><b><span lang=DE style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNoSpacing><b><span lang=PL style='font-family:"Times New Roman",serif'>PL</span></b></p>
  <p class=MsoNoSpacing><span lang=PL style='font-family:"Times New Roman",serif;
  color:black'>Pfizer Polska Sp. z o.o.</span></p>
  <p class=MsoNoSpacing><span lang=EN-GB style='font-family:"Times New Roman",serif'>Tel:
  </span><span style='font-family:"Times New Roman",serif;color:black'>+48 22
  335 61 00</span></p>
  <p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNoSpacing><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>FR</span></b></p>
  <p class=MsoNoSpacing><span lang=EN-GB style='font-family:"Times New Roman",serif'>Pfizer</span></p>
  <p class=MsoNoSpacing><span lang=EN-GB style='font-family:"Times New Roman",serif'>Tl:
  + 33 (0)1 58 07 34 40</span></p>
  <p class=MsoNoSpacing><b><span lang=DE style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNoSpacing><b><span lang=PT style='font-family:"Times New Roman",serif'>PT</span></b></p>
  <p class=MsoNoSpacing><span lang=PT style='font-family:"Times New Roman",serif'>Laboratrios
  Pfizer, Lda.</span></p>
  <p class=MsoNoSpacing><span lang=PT style='font-family:"Times New Roman",serif'>Tel:
  + 351 21 423 55 00</span></p>
  <p class=MsoNormal><b><span lang=PT>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=PT>HR</span></b></p>
  <p class=MsoNormal><span lang=PT>Pfizer Croatia d.o.o.</span></p>
  <p class=MsoNoSpacing><span style='font-family:"Times New Roman",serif'>Tel:
  +385 1 3908 777</span></p>
  <p class=MsoNoSpacing><span lang=DE style='font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=PT>RO</span></b></p>
  <p class=MsoNormal><span lang=PT>Pfizer Romnia S.R.L.<br>
  Tel: +40 (0)21 207 28 00</span></p>
  <p class=MsoNormal><b><span lang=PT>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNoSpacing><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>IE</span></b></p>
  <p class=MsoNoSpacing><span lang=EN-GB style='font-family:"Times New Roman",serif'>Pfizer
  Healthcare Ireland </span></p>
  <p class=MsoNoSpacing><span lang=EN-GB style='font-family:"Times New Roman",serif'>Tel:
  1800 633 363 (toll free)</span></p>
  <p class=MsoNormal><span lang=EN-GB>+44 (0) 1304 616161</span></p>
  <p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>SI</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Pfizer Luxembourg SARL</span></p>
  <p class=MsoNormal><span lang=EN-GB>Pfizer, podrunica za svetovanje s
  podro&#269;ja farmacevtske dejavnosti, Ljubljana</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +386 (0)1 52 11 400</span></p>
  <p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>IS</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Icepharma hf.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Smi: +354 540 8000</span></p>
  <p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNoSpacing><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>SK</span></b></p>
  <p class=MsoNoSpacing><span lang=EN-GB style='font-family:"Times New Roman",serif'>Pfizer
  Luxembourg SARL, organiza&#269;n zloka</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +42123355 5500</span></p>
  <p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNoSpacing><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>IT</span></b></p>
  <p class=MsoNoSpacing><span lang=EN-GB style='font-family:"Times New Roman",serif'>Pfizer
  S.r.l. </span></p>
  <p class=MsoNoSpacing><span lang=EN-GB style='font-family:"Times New Roman",serif'>Tel:
  +39 06 33 18 21</span></p>
  <p class=MsoNoSpacing><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>FI</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Pfizer Oy</span></p>
  <p class=MsoNormal><span lang=EN-GB>Puh/Tel: +358 (0)9 430 040</span></p>
  <p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNoSpacing><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>CY</span></b><b><span
  lang=EN-GB style='font-family:"Times New Roman",serif'> </span></b></p>
  <p class=MsoNoSpacing><span lang=EN-GB style='font-family:"Times New Roman",serif'>Pharmaceutical
  Trading Co Ltd</span></p>
  <p class=MsoNoSpacing><span style='font-family:"Times New Roman",serif;
  color:black'>&#932;&#951;&#955;:</span><span style='font-family:"Times New Roman",serif;
  color:black'> </span><span lang=EN-GB style='font-family:"Times New Roman",serif'>24656165</span></p>
  <p class=MsoNoSpacing><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>SE</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Pfizer AB</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +46 (0)8 550 520 00</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNoSpacing style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-family:"Times New Roman",serif'>LV</span></b></p>
  <p class=MsoNoSpacing style='page-break-after:avoid'><span lang=EN-GB
  style='font-family:"Times New Roman",serif'>Pfizer Luxembourg SARL
  fili&#257;le Latvij&#257;</span></p>
  <p class=MsoNoSpacing style='page-break-after:avoid'><span lang=EN-GB
  style='font-family:"Times New Roman",serif'>Tel.: + 371 670 35 775</span></p>
  <p class=MsoNoSpacing style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNoSpacing><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>UK</span></b></p>
  <p class=MsoNoSpacing><span lang=EN-GB style='font-family:"Times New Roman",serif'>Hospira
  UK Limited</span></p>
  <p class=MsoNoSpacing><span lang=EN-GB style='font-family:"Times New Roman",serif'>Tel:
  + 44 (0) </span><span style='font-family:"Times New Roman",serif;color:black'>1628
  515500</span></p>
  <p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>This leaflet was last revised in </span></b><b><span lang=EN-GB>month
YYYY</span></b><span lang=EN-GB>.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Detailed information on this medicine is available on the European
Medicines Agency web site: </span><span lang=EN-GB><a
href="http://www.ema.europa.eu">http://www.ema.europa.eu</a></span><span
lang=EN-GB style='color:blue'>.</span><span lang=EN-GB> </span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>This leaflet is
available in all EU/EEA languages on the European Medicines Agency website.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>------------------------------------------------------------------------------------------------------------------------</span></p>

<p class=MsoNormal style='margin-right:-1.4pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.4pt;margin-bottom:
0in;margin-left:-1.85pt;margin-bottom:.0001pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>The following information is intended for healthcare
professionals only:</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>Instructions for use, handling and
disposal</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:13.5pt;text-indent:-13.5pt;line-height:
normal'><span lang=EN-GB>1. Use aseptic techniques during the reconstitution
and further dilution of pemetrexed for intravenous infusion administration. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:13.5pt;text-indent:-13.5pt;line-height:
normal'><span lang=EN-GB>2. Calculate the dose and the number of Pemetrexed
Hospira vials needed. Each vial contains an excess of pemetrexed to facilitate
delivery of label amount. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:13.5pt;text-indent:-13.5pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>3. Reconstitute each 100&nbsp;mg
vial with 4.2&nbsp;ml of 9&nbsp;mg/ml (0.9%) sodium chloride solution for
injection, without preservative, resulting in a solution containing 25&nbsp;mg/ml
pemetrexed.</span></p>

<p class=MsoNormal style='margin-left:13.5pt;text-indent:-13.5pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:13.5pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>Reconstitute each 500&nbsp;mg vial with 20&nbsp;ml of 9&nbsp;mg/ml
(0.9%) sodium chloride solution for injection, without preservative, resulting
in a solution containing 25&nbsp;mg/ml pemetrexed.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:13.5pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>Reconstitute each 1,000&nbsp;mg vial with 40&nbsp;ml of
9&nbsp;mg/ml (0.9%) sodium chloride solution for injection, without
preservative, resulting in a solution containing 25&nbsp;mg/ml pemetrexed.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:13.5pt;line-height:normal'><span
lang=EN-GB>Gently swirl each vial until the powder is completely dissolved. The
resulting solution is clear and ranges in colour from colourless to yellow or
green-yellow without adversely affecting product quality. The pH of the
reconstituted solution is between 6.6 and 7.8. <b>Further dilution is required.</b>
</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:13.5pt;text-indent:-13.5pt;line-height:
normal'><span lang=EN-GB>4. The appropriate volume of reconstituted pemetrexed
solution must be further diluted to 100&nbsp;ml with 9&nbsp;mg/ml (0.9%) sodium
chloride solution for injection, without preservative, and administered as an
intravenous infusion over 10&nbsp;minutes. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:13.5pt;text-indent:-13.5pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>5. Pemetrexed infusion solutions
prepared as directed above are compatible with polyvinyl chloride- and
polyolefin-lined administration sets and infusion bags. </span>Pemetrexed is
incompatible</p>

<p class=MsoNormal style='margin-left:22.5pt;text-indent:-9.0pt;line-height:
normal'>with diluents containing calcium, including lactated Ringers Injection
and Ringers Injection.</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:13.5pt;text-indent:-13.5pt;line-height:
normal'><span lang=EN-GB>6. Parenteral medicinal products must be inspected
visually for particulate matter and discolouration prior to administration. If
particulate matter is observed, do not administer. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:13.5pt;text-indent:-13.5pt;line-height:
normal'><span lang=EN-GB>7. Pemetrexed solutions are for single use only. Any
unused medicinal product or waste material must be disposed of in accordance
with local requirements. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Preparation
and administration precautions</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>As with other potentially
toxic anti-cancer agents, care should be exercised in the handling and
preparation of pemetrexed infusion solutions. The use of gloves is recommended.
If a pemetrexed solution contacts the skin, wash the skin immediately and
thoroughly with soap and water. If pemetrexed solutions contact the mucous
membranes, flush thoroughly with water. Pemetrexed is not a vesicant. There is
not a specific antidote for extravasation of pemetrexed. There have been few
reported cases of pemetrexed extravasation, which were not assessed as serious
by the investigator. Extravasation should be managed by local standard practice
as with other non-vesicants.</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>Package leaflet: Information for the user</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal;
background:white'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>Pemetrexed Hospira 25&nbsp;mg/ml concentrate for solution for
infusion</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>pemetrexed</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Read all of
this leaflet carefully before you start receiving this medicine because it
contains important information for you.</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Keep this leaflet. You may need to read it
again. </span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you have any further questions, ask your
doctor or pharmacist</span><span lang=EN-GB> </span>or nurse.</p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>- If you get any side effects, talk to your
doctor or pharmacist</span> or nurse<span lang=EN-GB>. </span><span lang=EN-GB>This
includes any possible side effects not listed in this leaflet. See section 4.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><b><span lang=EN-GB>What is in this leaflet</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>1. What Pemetrexed Hospira is and what it is used for </span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>2. What you need to know before you use Pemetrexed Hospira</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>3. How to use Pemetrexed Hospira</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>4. Possible side effects </span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>5. How to store Pemetrexed Hospira</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>6. Contents of the pack and other information</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>1. What Pemetrexed Hospira is and what it is used for</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Pemetrexed Hospira</span><span lang=EN-GB style='color:black'> is a
medicine used in the treatment of cancer.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Pemetrexed Hospira</span><span lang=EN-GB style='color:black'> is
given in combination with cisplatin, another anti-cancer medicine, as treatment
for malignant pleural mesothelioma, a form of cancer that affects the lining of
the lung, to patients who have not received prior chemotherapy.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Pemetrexed Hospira</span><span lang=EN-GB style='color:black'> is
also given in combination with cisplatin for the initial treatment of patients
with advanced stage of lung cancer.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Pemetrexed Hospira</span><span lang=EN-GB style='color:black'> can
be prescribed to you if you have lung cancer at an advanced stage if your
disease has responded to treatment or it remains largely unchanged after
initial chemotherapy.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Pemetrexed Hospira</span><span lang=EN-GB style='color:black'> is
also a treatment for patients with advanced stage of lung cancer whose disease
has progressed after other initial chemotherapy has been used.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>2. What you need to know before you use Pemetrexed Hospira</span></b></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Do not use
Pemetrexed Hospira</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>- if you are allergic (hypersensitive) to
pemetrexed or any of the other ingredients of this medicine (listed in section
6).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='color:black'>-  if
you are breast-feeding; you must discontinue breast-feeding during treatment
with </span><span lang=EN-GB>Pemetrexed Hospira</span><span lang=EN-GB
style='color:black'>.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB style='color:black'>-  if you have recently received or are
about to receive a vaccine against yellow fever.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Warnings and
precautions </span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Talk to your doctor or hospital pharmacist before receiving
Pemetrexed Hospira.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>If you currently have or have previously had problems with your
kidneys, talk to your doctor or hospital pharmacist as you may not be able to
receive Pemetrexed Hospira.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Before each infusion you will have samples of your blood taken to
evaluate if you have sufficient kidney and liver function and to check that you
have enough blood cells to receive Pemetrexed Hospira. Your doctor may decide
to change the dose or delay treating you depending on your general condition
and if your blood cell counts are too low. If you are also receiving cisplatin,
your doctor will make sure that you are properly hydrated and receive
appropriate treatment before and after receiving cisplatin to prevent vomiting.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>If you have had or are going to have radiation therapy, please tell
your doctor, as there may be an early or late radiation reaction with
Pemetrexed Hospira.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>If you have been recently vaccinated, please tell your doctor, as
this can possibly cause bad effects with Pemetrexed Hospira.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>If you have heart disease or a history of heart disease, please tell
your doctor.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>If you have an accumulation of fluid around your lungs, your doctor
may decide to remove the fluid before giving you Pemetrexed Hospira.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>Children and adolescents</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>This medicine
should not be used in children or adolescents, since there is no experience
with this medicine in children and adolescents under 18&nbsp;years of age.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>Other medicines and Pemetrexed Hospira</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Please tell your doctor if you are taking any medicine for pain or
inflammation (swelling), such as medicines called nonsteroidal
anti-inflammatory drugs (NSAIDs), including medicines purchased without a
doctors prescription (such as ibuprofen). There are many sorts of NSAIDs with
different durations of activity. Based on the planned date of your infusion of
pemetrexed and/or on the status of your kidney function, your doctor needs to
advise you on which medicines you can take and when you can take them. If you
are unsure, ask your doctor or pharmacist if any of your medicines are NSAIDs.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Please tell your doctor or hospital pharmacist if you are taking or
have recently taken any other medicines, including medicines obtained without a
prescription.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>Pregnancy</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>If you are pregnant, think you may be pregnant or are planning to
have a baby, tell your doctor. </span><span lang=EN-GB>The use of pemetrexed
should be avoided during pregnancy. Your doctor will discuss with you the
potential risk of taking pemetrexed during pregnancy. Women must use effective
contraception during treatment with pemetrexed.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>Breast-feeding</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>If you are breast-feeding, tell your doctor. Breast-feeding must be
discontinued during treatment with pemetrexed.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>Fertility</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Men are advised not to father a child during and up to 6&nbsp;months
following treatment with pemetrexed and should therefore use effective
contraception during treatment with pemetrexed and for up to 6&nbsp;months
afterwards. If you would like to father a child during the treatment or in the
6&nbsp;months following receipt of treatment, seek advice from your doctor or
pharmacist. You may want to seek counselling on sperm storage before starting
your therapy.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><b><span lang=EN-GB>Driving and using machines</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Pemetrexed Hospira may make you feel tired. Be careful when driving
a car or using machines.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>Pemetrexed Hospira contains sodium</span></b><span lang=EN-GB><br>
One 4 ml vial contains less than 1 mmol sodium (23 mg), that is to say
essentially sodium-free. </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>One 20 ml vial contains approximately 54&nbsp;mg sodium (main
component of cooking/table salt). This is equivalent to 2.7% of the recommended
maximum daily intake of sodium for an adult</span><span lang=EN-GB>.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>One 40 ml vial contains approximately 108&nbsp;mg sodium (main
component of cooking/table salt). This is equivalent to 5.4% of the recommended
maximum daily intake of sodium for an adult</span><span lang=EN-GB>.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>3. How to use Pemetrexed Hospira</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>The dose of Pemetrexed Hospira is 500&nbsp;milligrams for every
square metre of your bodys surface area. Your height and weight are measured
to work out the surface area of your body. Your doctor will use this body
surface area to work out the right dose for you. This dose may be adjusted, or
treatment may be delayed depending on your blood cell counts and on your
general condition. A hospital pharmacist, nurse or doctor will have mixed the
Pemetrexed Hospira concentrate with 9&nbsp;mg/ml (0.9 %) sodium chloride
solution for injection before it is given to you.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>You will always receive Pemetrexed Hospira by infusion into one of
your veins. The infusion will last approximately 10&nbsp;minutes.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>When using Pemetrexed Hospira in combination with cisplatin:</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>The doctor or hospital pharmacist will work out the dose you need
based on your height and weight. Cisplatin is also given by infusion into one
of your veins, and is given approximately 30&nbsp;minutes after the infusion of
Pemetrexed Hospira has finished. The infusion of cisplatin will last
approximately 2&nbsp;hours.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>You should usually receive your infusion once every 3&nbsp;weeks.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Additional medicines:</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Corticosteroids: your doctor will prescribe you steroid tablets
(equivalent to 4&nbsp;milligram of dexamethasone twice a day) that you will
need to take on the day before, on the day of, and the day after Pemetrexed
Hospira treatment. This medicine is given to you to reduce the frequency and
severity of skin reactions that you may experience during your anticancer
treatment.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Vitamin supplementation: your doctor will prescribe you oral folic
acid (vitamin) or a multivitamin containing folic acid (350 to 1,000&nbsp;micrograms)
that you must take once a day while you are taking Pemetrexed Hospira. You must
take at least 5&nbsp;doses during the seven days before the first dose of
Pemetrexed Hospira. You must continue taking the folic acid for </span><span
lang=EN-GB>21&nbsp;days</span><span lang=EN-GB> after the last dose of
Pemetrexed Hospira. You will also receive an injection of vitamin B<sub>12</sub>
(1,000&nbsp;micrograms) in the week before administration of Pemetrexed Hospira
and then approximately every 9&nbsp;weeks (corresponding to 3 courses of
Pemetrexed Hospira treatment). Vitamin B<sub>12</sub> and folic acid are given
to you to reduce the possible toxic effects of the anticancer treatment.</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>If you have any further questions on the use of this medicine, ask
your doctor or pharmacist.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>4. Possible side effects</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB style='color:black'>Like all medicines, this medicine can cause side
effects, although not everybody gets them.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB style='color:black'>You must contact your doctor immediately if you
notice any of the following:</span></p>

<p class=MsoListParagraphCxSpFirst style='text-indent:-.25in;line-height:normal;
text-autospace:none'><span lang=EN-GB style='font-family:Symbol;color:black'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>Fever or infection (common):
if you have a temperature of 38C or greater, sweating or other signs of
infection (since you might have fewer white blood cells than normal which is
very common). Infection (sepsis) may be severe and could lead to death.</span></p>

<p class=MsoListParagraphCxSpMiddle style='text-indent:-.25in;line-height:normal;
text-autospace:none'><span lang=EN-GB style='font-family:Symbol;color:black'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>If you start feeling chest
pain (common) or having a fast heart rate (uncommon).</span></p>

<p class=MsoListParagraphCxSpMiddle style='text-indent:-.25in;line-height:normal;
text-autospace:none'><span lang=EN-GB style='font-family:Symbol;color:black'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>If you have pain, redness,
swelling or sores in your mouth (very common).</span></p>

<p class=MsoListParagraphCxSpMiddle style='text-indent:-.25in;line-height:normal;
text-autospace:none'><span lang=EN-GB style='font-family:Symbol;color:black'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>Allergic reaction: if you
develop skin rash (very common) / burning or prickling sensation (common), or
fever (common). Rarely, skin reactions may be severe and could lead to death</span><span
lang=EN-GB style='color:blue'>. </span><span lang=EN-GB style='color:black'>Contact
your doctor if you get a severe rash</span><span lang=EN-GB style='color:blue'>,
</span><span lang=EN-GB style='color:black'>or itching</span><span lang=EN-GB
style='color:blue'>, </span><span lang=EN-GB style='color:black'>or blistering
(Stevens-Johnson syndrome or toxic epidermal necrolysis).</span></p>

<p class=MsoListParagraphCxSpMiddle style='text-indent:-.25in;line-height:normal;
text-autospace:none'><span lang=EN-GB style='font-family:Symbol;color:black'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>If you experience tiredness,
feeling faint, becoming easily breathless or if you look pale (since you might
have less haemoglobin than normal which is very common).</span></p>

<p class=MsoListParagraphCxSpMiddle style='text-indent:-.25in;line-height:normal;
text-autospace:none'><span lang=EN-GB style='font-family:Symbol;color:black'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>If you experience bleeding
from the gums, nose or mouth or any bleeding that would not stop, reddish or
pinkish urine, unexpected bruising (since you might have fewer platelets than
normal which is very common).</span></p>

<p class=MsoListParagraphCxSpLast style='text-indent:-.25in;line-height:normal;
text-autospace:none'><span lang=EN-GB style='font-family:Symbol;color:black'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>If you experience sudden
breathlessness, intense chest pain or cough with bloody sputum (uncommon) (may
indicate a blood clot in the blood vessels of the lungs).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB style='color:black'>Side effects with pemetrexed may include:</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><span
lang=EN-GB style='color:black'>&nbsp;</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Very
common </span></i><i><span lang=EN-GB>(may affect more than 1 in 10 people)</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Infection</span></p>

<p class=MsoNormal><span lang=EN-GB>Pharyngitis (a sore throat)</span></p>

<p class=MsoNormal><span lang=EN-GB>Low number of neutrophil granulocytes (a
type of white blood cell)</span></p>

<p class=MsoNormal><span lang=EN-GB>Low white blood cells</span></p>

<p class=MsoNormal><span lang=EN-GB>Low haemoglobin level </span></p>

<p class=MsoNormal><span lang=EN-GB>Pain, redness, swelling or sores in your
mouth</span></p>

<p class=MsoNormal><span lang=EN-GB>Loss of appetite</span></p>

<p class=MsoNormal><span lang=EN-GB>Vomiting</span></p>

<p class=MsoNormal><span lang=EN-GB>Diarrhoea </span></p>

<p class=MsoNormal><span lang=EN-GB>Nausea<br>
Skin rash</span></p>

<p class=MsoNormal><span lang=EN-GB>Flaking skin</span></p>

<p class=MsoNormal><span lang=EN-GB>Abnormal blood tests showing reduced
functionality of kidneys <br>
Fatigue (tiredness)</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Common
(may affect up to 1 in 10 people)</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Blood infection</span></p>

<p class=MsoNormal><span lang=EN-GB>Fever with low number of neutrophil
granulocytes (a type of white blood cell)</span></p>

<p class=MsoNormal><span lang=EN-GB>Low platelet count</span></p>

<p class=MsoNormal><span lang=EN-GB>Allergic reaction</span></p>

<p class=MsoNormal><span lang=EN-GB>Loss of body fluids</span></p>

<p class=MsoNormal><span lang=EN-GB>Taste change</span></p>

<p class=MsoNormal><span lang=EN-GB>Damage to the motor nerves which may cause
muscle weakness and atrophy (wasting) primary in the arms and legs</span></p>

<p class=MsoNormal><span lang=EN-GB>Damage to the sensory nerves that may cause
loss of sensation, burning pain and unsteady gait</span></p>

<p class=MsoNormal><span lang=EN-GB>Dizziness</span></p>

<p class=MsoNormal><span lang=EN-GB>Inflammation or swelling of the conjunctiva
(the membrane that lines the eyelids and covers the white of the eye)</span></p>

<p class=MsoNormal><span lang=EN-GB>Dry eye</span></p>

<p class=MsoNormal><span lang=EN-GB>Watery eyes</span></p>

<p class=MsoNormal><span lang=EN-GB>Dryness of the conjunctiva (the membrane
that lines the eyelids and covers the white of the eye) and cornea (the clear
layer in front of the iris and pupil).</span></p>

<p class=MsoNormal><span lang=EN-GB>Swelling of the eyelids</span></p>

<p class=MsoNormal><span lang=EN-GB>Eye disorder with dryness, tearing,
irritation, and/or pain</span></p>

<p class=MsoNormal><span lang=EN-GB>Cardiac Failure (Condition that affects the
pumping power of your heart muscles)</span></p>

<p class=MsoNormal><span lang=EN-GB>Irregular heart rhythm</span></p>

<p class=MsoNormal><span lang=EN-GB>Indigestion</span></p>

<p class=MsoNormal><span lang=EN-GB>Constipation</span></p>

<p class=MsoNormal><span lang=EN-GB>Abdominal pain</span></p>

<p class=MsoNormal><span lang=EN-GB>Liver: increases in the chemicals in the
blood made by the liver </span></p>

<p class=MsoNormal><span lang=EN-GB>Increased skin pigmentation</span></p>

<p class=MsoNormal><span lang=EN-GB>Itchy skin</span></p>

<p class=MsoNormal><span lang=EN-GB>Rash on the body where each mark resembles
a bullseye</span></p>

<p class=MsoNormal><span lang=EN-GB>Hair loss</span></p>

<p class=MsoNormal><span lang=EN-GB>Hives</span></p>

<p class=MsoNormal><span lang=EN-GB>Kidney stop working</span></p>

<p class=MsoNormal><span lang=EN-GB>Reduced functionality of kidney </span></p>

<p class=MsoNormal><span lang=EN-GB>Fever</span></p>

<p class=MsoNormal><span lang=EN-GB>Pain</span></p>

<p class=MsoNormal><span lang=EN-GB>Excess fluid in body tissue, causing
swelling</span></p>

<p class=MsoNormal><span lang=EN-GB>Chest pain</span></p>

<p class=MsoNormal><span lang=EN-GB>Inflammation and ulceration of the mucous
membranes lining the digestive tract</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Uncommon
(may affect up to 1 in 100 people)</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Reduction in the number of red, white blood
cells and platelets</span></p>

<p class=MsoNormal><span lang=EN-GB>Stroke<br>
Type of stroke when an artery to the brain is blocked</span></p>

<p class=MsoNormal><span lang=EN-GB>Bleeding inside the skull</span></p>

<p class=MsoNormal><span lang=EN-GB>Angina (Chest pain caused by reduced blood
flow to the heart)</span></p>

<p class=MsoNormal><span lang=EN-GB>Heart attack</span></p>

<p class=MsoNormal><span lang=EN-GB>Narrowing or blockage of the coronary
arteries<br>
Abnormal heart rhythm<br>
Deficient blood distribution to the limbs</span></p>

<p class=MsoNormal><span lang=EN-GB>Blockage in one of the pulmonary arteries
in your lungs</span></p>

<p class=MsoNormal><span lang=EN-GB>Inflammation and scarring of the lining of
the lungs with breathing problems</span></p>

<p class=MsoNormal><span lang=EN-GB>Passage of bright red blood from the anus<br>
Bleeding in the gastrointestinal tract<br>
Ruptured bowel</span></p>

<p class=MsoNormal><span lang=EN-GB>Inflammation of the lining of the
oesophagus</span></p>

<p class=MsoNormal><span lang=EN-GB>Inflammation of the lining of the large
bowel, which may be accompanied by intestinal or rectal bleeding (seen only in
combination with cisplatin)<br>
Inflammation, edema, erythema, and erosion of the mucosal surface of the
esophagus caused by radiation therapy<br>
Inflammation of the lung caused by radiation therapy</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Rare (may
affect up to 1 in 1,000 people)</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Destruction of red blood cells<br>
Anaphylactic shock (severe allergic reaction)<br>
Inflammatory condition of the liver</span></p>

<p class=MsoNormal><span lang=EN-GB>Redness of the skin</span></p>

<p class=MsoNormal><span lang=EN-GB>Skin rash that develops throughout a
previously irradiated area</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Very rare (affect up to 1 of 10 000
people)<br>
</span></i><span lang=EN-GB>Infections of skin and soft tissues</span></p>

<p class=MsoNormal><span lang=EN-GB>Stevens-Johnson syndrome (a type of severe
skin and mucous membranes reaction that may be life threatening)</span></p>

<p class=MsoNormal><span lang=EN-GB>Toxic epidermal necrolysis (a type of
severe skin reaction that may be life threatening)</span></p>

<p class=MsoNormal><span lang=EN-GB>Autoimmune disorder that results in skin
rashes and blistering on the legs, arms, and abdomen</span></p>

<p class=MsoNormal><span lang=EN-GB>Inflammation of the skin characterized by
the presence of bullae which are filled with fluid</span></p>

<p class=MsoNormal><span lang=EN-GB>Skin fragility, blisters and erosions and
skin scarring</span></p>

<p class=MsoNormal><span lang=EN-GB>Redness, pain and swelling mainly of the
lower limbs</span></p>

<p class=MsoNormal><span lang=EN-GB>Inflammation of the skin and fat beneath
the skin (pseudocellulitis)</span></p>

<p class=MsoNormal><span lang=EN-GB>Inflammation of the skin (dermatitis)</span></p>

<p class=MsoNormal><span lang=EN-GB>Skin to become inflamed, itchy, red,
cracked, and rough</span></p>

<p class=MsoNormal><span lang=EN-GB>Intensely itchy spots </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Not known (frequency cannot be estimated
from the available data)</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Form of diabetes primarily due to pathology
of the kidney</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Disorder of the kidneys involving the death of tubular epithelial
cells that form the renal tubules</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>You might have any of these symptoms and/or
conditions. You must tell your doctor as soon as possible when you start
experiencing any of these side effects.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>If you are concerned about any side effects, talk to your doctor.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>Reporting of side effects</span></b></p>

<p class=MsoNormal><span lang=EN-GB>If you get any side effects, talk to your
doctor. </span><span lang=EN-GB>This includes any possible side effects not
listed in this leaflet. You can also report side effects directly via<span
style='color:navy'> </span><span style='background:lightgrey'>the national
reporting system listed in </span></span><span lang=EN-GB><a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span
style='background:lightgrey'>Appendix V</span></a></span><span lang=EN-GB>. By
reporting side effects you can help provide more information on the safety of
this medicine.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='background:yellow'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='background:yellow'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>5. How to store Pemetrexed Hospira</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Keep this medicine out of the sight and reach of children.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Do not use this medicine after the expiry date which is stated on
the carton and vial label after EXP. The expiry date refers to the last day of
that month.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>This medicine
does not require any special storage conditions.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>Infusion solution:
</span><span lang=EN-GB>Chemical and physical in-use stability of infusion
solution of pemetrexed has been demonstrated for 24 hours at 2C to 8C. From a
microbiological point of view, the product should be used immediately. If not
used immediately, in-use storage times and conditions prior to use are the
responsibility of the user and would normally not be longer than 24 hours at
2C to 8C.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Parenteral medicines must be inspected visually for particulate
matter and discolouration prior to administration. If particulate matter is
observed, do not administer.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>This medicine is for single use only; any unused solution must be
disposed of in accordance with local requirements.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>Medicines should
not be disposed of via wastewater or household waste. Ask your pharmacist how
to dispose of medicines no longer required. These measures will help to protect
the environment. </span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><b><span lang=EN-GB>6. Contents of the pack and other information</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><b><span lang=EN-GB>What Pemetrexed Hospira contains </span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>The active substance is pemetrexed. One ml of
concentrate contains pemetrexed disodium equivalent to 25 mg of pemetrexed.
Further dilution by a healthcare provider is required prior to administration.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>One vial of 4 ml concentrate contains pemetrexed disodium equivalent
to 100&nbsp;mg of pemetrexed.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>One vial of 20 ml concentrate contains pemetrexed disodium
equivalent to 500&nbsp;mg of pemetrexed.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>One vial of 40 ml concentrate contains</span><span
lang=EN-GB> </span><span lang=EN-GB>pemetrexed disodium equivalent to
1,000&nbsp;mg of pemetrexed.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=Default><span style='font-size:11.0pt'>The other ingredients are monothioglycerol,
sodium hydroxide (for pH adjustment) and water for injections. Refer to section
2 Pemetrexed Hospira contains sodium. </span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>What Pemetrexed Hospira looks like and contents of the pack</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Pemetrexed
Hospira concentrate for solution for infusion (sterile concentrate) is a clear,
colourless to pale yellow or green yellow solution practically free from
visible particulates in a glass vial. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Each pack
contains one vial<b> </b>of 100&nbsp;mg/4 ml, 500&nbsp;mg/20 ml or 1,000&nbsp;mg/40
ml pemetrexed (as pemetrexed disodium).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Not all pack
sizes may be marketed.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Marketing Authorisation Holder</span></b></p>

<p style='margin:0in'><span lang=DE style='font-size:11.0pt'>Pfizer Europe MA
EEIG</span></p>

<p style='margin:0in'><span lang=DE style='font-size:11.0pt'>Boulevard de la
Plaine 17</span></p>

<p style='margin:0in'><span lang=DE style='font-size:11.0pt'>1050 Bruxelles</span></p>

<p style='margin:0in'><span lang=DE style='font-size:11.0pt'>Belgium</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Manufacturer</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Pfizer Service Company BVBA</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Hoge Wei 10</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>1930 Zaventem</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Belgium</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>For any information about this medicine, please contact
the local representative of the Marketing Authorisation Holder:</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=621
 style='border-collapse:collapse'>
 <tr style='page-break-inside:avoid'>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>BE</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Pfizer SA/NV</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tl/Tel: +32 2 554 62 11</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>LT</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Pfizer Luxembourg SARL filialas Lietuvoje</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel. + 370 52 51 4000</span></p>
  <p class=MsoNoSpacing><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNoSpacing><b><span lang=DE style='font-family:"Times New Roman",serif'>BG</span></b></p>
  <p class=MsoNoSpacing><span lang=EN-GB style='font-family:"Times New Roman",serif'>&#1055;&#1092;&#1072;&#1081;&#1079;&#1077;&#1088;
  &#1051;&#1102;&#1082;&#1089;&#1077;&#1084;&#1073;&#1091;&#1088;&#1075;
  &#1057;&#1040;&#1056;&#1051;, &#1050;&#1083;&#1086;&#1085;
  &#1041;&#1098;&#1083;&#1075;&#1072;&#1088;&#1080;&#1103;</span></p>
  <p class=MsoNoSpacing><span lang=EN-GB style='font-family:"Times New Roman",serif'>&#1058;&#1077;&#1083;.:
  +359 2 970 4333</span></p>
  <p class=MsoNoSpacing><b><span lang=DE style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>LU</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Pfizer SA/NV</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tl/Tel: +32 2 554 62 11</span></p>
  <p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNoSpacing><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>CZ</span></b></p>
  <p class=MsoNoSpacing><span lang=EN-GB style='font-family:"Times New Roman",serif'>Pfizer,
  spol. s r.o.</span></p>
  <p class=MsoNoSpacing><span lang=EN-GB style='font-family:"Times New Roman",serif'>Tel:
  +420-283-004-111</span></p>
  <p class=MsoNoSpacing><b><span lang=DE style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNoSpacing><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>HU</span></b></p>
  <p class=MsoNoSpacing><span lang=EN-GB style='font-family:"Times New Roman",serif'>Pfizer
  Kft.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: + 36 1 488 37 00</span></p>
  <p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNoSpacing><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>DK</span></b></p>
  <p class=MsoNoSpacing><span lang=EN-GB style='font-family:"Times New Roman",serif'>Pfizer
  ApS</span></p>
  <p class=MsoNoSpacing><span lang=EN-GB style='font-family:"Times New Roman",serif'>Tlf:
  + 45 44 20 11 00</span></p>
  <p class=MsoNoSpacing><b><span lang=DE style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNoSpacing><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>MT</span></b></p>
  <p class=MsoNoSpacing><span lang=SV style='font-family:"Times New Roman",serif'>Drugsales
  Ltd </span></p>
  <p class=MsoNoSpacing><span style='font-family:"Times New Roman",serif'>Tel.:
  + 356 21 419 070/1/2</span></p>
  <p class=MsoNoSpacing><b><span lang=DE style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNoSpacing><b><span lang=DE style='font-family:"Times New Roman",serif'>DE
  </span></b></p>
  <p class=MsoNoSpacing><span lang=DE style='font-family:"Times New Roman",serif'>PFIZER
  PHARMA GmbH </span></p>
  <p class=MsoNoSpacing><span lang=DE style='font-family:"Times New Roman",serif'>Tel:
  +49 (0)30 550055-51000</span></p>
  <p class=MsoNoSpacing><b><span lang=DE style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=CS>NL</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Pfizer bv</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +31 (0)10 406 43 01</span></p>
  <p class=MsoNoSpacing><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNoSpacing><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>EE</span></b></p>
  <p class=MsoNoSpacing><span lang=EN-GB style='font-family:"Times New Roman",serif'>Pfizer
  Luxembourg SARL Eesti filiaal</span></p>
  <p class=MsoNoSpacing><span lang=EN-GB style='font-family:"Times New Roman",serif'>Tel:
  +372 666 7500</span></p>
  <p class=MsoNoSpacing><b><span lang=DE style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNoSpacing><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>NO</span></b></p>
  <p class=MsoNoSpacing><span lang=EN-GB style='font-family:"Times New Roman",serif'>Pfizer
  AS</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tlf: +47 67 52 61 00</span></p>
  <p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNoSpacing><b><span lang=DE style='font-family:"Times New Roman",serif'>EL</span></b></p>
  <p class=MsoNoSpacing><span lang=SV style='font-family:"Times New Roman",serif'>Pfizer
  </span><span lang=EL style='font-family:"Times New Roman",serif'>&#917;&#923;&#923;&#913;&#931;
  </span><span lang=SV style='font-family:"Times New Roman",serif'>A</span><span
  style='font-family:"Times New Roman",serif'>.</span><span lang=SV
  style='font-family:"Times New Roman",serif'>E</span><span style='font-family:
  "Times New Roman",serif'>.</span></p>
  <p class=MsoNoSpacing><span lang=EN-GB style='font-family:"Times New Roman",serif'>&#932;&#951;&#955;.:
  +30 210 6785 800</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNoSpacing><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>AT</span></b></p>
  <p class=MsoNoSpacing><span lang=EN-GB style='font-family:"Times New Roman",serif'>Pfizer
  Corporation Austria Ges.m.b.H.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +43 (0)1 521 15-0</span></p>
  <p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNoSpacing style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-family:"Times New Roman",serif'>ES</span></b></p>
  <p class=MsoNoSpacing style='page-break-after:avoid'><span lang=EN-GB
  style='font-family:"Times New Roman",serif'>Pfizer, S.L.</span></p>
  <p class=MsoNoSpacing style='page-break-after:avoid'><span lang=EN-GB
  style='font-family:"Times New Roman",serif'>Tel: +34 91 490 99 00</span></p>
  <p class=MsoNoSpacing><b><span lang=DE style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNoSpacing><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>PL</span></b></p>
  <p class=MsoNoSpacing><span style='font-family:"Times New Roman",serif;
  color:black'>Pfizer Polska Sp. z o.o.</span></p>
  <p class=MsoNoSpacing><span lang=EN-GB style='font-family:"Times New Roman",serif'>Tel:
  </span><span style='font-family:"Times New Roman",serif;color:black'>+48 22
  335 61 00</span></p>
  <p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNoSpacing><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>FR</span></b></p>
  <p class=MsoNoSpacing><span lang=EN-GB style='font-family:"Times New Roman",serif'>Pfizer</span></p>
  <p class=MsoNoSpacing><span lang=EN-GB style='font-family:"Times New Roman",serif'>Tl:
  + 33 (0)1 58 07 34 40</span></p>
  <p class=MsoNoSpacing><b><span lang=DE style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNoSpacing><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>PT</span></b></p>
  <p class=MsoNoSpacing><span style='font-family:"Times New Roman",serif'>Laboratrios
  Pfizer, Lda.</span></p>
  <p class=MsoNoSpacing><span lang=EN-GB style='font-family:"Times New Roman",serif'>Tel:
  + 351 21 423 55 00</span></p>
  <p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>HR</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Pfizer Croatia d.o.o.</span></p>
  <p class=MsoNoSpacing><span style='font-family:"Times New Roman",serif'>Tel:
  +385 1 3908 777</span></p>
  <p class=MsoNoSpacing><span lang=DE style='font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>RO</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Pfizer Romnia S.R.L.<br>
  Tel: +40 (0)21 207 28 00</span></p>
  <p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNoSpacing><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>IE</span></b></p>
  <p class=MsoNoSpacing><span lang=EN-GB style='font-family:"Times New Roman",serif'>Pfizer
  Healthcare Ireland </span></p>
  <p class=MsoNoSpacing><span lang=EN-GB style='font-family:"Times New Roman",serif'>Tel:
  1800 633 363 (toll free)</span></p>
  <p class=MsoNormal><span lang=EN-GB>+44 (0) 1304 616161</span></p>
  <p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>SI</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Pfizer Luxembourg SARL</span></p>
  <p class=MsoNormal><span lang=EN-GB>Pfizer, podrunica za svetovanje s
  podro&#269;ja farmacevtske dejavnosti, Ljubljana</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +386 (0)1 52 11 400</span></p>
  <p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>IS</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Icepharma hf.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Smi: +354 540 8000</span></p>
  <p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNoSpacing><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>SK</span></b></p>
  <p class=MsoNoSpacing><span lang=EN-GB style='font-family:"Times New Roman",serif'>Pfizer
  Luxembourg SARL, organiza&#269;n zloka</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +42123355 5500</span></p>
  <p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNoSpacing style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-family:"Times New Roman",serif'>IT</span></b></p>
  <p class=MsoNoSpacing><span lang=EN-GB style='font-family:"Times New Roman",serif'>Pfizer
  S.r.l.</span></p>
  <p class=MsoNoSpacing><span lang=EN-GB style='font-family:"Times New Roman",serif'>Tel:
  +39 06 33 18 21</span></p>
  <p class=MsoNoSpacing><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>FI</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Pfizer Oy</span></p>
  <p class=MsoNormal><span lang=EN-GB>Puh/Tel: +358 (0)9 430 040</span></p>
  <p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNoSpacing style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-family:"Times New Roman",serif'>CY</span></b><b><span lang=EN-GB
  style='font-family:"Times New Roman",serif'> </span></b></p>
  <p class=MsoNoSpacing><span lang=EN-GB style='font-family:"Times New Roman",serif'>Pharmaceutical
  Trading Co Ltd</span></p>
  <p class=MsoNoSpacing><span style='font-family:"Times New Roman",serif;
  color:black'>&#932;&#951;&#955;:</span><span style='font-family:"Times New Roman",serif;
  color:black'> </span><span lang=EN-GB style='font-family:"Times New Roman",serif'>24656165</span></p>
  <p class=MsoNoSpacing><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>SE</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Pfizer AB</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +46 (0)8 550 520 00</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNoSpacing style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-family:"Times New Roman",serif'>LV</span></b></p>
  <p class=MsoNoSpacing><span lang=EN-GB style='font-family:"Times New Roman",serif'>Pfizer
  Luxembourg SARL fili&#257;le Latvij&#257;</span></p>
  <p class=MsoNoSpacing><span lang=EN-GB style='font-family:"Times New Roman",serif'>Tel.:
  + 371 670 35 775</span></p>
  <p class=MsoNoSpacing><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNoSpacing><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>UK</span></b></p>
  <p class=MsoNoSpacing><span lang=EN-GB style='font-family:"Times New Roman",serif'>Hospira
  UK Limited</span></p>
  <p class=MsoNoSpacing><span lang=EN-GB style='font-family:"Times New Roman",serif'>Tel:
  + 44 (0) </span><span style='font-family:"Times New Roman",serif;color:black'>1628
  515500</span></p>
  <p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>This leaflet was last revised in </span></b><b><span lang=EN-GB>month
YYYY</span></b><span lang=EN-GB>.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Detailed information on this medicine is available on the European
Medicines Agency web site: </span><span lang=EN-GB><a
href="http://www.ema.europa.eu">http://www.ema.europa.eu</a></span><span
lang=EN-GB style='color:blue'>.</span><span lang=EN-GB> </span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>This leaflet is
available in all EU/EEA languages on the European Medicines Agency website.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>------------------------------------------------------------------------------------------------------------------------</span></p>

<p class=MsoNormal style='margin-right:-1.4pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.4pt;margin-bottom:
0in;margin-left:-1.85pt;margin-bottom:.0001pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>The following information is intended for healthcare
professionals only:</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>Instructions for use, handling and
disposal</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:13.5pt;text-indent:-13.5pt;line-height:
normal'><span lang=EN-GB>1. Use aseptic technique during dilution of pemetrexed
for intravenous infusion administration. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:13.5pt;text-indent:-13.5pt;line-height:
normal'><span lang=EN-GB>2. Calculate the dose and the number of Pemetrexed
Hospira vials needed. Each vial contains an excess of pemetrexed to facilitate
delivery of label amount. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:13.5pt;text-indent:-13.5pt;line-height:
normal'><span lang=EN-GB>3. The appropriate volume of pemetrexed solution must
be further diluted to 100&nbsp;ml with 9&nbsp;mg/ml (0.9%) sodium chloride
solution for injection, without preservative, and administered as an
intravenous infusion over 10&nbsp;minutes. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:13.5pt;text-indent:-13.5pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>4. Pemetrexed infusion solution
prepared as directed above are compatible with polyvinyl chloride- and
polyolefin-lined administration sets and infusion bags. </span>Pemetrexed is
incompatible</p>

<p class=MsoNormal style='margin-left:22.5pt;text-indent:-9.0pt;line-height:
normal'>with diluents containing calcium, including lactated Ringers Injection
and Ringers Injection.</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:13.5pt;text-indent:-13.5pt;line-height:
normal'><span lang=EN-GB>5. Parenteral medicinal products must be inspected
visually for particulate matter and discolouration prior to administration. If
particulate matter is observed, do not administer. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>6. Pemetrexed
solutions are for single use only. Any unused medicinal product or waste
material must be disposed of in accordance with local requirements. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Preparation
and administration precautions</span></b><span lang=EN-GB> </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>As with other
potentially toxic anti-cancer agents, care should be exercised in the handling
and preparation of pemetrexed infusion solution. The use of gloves is
recommended. If a pemetrexed solution contacts the skin, wash the skin
immediately and thoroughly with soap and water. If pemetrexed solutions contact
the mucous membranes, flush thoroughly with water. Pemetrexed is not a
vesicant. There is not a specific antidote for extravasation of pemetrexed.
There have been few reported cases of pemetrexed extravasation, which were not
assessed as serious by the investigator. Extravasation should be managed by
local standard practice as with other non-vesicants.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

</div>

</body>

</html>
